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B cell antigen receptor (BCR) ligation leads to activation of a number of intracellular signaling 
events that decide the fate of the B cell and thus is a key event in humoral immunity. BCR 
activation is tightly controlled by different inhibiting and activating coreceptors and Fc receptors. 
Dysregulation or imbalance between inhibiting and activating receptors can result in 
autoimmunity. The recombinant soluble (s)FcγRIIB has been tested in clinical trials as a promising 
treatment option for autoimmune diseases. Besides competing with membrane-bound Fcγ 
receptors for pathogenic immune-complexes, sFcγRIIB is also suggested to interfere with BCR 
signaling by binding to membrane IgG on memory B cells. Here, I showed that multimeric 
variants of recombinant sFcγRIIB induce BCR signaling events in human IgG-B cells, most 
probably by direct interaction with the IgG-BCR. BCR signaling induced by multimeric sFcγRIIB 
indicated an alternative pathway for activation of extracellular signal regulated kinase (Erk). 
Based on these findings, I revisited the Erk pathway in human B cells. According to current 
knowledge based on chicken and mouse B cells, BCR-mediated Erk activation is mainly mediated 
via diacylglycerol (DAG) and Ras guanyl nucleotide-releasing proteins (RasGRPs) and thus 
requires activation of phosphoinositide phospholipase C (PLC) γ2. In contrast, my data from 
human B cells showed no correlation between PLCγ activity and Erk activation, revealing species 
specific differences between chicken, mice and human. Instead, I showed that Erk activation 
depends on the growth factor receptor bound protein 2 (Grb2). This led to the suggestion that 
Erk activation in human B cells relies on the Grb2-Son of sevenless (Sos) signaling axis as 
described for many other receptor systems. The involvement of Grb2 in BCR-induced Erk 
activation raised the question for a Grb2-membrane anchor, linking the activated BCR to Erk 
activation. Indirect recruitment of Grb2 to the BCR complex via the adapter protein SHC1 turned 
out to be not important for Erk activation. Thus, I investigated another potential Grb2 membrane 
anchor, namely the recently-discovered Fc receptor for IgM (FcµR). In experiments with chimeric 
IgG2a-FcµR receptors, I showed that the cytoplasmic domain of the FcµR indeed harbors a Grb2 
binding site, which confers costimulatory functions, at least to the chimeric protein. Rigorous 
elucidation of BCR signaling provides important knowledge to understand the molecular biology 
of lymphomagenesis and autoimmune disorders for the development of potential therapeutics. 
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1.1 The immune system – an overview 
The human body is exposed to a wide variety of potential pathogens every day, including 
bacteria, viruses, fungi or parasites. To prevent diseases, vertebrates developed a complex, 
multicellular immune system during hundreds of millions of years of evolution. While simple 
defense mechanisms can even be observed in single-cell organisms, the immune system of 
higher vertebrates divides into two branches: the innate and the adaptive immune system that 
cooperate in recognition and elimination of potential pathogenic invaders (Beck & Habicht, 
1996). The innate immune system as the first line of defense provides an immediate response to 
pathogens that breached the anatomical barriers. Elimination of intruders is facilitated by 
antimicrobial molecules such as defensines, lysozyme and the complement system as well as by 
the cells of the innate immune system, namely dendritic cells, macrophages, granulocytes and 
natural killer cells. However, this immediate early response is not pathogen specific, but rather 
relies on the differentiation between “self” and “non-self” by so called pattern recognition 
receptors (PRRs) expressed by the innate immune cells. PRRs recognize molecular microbial 
patterns, commonly shared by many types of microorganisms but not by the host (Medzhitov & 
Janeway, 2002; Kumar et al, 2009). The adaptive immune system complements the immune 
response by providing high specificity against a wide variety of potential pathogens as well as 
the ability to form a long term memory against pathogens to prevent recurrent infections. The 
cells of the adaptive immune system are T and B lymphocytes. In contrast to innate immune 
cells, each and every single B and T cell expresses an antigen receptor with individual specificity, 
ensuring the recognition of virtually all possible pathogens. These receptors are not germ-line 
encoded, but acquire their antigen specificity by somatic recombination during T and B cell 
development (Nemazee, 2000). T lymphocytes exert the cellular part of the adaptive immune 
response by killing of virus infected cells and by providing costimulatory signals for the 
differentiation of other lymphocyte types. B lymphocytes contribute to humoral immunity with 
the production of antibodies (Dempsey et al, 2003; Ahmed & Gray, 1996).  
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1.2 B cell biology  
B cells were recognized as a functionally and developmentally separate lineage of lymphocytes 
in 1965 by Max Cooper, although the existence of antibody producing cells has been proposed 
already in 1897 by Paul Ehrlich. B cells were named after the bursa of Fabricius, a hind gut 
lymphoid organ in birds that was identified by Bruce Glick in 1956 to be the site for antibody 
production in chicken (reviewed in Cooper, 2015). In human as in all mammals, development of 
B cells takes place in the bone marrow, where they undergo random rearrangement of the 
immunoglobulin gene segments (V(D)J recombination). This leads to the formation of a B cell 
repertoire, expressing antigen receptors specific for a vast variety of antigens (reviewed in Pieper 
et al, 2013). However, due to the unpredictability of specificities resulting from this random 
rearrangement, this process also bears the risk of producing autoreactive B cells that could 
induce auto immune reactions. In order to prevent autoreactivity B cells undergo a number of 
self-tolerance mechanisms during the stages of development leading to elimination or 
inactivation of autoreactive T and B cells (Shlomchik, 2008; Ubelhart & Jumaa, 2015). For final 
development into mature naïve B cells, newly formed B cells migrate to the spleen (Osmond, 
1986). Naïve B cells keep circulating through the bloodstream, thereby homing to secondary 
lymphoid organs (lymph nodes, spleen and other lymphoid tissues) regularly in order to raise the 
chance to come in contact with the corresponding antigen (Andrian & Mempel, 2003). B cells 
either recognize antigen in soluble form or presented on antigen presenting cells (APC) as 
dendritic cells or macrophages within the secondary lymphoid organs (Yuseff et al, 2013). Upon 
encounter with its antigen the B cell gets initially activated. Dependent on the B cell subtype the 
activated B cell requires costimulatory signals from helper T cells. Activation leads to proliferation 
and differentiation into memory B cells or antibody-secreting plasma cells. During the so called 
germinal center reaction some of the B cells additionally undergo somatic hypermutation of 
antigen receptor genes as well as affinity maturation to increase affinity of antigen receptors. 
Furthermore, some B cells also undergo class-switch recombination, in order to increase 
functional diversity of immunoglobulins by the generation of different antigen receptors 
subtypes depending on the type of antigen (Heesters et al, 2014; Silva & Klein, 2015). Compared 
to the innate immune response which takes a few hours to respond to an antigen, the adaptive 
immune response takes about a week to set in upon primary encounter of a pathogen. However, 
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memory B cell activation and differentiation into plasma cells upon secondary encounter with an 
antigen is much faster and hence requires less costimulatory signals by T cells (Engels et al, 2009; 
Kurosaki et al, 2015). This enables the organism to react faster and more effective against 
recurrent pathogens to prevent or ameliorate a second infection. This effect also underlies the 
principle of vaccination, where adaptive immunity is induced by administration of inactivated or 
attenuated antigenic material that mimics a natural infection. 
1.2.1 Immunoglobulins: structure and function 
Antibodies or immunoglobulins (Igs) are Y-shaped proteins and occur in two forms: membrane 
bound as part of the B cell antigen receptor (BCR) and as soluble form, secreted in large 
numbers by plasma cells (PCs), which represent finally differentiated B cells. The secreted form 
has the same antigen specificity and isotype as the BCR on naïve or memory B cell the plasma 
cell has differentiated from in response to the corresponding antigen. The main functions of 
secreted antibodies are neutralization of antigens, labelling of antigens for elimination by 
phagocytes (opsonization), activation of the complement system and antibody-dependent cell-
mediated cytotoxicity (ADCC) by NK cells (Ravetch & Kinet, 1991).  
Structurally, immunoglobulins (Ig) are composed of two Ig heavy chains and two Ig light chains. 
Both heavy chains are linked to each other and each light chain is linked to one of the heavy 
chains by disulfide bonds (figure 1). Each light chain is composed of a constant and a variable 
domain (CL and VL), while each heavy chain contains one variable domain (VH) and, depending on 
the Ig subtype, three to four constant domains (CH) (Woof & Burton, 2004). The immunoglobulin 
molecule can be dissected in two parts, defined as the fragment of antigen binding (Fab) 
consisting of the V region and the Fc fragment (fragment crystallizable) linked by a hinge region. 
This definition is based on experiments by Rodney R. Porter who observed that papain cleaves 
rabbit IgG-antibodies into three fragments; two of them retained antibody function, whereas the 
third one crystallized (Porter, 1959). Porter was, together with Gerald M. Edelmann, awarded the 
Nobel prize for medicine in 1972 for determining the chemical structure of antibodies. As its 
name implies, the Fab fragments mediates antigen recognition, while the Fc portion binds to 
certain receptors termed as Fc receptors mediating the antibodies effector function according to 
the Ig subtype. Fc receptors are membrane bound receptors specific for the Fc portion of the 
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respective Ig isotype, connecting the humoral to the cellular immune response, thereby 
mediating the major part of antibody effector functions as describe above (Woof & Burton, 
2004). The role of Fc receptors in B cells will be reviewed later in this introduction. 
 
Figure 1. Representative depiction of an immunoglobulin. Immunoglobulin (here using the example of IgG) are composed of 
two heavy (H) chains (dark blue) and two light (L) chains linked by disulfide bonds. Each light and heavy chain contains 
variable (V) and constant (C) domains. The paired variable domains (VH and VL) constitute the antigen binding sites. 
Functionally, immunoglobulins are dissected into the Fragment of antigen binding (Fab) and the Fragment crystallizable (Fc), 
which by binding to Fc receptors expressed on different immune cells and by activation of the complement systems mediates 
the major part of antibody effector functions.  
In order to achieve the extraordinary diversity of the immunoglobulin repertoire, rearrangement 
of immunoglobulin genes by V(D)J recombination, a unique mechanism of somatic 
recombination, is required. Ig H and L chain are encoded by genes on three independent loci, 
one for the H chain (IgH) and two for the L chain (Igκ and Igλ). Each contains multiple copies of 
variable (V), joining (J) and diversity (D; only IgH chain) gene segments as well as exons encoding 
the constant (C) regions. Random rearrangement of V and J gene segments on the Ig L chain loci 
and V, D and J gene segments on the Ig H locus leads to assembly of a complete VL-region exon 
or VH-region exon, respectively. The C region exons are joined to the VH- or VL-region exon by 
mRNA splicing for expression of a complete H or L chain (Tonegawa, 1983; Matsuda et al, 1998; 
Schatz & Ji, 2011; Jung et al, 2006). Following B cell activation, Igs are further modified by 
somatic hypermutation during the germinal center reaction. This process involves the 
introduction of point mutations into the V regions of heavy and light chain at a high rate, 
leading to alterations in antigen binding affinity. B cells with improved antigen binding affinity 
are selected for proliferation and further maturation, while B cells with decreased affinity die. This 
process is termed affinity maturation (Li et al, 2004; Odegard & Schatz, 2006).  
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Igs come in different isotypes: IgM, IgD, IgG, IgE and IgA. The class or isotype of Igs is defined 
according to the H chain constant region (CH) that accordingly is termed µ, δ, γ, ε or α CH region. 
The CH region determines the effector function of an antibody by binding to specific Fc receptors 
expressed on almost all types of immune cells, mediating the major antibody functions as ADCC, 
elimination of pathogens by activation of phagocytes or release of inflammatory mediators 
(Raghavan & Bjorkman, 1996; Woof & Burton, 2004)  
IgM is expressed on naïve B cells and hence is the first isotype secreted during an immune 
response. Since it is expressed before B cell activation, it has not undergone somatic 
hypermutation and affinity maturation and thus has a relatively low binding affinity (Boes, 2000; 
Schroeder, JR & Cavacini, 2010). Along with IgM also IgD is expressed on the cell surface of naïve 
B cells and to some extent is secreted. However, its role has not been fully elucidated (Chen & 
Cerutti, 2010). The other isotypes emerge after primary response to an antigen during the 
germinal center reaction in a process termed class-switch recombination or Ig isotype switching. 
This process involves the replacement of the µ and δ CH regions with γ, ε or α CH regions by DNA 
recombination of the C region exons on the H chain locus, leading to a switch from IgM and IgD 
surface expression to IgG, IgE or IgA expression (Stavnezer et al, 2008; Stavnezer & Schrader, 
2014). 
The most abundant Ig isotype is IgG which is found in blood and extracellular fluids. IgA is less 
abundant than IgG in serum but concentrates at mucosal surfaces and secretions, including 
saliva and breast milk. IgE is the least abundant immunoglobulin in serum, but constantly binds 
with high affinity to Fc receptors for IgE (Fcε receptors) on mast cells, eosinophils or basophils, 
thus being involved in hypersensitivity, allergy as well as in the response to worm infections 
(Schroeder, JR & Cavacini, 2010).  
1.2.2 The B cell antigen receptor 
Membrane and secreted forms of immunoglobulins originate from the same genetic loci and are 
processed by alternative mRNA splicing. The C-terminal part of the membrane Igs contains a 
transmembrane region as well as a cytoplasmic segment that are not found in the secreted form. 
However, the cytoplasmic domains differ between the different Ig isotypes: the cytoplasmic 
segment of IgD and IgM encompasses only three amino acids, while the cytoplasmic domain of 
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IgG and IgE comprises 28 amino acids. To form a functional BCR complex, the membrane 
immunoglobulin is noncovalently associated with two invariant protein chains, namely Igα 
(CD79a) and Igβ (CD79b), forming a heterodimer linked by disulfide bonds (Reth et al, 1991). 
This heterodimer is not only important for the transport of the BCR to the cell surface, but also 
mediates the signaling function of the BCR complex via so called immunoreceptor tyrosine-
based activation motifs (ITAMs) with the consensus sequence D/E-x7-D/E-x2-Y-x2-I/L-x7-Y-x2-I/L 
(x can be any amino acid). ITAMs are also present within the signaling chains of the T cell antigen 
receptor and certain Fc receptors (Reth, 1992; Reth & Wienands, 1997). Upon BCR stimulation 
and activation of protein tyrosine kinases the tyrosine (Y) residues within the ITAMs of Igα and 
Igβ get phosphorylated, leading to the initiation of several signaling pathways from the BCR 
(Gold et al, 1991; Clark et al, 1994).  
1.2.3 B cell antigen receptor signaling  
The mode of BCR activation on the cell surface has been discussed at least in two partially 
controversial models. Originally, antigen-specific activation of the BCR was explained by the 
cross-linking model, assuming that the BCR exists as a monomer and requires oligomerization by 
a polyvalent antigen in order to get activated and induce further downstream signaling 
(discussed in Yang & Reth, 2010b and Pierce & Liu, 2010). This model was supported by 
observations made in other receptors as well as by the finding that only bivalent F(ab’)2 
fragments derived from BCR specific antibodies were able to induce BCR signaling, while 
monovalent Fab fragments were not (Metzger, 1992; Lemmon & Schlessinger, 2010; Woodruff et 
al, 1967). However, Yang and Reth proposed an alternative model which they termed 
dissociation activation model: This model suggests the organization of the resting BCR in 
preformed clusters, forming stable auto-inhibiting oligomers that dissociate upon antigen 
binding and thereby form signaling active monomers (Yang & Reth, 2010b; Yang & Reth, 2010a; 
Klasener et al, 2014). Nevertheless, while the conformation and activation of the resting BCR is 
still controversially discussed, the knowledge about the downstream signaling events emerging 
from the BCR is more profound.  
BCR ligation leads to phosphorylation of the ITAMs within the Igα/β hetero dimer by Src family 
kinases (SFKs) such as Lyn and Fyn and spleen tyrosine kinase (Syk). The doubly phosphorylated 
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ITAMs serve as docking sites for the tandemly arranged Src homology 2 (SH2) domains of Syk 
resulting in further activation of Syk. This leads to amplification of BCR signal transduction by Syk 
mediated ITAM phosphorylation of neighboring BCRs (Clark et al, 1994; Rowley et al, 1995; 
Futterer et al, 1998; Rolli et al, 2002). Furthermore, activated Lyn and Syk contribute to the 
activation of several downstream effectors resulting in various signaling pathways determining 
the B cells’ fate in immune response and differentiation. Two early events, namely the activation 
of phosphoinositide-3 kinase (PI3K) and the activation of phosphoinositide 
phospholipase C (PLC) γ2, were shown to be important for propagation of downstream signals 
by the production of second messengers (figure 2) (Marshall et al, 2000). 
1.2.3.1 PI3 kinase/Akt pathway 
Following BCR activation the BCR co-receptor CD19 and the adapter protein B cell adapter for 
PI3K (BCAP) get phosphorylated by Lyn and brutons tyrosine kinase (Btk) which leads to the 
recruitment of PI3K to the plasma membrane (figure 2 ①) (Tuveson et al, 1993). Once activated, 
PI3K phosphorylates the membrane inositol phospholipid PIP2 (phosphatidylinositol 
4,5-bisphosphate) leading to generation of PIP3 (phosphatidylinositol 3,4,5-bisphosphate) 
(reviewed in (Tuosto et al, 2015). PIP3 mediates translocation of Akt kinase to the plasma 
membrane where it gets activated by phosphoinositide dependent kinase (PDK) 1 and PDK2 
(Osaki et al, 2004). Akt in turn leads to inactivation of several factors including GSK3β and FOXO1 
that are involved in negative regulation of cell cycle progression (reviewed in Rickert, 2013).  
1.2.3.2  Formation of the Ca2+ initiation complex and activation of PLCγ2 
PIP2 also serves as substrate for PLCγ2 whose enzymatic products facilitate regulation of the 
most crucial signaling events following B cell activation. Activation of PLCγ2 requires formation 
of the so called Ca2+ initiation complex consisting of Btk, PLCγ2 itself and the adapter protein 
Src homology [SH2] domain–containing leukocyte protein of 65 kD (SLP65) also termed BLNK or 
BASH (Wienands et al, 1998; Fu et al, 1998; Goitsuka et al, 1998). SLP65 has been shown to be 
indispensable for B cell development and is a critical component in signal integration following 
BCR activation (Ishiai et al, 1999; Hayashi et al, 2000; Pappu et al, 1999). Following BCR activation 
SLP65 gets recruited to the plasma membrane which requires constitutive interaction with 
Cbl-interacting protein of 85 kDa (CIN85) (Kometani et al, 2011; Oellerich et al, 2011). 
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Additionally, SLP65 gets recruited to Igα by binding to a non-ITAM tyrosine and to 
auto-phosphorylated Syk via its SH2 domain (Engels et al, 2001; Kulathu et al, 2008). This in turn 
leads to tyrosine phosphorylation of SLP65 by Syk (Chiu, 2002). Once phosphorylated, it provides 
docking sites for Btk and PLCγ2, bringing them into close vicinity within the Ca2+ initiation 
complex. Syk phosphorylates and thereby activates Btk which in turn phosphorylates PLCγ2. 
Activated PLCγ2 mediates hydrolysis of PIP2 which results in the generation of the second 
messengers IP3 (inositol-1,4,5-trisphosphate) and membrane bound DAG diacylglycerol (DAG) 
(figure 2 ②) (Kurosaki et al, 2000).  
1.2.3.3  Downstream of the Ca2+ initiation complex 
IP3 mediates the mobilization of the second messenger Ca2+ from intracellular stores and from 
the extracellular space. In detail, IP3 binds to a set of IP3 receptors (IP3R1-3) that are located in 
the membrane of the endoplasmic reticulum (ER) and serve as ligand operated Ca2+ channels, 
leading to the release of Ca2+ from the ER into the cytosol. The rapid decrease of Ca2+ in the ER 
lumen is sensed by so called stromal interaction molecules (STIMs), transmembrane proteins in 
the ER membrane. Upon Ca2+ binding STIMs interact with and activate Calcium release activated 
channels (CRACs) in the plasma membrane that operate the influx of extracellular Ca2+ into the 
cytoplasm (figure 2 ③) (reviewed in Engelke et al, 2007; Scharenberg et al, 2007). The sustained 
increase in Ca2+ is required for the activation of the transcription factor nuclear factor of 
activated T cells (NFAT) via the phosphatase Calcineurin which is activated by the Ca2+sensor 
Calmodulin (CaM) (figure 2 ④) (Macian, 2005). NFAT modulates proliferation and survival of 
peripheral B cells and differentiation into plasma cells (Engelke et al, 2007; Hock et al, 2013).  
DAG, on the other hand, was shown to be involved in activation of the transcription factor NFκB 
(nuclear factor of kappa light polypeptide gene enhancer in B cells) (figure 2 ⑤) and 
extracellular signal regulated kinase (Erk) (figure 2 ⑥) (Spitaler & Cantrell, 2004). The activation 
of Erk following BCR activation is discussed in more detail in the following section. Activation of 
NFκB requires the recruitment of the serine/threonine protein kinase C (PKC)β to the membrane 
bound DAG. PKCβ gets fully activated upon Ca2+ binding and mediates activation of the IκBα 
kinase complex (IKK) which in turn phosphorylates the NFκB inhibitor IκB and marks it for 
proteasomal degradation. Consequently, NFκB is released from cytosolic retardation and 
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translocates to the nucleus where it is involved in regulation of various genes that regulate the 
immune response (figure 2 ⑤) (Li & Verma, 2002).  
 
Figure 2. Schematic depiction of B cell antigen receptor (BCR) signaling. Following BCR ligation, activation of CD19 and BCAP 
leads to the recruitment of PI3K ①. PI3K mediates hydrolysis of PIP2 to PIP3, which recruits Akt kinase to the plasma 
membrane. Activated Akt inactivates nuclear transcription factors involved in negative regulation of cell cycle progression. 
Furthermore, Lyn and Syk activity leads to phosphorylation of the ITAMs within the Igα/β heterodimer and to 
phosphorylation of the Igα non-ITAM tyrosine. This in turn leads to phosphorylation of SLP65, which recruits Btk and PLCγ2 
and mediates the formation of the Ca
2+.
initiation complex ②. Syk activates Btk, which in turn activates PLCγ2. PLCγ2 
mediates hydrolysis of PIP2 to IP3 and DAG. IP3 induces mobilization of Ca
2+
 from intra- and extracellular sources via IP3R, 
STIM1 and CRACs ③. Increased Ca
2+
 entry is sensed by CaM, which via calcineurin mediates the activation of NFAT ④. DAG 
mediates the recruitment of PKCβ or RasGRPs to the plasma membrane which leads to activation of NFκB ⑤ and Erk via the 
Ras/Raf/MEK1/2 pathway ⑥. Solid arrows indicate direct effector functions, discontinuous arrow indicates indirect effector 
functions, blunt arrow indicates inhibition and dashed arrows indicate translocation. 
 
1.2.4 Activation of Erk following BCR activation 
Another crucial effector that was shown to get activated upon BCR activation is Erk. Erk plays an 
important role in cell cycle progression as well as survival and was shown to be essential for the 
differentiation of naïve and memory B cells into plasma cells (Yasuda et al, 2011). Activation is 
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mediated via the GTPase Ras which by virtue of farnesyl residues is associated with cellular 
membranes. Ras activates the protein kinase Raf that in turn activates MAPK/Erk kinase (MEK) 
which results in the activation of Erk (McCubrey et al, 2007; Yasuda & Kurosaki, 2008). Ras 
activity is regulated by guanine nucleotide exchange factors (GEFs). Initially, the RasGEFs Son of 
seven less 1 and 2 (Sos1/2) were assumed to mediate Ras activation following BCR ligation as it 
was described for growth factor receptors (Campbell et al, 1998; Egan et al, 1993; Buday & 
Downward, 1993). Sos is delivered to the activated receptor by the adapter protein growth factor 
receptor-bound protein 2 (Grb2), which constitutively interacts with Sos (Bar-Sagi, 1994). 
Supporting evidence came from in vitro kinase assays showing that Grb2 is partially required for 
activation of Erk (Hashimoto et al, 1998). However, studies in Sos1/2 deficient cells derived from 
the chicken B cell line DT40 revealed that Sos is dispensable for the BCR induced activation of 
Ras and Erk in this cell line. Moreover, further genetic analysis from the same study implied that 
rather the RasGEF Ras guanyl releasing protein 3 (RasGRP3) and PLCγ2 are important for Erk 
activation (Oh-hora et al, 2003). This was supported by data from RasGRP and PLCγ2 deficient 
mice (Coughlin et al, 2005; Bell et al, 2004). The necessity for PLCγ2 in Erk activation can be 
explained by the requirement for the recruitment of RasGRP to DAG, which is a product of PIP2 
hydrolysis by PLCγ2 (figure 2 ⑥). However, a more recent study implied that both families of 
RasGEFs cooperate in the activation of Ras by revealing that Sos facilitates Erk activation upon 
suboptimal BCR stimulation via a RasGTP dependent positive-feedback loop (Roose et al, 2007; 
Das et al, 2009).  
It is necessary to point out that all of the studies regarding Grb2/Sos involvement in BCR 
mediated Erk activation were conducted in the chicken cell line DT40 or in mouse models. How 
Erk activation following BCR ligation is mediated in human B cells is not known. Investigation of 
the role of Grb2 in Erk activation in human B cells is part of this thesis.  
1.2.6 The adapter protein Grb2  
Adapter proteins in general are important players in the initiation of signaling pathways from the 
activated antigen receptor. By providing distinct protein domains and phosphorylation sites they 
are important for mediating protein-protein interactions and the formation of larger complexes, 
thereby generating platforms for signal propagation. The adapter protein Grb2 is a simple 
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adapter protein that is abundantly expressed and involved in numerous signaling processes 
mediating activating as well as inhibiting functions. As mentioned before, Grb2 was first 
discovered as being recruited to growth factor receptors via its SH2 domain, thereby linking the 
activated receptor to Ras activation via the interaction with Sos (Lowenstein et al, 1992; Buday & 
Downward, 1993; Bar-Sagi, 1994). Null mutation of the Grb2 gene results in embryonic lethality 
supporting a crucial role for Grb2 in developmental processes (Cheng et al, 1998).  
Grb2 has a molecular weight of 25 kDa and belongs to the Grb2 family of adapter proteins which 
also includes Grb2-related adapter protein (GRAP) and GRB2-related adapter downstream of Shc 
(Gads). While Grb2 is ubiquitously expressed in all cell types, GRAP and Gads expression is 
restricted to hematopoietic cells including T and B cells. Grb2 and GRAP share 60 % sequence 
homology (Trüb et al, 1997; Liu et al, 2001). Grb2 is composed of a central SH2 domain flanked 
by two SH3 domains (Lowenstein et al, 1992). The constitutive association with Sos is mediated 
by both SH3 domains (Rozakis-Adcock et al, 1993; Neumann et al, 2009), while the SH2 domain 
directly recognizes phospho-tyrosine containing sites with the consensus sequence pYXN 
(Kessels, Helmut W H G et al, 2002).  
1.2.6.1 The differential role of Grb2 in BCR signaling 
Despite its simple structural organization, Grb2 plays a versatile role in the regulation of BCR 
signaling. Many Grb2 interaction partners have been identified that play a crucial role in 
regulation of BCR signaling (figure 3) (Neumann et al, 2009). Hence, Grb2 is implied to act either 
as a negative or positive regulatory element by binding to different coreceptors or membrane 
adapter proteins that provide docking sites for Grb2. Whether Grb2 acts as a negative or positive 
regulatory element strongly depends on the developmental and differentiation stage of the 
B cell (Jang et al, 2009).  




Figure 3. Selection of Grb2 interaction partners involved in BCR signaling. Grb2 interacts with both SH3 domains and the 
central SH2 domain with negative (red) and positive (green) regulators of BCR signaling. Interaction with some of the proteins 
requires involvement of more than one Grb2 domain. Based on Neumann et al, 2009, Engels et al, 2009 (*) and Engels et al, 
2014 (**).  
Grb2 was shown to be involved in amplification of signals initiated from the IgG/IgE-BCR of 
memory B cells. In contrast to the IgM-BCR, the IgG-and the IgE-BCR have an extended 
cytoplasmic domain that comprises a conserved tyrosine motif termed as immunoglobulin tail 
tyrosine (ITT) matching the consensus sequence pYXN. ITT phosphorylation following BCR 
activation leads to recruitment of Grb2 that confers signal amplification to the mIgG-BCR via 
recruitment of Btk (Engels et al, 2009; Engels et al, 2014). The ITT facilitates fast reactivation of 
memory B cells during a secondary immune response (Lutz et al, 2016). 
A positive regulatory role for Grb2 was also proposed for CD19 signaling, thereby playing an 
important role in amplification of the signals emerging from the BCR and initiation of the 
PI3K/Akt pathway, probably by increasing the avidity of effector proteins that bind to CD19 
(Rickert, 2005).  
On the other hand, studies in chicken DT40 cells as well as in mice revealed a negative regulatory 
role of Grb2 in Ca2+ mobilization following BCR activation (Stork et al, 2004; Ackermann et al, 
2011). Following BCR activation Grb2 gets recruited to the phosphorylated adapter protein 
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Downstream of kinase-3 (Dok3), which is located at the inner leaflet of the plasma membrane. 
Plasma membrane recruitment via Dok3 brings Grb2 into close proximity with Btk, inhibiting Btk-
mediated PLCγ2 activation either by allosteric inhibition of Btk or by preventing the entry of Btk 
into the Ca2+ initiation complex. This process is antagonized by the transmembrane adapter non-
T-cell activation linker (NTAL) that upon activation sequesters Grb2 via a phospho-YXN site 
(Stork et al, 2007; Stork et al, 2004).  
Moreover, Grb2 is suggested to be involved in the negative regulation of B cell receptor 
signaling by inhibitory coreceptors such as CD22, CD27 and the low affinity Fc receptor for IgG 
(FcγRIIB). These receptors exert their function via so called immunoreceptor tyrosine-based 
inhibition motifs (ITIMs) that upon ligation get phosphorylated leading to the recruitment of 
protein-tyrosine phosphatases including SH2 domain-containing protein phosphatase 1 (SHP1) 
and 2 (SHP2) as well as the lipid phosphatase SH2-containing inositol polyphosphate 5-
phosphatase (SHIP). This leads to dephosphorylation of important effectors as for example Igα 
and Igβ or hydrolysis of the second messenger PIP3 in order to downmodulate BCR signaling 
(Nitschke & Tsubata, 2004; Ono et al, 1996). While the involvement of Grb2 in negative signaling 
of CD27 is not elucidated, the formation of a quaternary complex between CD22 with Grb2, SHIP 
and the adapter protein SHC seems to be important for the CD22 mediated negative regulation 
of BCR signaling (Poe et al, 2000). In FcγRIIB dependent inhibition of BCR signaling, Grb2 seems 
to act as a stabilizer for SHIP and hence for SHIP-mediated signal inhibition (Neumann et al, 
2011).  
1.2.7 The role of Fc receptors on B cells 
Fc receptors are expressed on almost all types of immune cells beside T cells, thereby 
transducing the main functions of antibodies as phagocytosis of opsonized pathogens, ADCC 
(antibody-dependent cell mediated cytotoxicity), degranulation and release of 
immunoregulatory molecules (Woof & Burton, 2004; Nimmerjahn & Ravetch, 2007). Several Fc 
receptors specific for the respective Ig isotypes are well described in structure and function. 
According to the Ig isotypes IgA, IgE and IgG they are termed Fcα, Fcε and Fcγ receptors 
(figure 4). An Fc receptor for IgM (FcµR) has only been identified recently. Cellular distribution 
and function of the FcµR is conversely discussed and still under investigation. However, in human 
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it is primarily if not exclusively expressed on cells of the adaptive immune system, namely T and 
B cells (Kubagawa et al, 2009). The most important and so far best described Fc receptor on B 
cells is the before mentioned FcγRIIB. As outlined in the previous section, the FcγRIIB plays an 
important regulatory role by downmodulating BCR mediated signaling. 
 
Figure 4. Human Fc receptors and their cellular distribution. ITAMs are indicated in green, ITIMs are indicated in red. are 
BG=basophil granulocytes, EG=eosinophil granulocytes, NG=neutrophils granulocytes, DC=dendritic cell, LC=langerhans cell, 
MC=Monocyte, MΦ=Macrophage, mast=mast cell, PL=platelets, EC=epithelial cell; (*pseudogene). Adapted from (Pleass & 
Woof, 2001). 
1.2.7.1  The regulatory function of FcγRIIB 
The FcγRIIB belongs to the Fcγ receptor family, the largest Fc receptor family specific for IgG. In 
human it contains six members, including five activating, namely FcγRI, FcγRIIA, FcγRIIC, FcγRIIIA, 
FcγRIIIB and the inhibitory FcγRIIB. Correspondingly, the different Fcγ receptor subtypes bind the 
different IgG subtypes IgG1-4 with varying affinities. Members of the Fcγ receptor family are 
expressed on virtually all immune cells including dendritic cells, macrophages, neutrophils, NK 
cells, B cells but not T cells. Activating Fcγ receptors mediate their function through ITAMs, while 
the inhibitory FcγRIIB encompasses an ITIM and thereby modulates ITAM mediated signaling 
and prevents overwhelming reactions (figure 4). Hence, simultaneous expression of both, 
activating and inhibitory Fc receptors on immune cells facilitates tight regulation of the immune 
response (Nimmerjahn & Ravetch, 2007; Nimmerjahn & Ravetch, 2008; Nimmerjahn & Ravetch, 
2010). 
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While monocytes, macrophages, dendritic cells, basophils and mast cells express both types of 
Fcγ receptors, B cells only express the inhibitory FcγRIIB. It thereby is involved in modulation of 
signals emerging from the BCR and regulation of antibody homoeostasis by controlling plasma 
cell survival on several levels of B cell differentiation (Bolland & Ravetch, 1999; Baerenwaldt & 
Nimmerjahn, 2008). Lack or polymorphisms of FCγRIIB gene in human as well as in mice lead to 
the development of autoimmunity, underlining the important immunoregulatory role of this 
inhibitory receptor (Nimmerjahn & Ravetch, 2008; Baerenwaldt & Nimmerjahn, 2008). For 
example, a polymorphism in the human FCγRIIB gene resulting in the exclusion of FcγRIIB from 
lipid rafts is associated with the development of systemic lupus erythematosus (SLE) (Floto et al, 
2005). SLE is a systemic autoimmune disease that can affect destruction of healthy tissue in 
multiple organs by the production of autoantibodies and is hence characterized by various 
symptoms (Bengtsson & Ronnblom, 2016). 
1.2.7.2 A recombinant soluble FcγRIIB as treatment option in autoimmune diseases 
In autoimmune diseases that are characterized by the production of autoantibodies, as for 
example SLE or immune thrombocytopenia (ITP), tissue destruction is driven by constant ligation 
of activating Fc receptors by immune complexes. This in turn leads to proinflammatory 
responses and chronic inflammation through the activation of macrophages and other Fc 
receptor expressing cells. Cell debris further activate the immune response, perpetuating the 
cycle of autoantigen presentation and generation of autoantibodies. In ITP for example, the body 
develops autoantibodies against several platelet surface antigens, resulting in the destruction of 
platelets by splenic macrophages and hence in a low platelet count (Cines & Blanchette, 2002; 
Coopamah et al, 2003; Rodeghiero et al, 2009). Treatment of ITP and other Ig driven 
autoimmune disease involves immune suppressive drugs as corticosteroids and immunoglobulin 
therapy. In persistent or chronic ITP depletion of the B cell compartment by rituximab, a 
monoclonal antibody against the pan B cell marker CD20 or splenectomy are applied (Cines & 
Bussel, 2005). However, a new promising treatment option for Ig mediated autoimmune diseases 
is provided by a recombinant soluble FcγRIIB as antagonist for the membrane bound Fc 
receptors in immune-complex binding (Sondermann, 2016). Early studies already revealed the 
therapeutic potential of recombinantly expressed soluble Fcγ receptors in immune complex 
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mediated tissue damage. Several in vitro and in vivo studies revealed that soluble Fcγ receptors 
interfere with the formation of immune complexes and their binding to membrane bound Fcγ 
receptors, thereby inhibit immune cell activation (Gavin et al, 1995; Wines et al, 2003; Astier et al, 
1994). Ierino et al showed that recombinant human FγRII competes with membrane bound FcγR 
in vitro and that it inhibited immune-complex mediated inflammatory response (Arthus reaction) 
in a rat model (Ierino et al, 1993). Another study revealed an ameliorative effect of recombinant 
soluble FcγIIIa in the disease course of SLE in lupus prone NZB/NZW mice, characterized by 
lowered levels of autoantibodies and an improved disease course (Watanabe et al, 1998). A new 
generation of recombinant human soluble FcγRIIB was expressed in E. coli to prevent 
contamination and crossreaction through co-purified TGF-β (Sondermann & Jacob, 1999; 
Sondermann et al, 1999; Galon et al, 1995). Successful preclinical studies revealed amelioration 
and suppression of the disease course in rheumatoid arthritis-, SLE- and epidermolysis bullosa 
acquisita-animal models also with the E. coli-derived soluble FcγRIIB (Magnusson et al, 2008; 
Werwitzke et al, 2008; Iwata et al, 2015; Sondermann, 2016). A Phase 0/Ia clinical trial revealed 
excellent safety and tolerability of the sFcγRIIB in healthy volunteers (Tillmanns et al 2011). 
Moreover, the sFcγRIIB has been tested in phase II clinical studies in patients with chronic ITP or 
SLE with promising results (Konstantinova 2012, Tillmanns 2014). After only a single cycle of 
treatment with four infusions of 12 mg/kg sFcγRIIB, patients with chronic ITP exhibited a 
sustained increase in platelet counts from 30 x 109/L to a median platelet count of 70 x 109/L for 
up to three months (Konstantinova, 2012). Although, the sFcγRIIB efficiently can compete for 
pathogenic immune complexes, this is, due to the short half-life time of sFcγRIIB, no sufficient 
explanation for the long term effect observed in ITP patients. Moreover, it is conceivable that the 
sFcγRIIB also interacts with the Fc portion of membrane IgG as part of the BCR and hence 
interferes with the activation of memory B cells and formation of plasma cells. Whether the 
sFcγRIIB is capable of binding to the IgG-BCR and whether it interferes with BCR mediated 
signaling has been investigated as part of this thesis.  
1.2.7.3 The enigmatic FcµR 
Another Fc receptor that has been recently discovered to be expressed on B cells is the long 
sought-after Fc receptor for IgM, the FcµR. It was originally designated as Toso/Faim3 with 
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inhibitory activity on Fas mediated apoptosis and was rediscovered as Fc receptor solely binding 
IgM seven years ago (Kubagawa et al, 2009). The cellular distribution of the FcµR is still 
controversially discussed. RNA expression analyses in human and mice revealed broad transcript 
expression in almost all lymphoid and myeloid cells, while the highest transcript levels were 
measured in B cells (Choi et al, 2013; Hitoshi et al, 1998; Shima et al, 2010). However, reports 
about FcµR protein expression are quite divergent. Kubagawa et al. initially reported that FcµR 
expression is restricted to T-, B- and NK cell in human and to B cells in mice which was confirmed 
for mice by Ohno et al. (Kubagawa et al, 2009; Shima et al, 2010). On the other hand, another 
group found the FcµR to be expressed also on myeloid cells, including monocytes, macrophages, 
granulocytes and DCs (Lang et al, 2013; Lang et al, 2015). As divergent as reports about FcµR 
expression are studies dealing with the phenotype of FcµR deficient mice. Two different mouse 
models have been investigated by three groups with conflicting results, especially with regard to 
B cell development and distribution of B cells (summarized in Wang et al, 2016). However, all of 
them commonly observed increased levels of autoreactive antibodies (Choi et al, 2013; Honjo et 
al, 2012; Ouchida et al, 2012).  
Results from the same studies revealed a positive modulatory role of the FcµR in tonic BCR 
signaling as well as a reduction in proliferation and survival following BCR activation of splenic 
B cells isolated from FcµR-/- mice in vitro (Ouchida et al, 2012; Choi et al, 2013). Hence, these 
results reveal a regulatory role of FcµR in BCR signaling mediating survival. Accordingly, ligation 
of FcµR led to serine and tyrosine phosphorylation of its cytoplasmic domain in B cells and to 
PLCγ and Erk activation in NK cells (Kubagawa et al, 2009; Murakami et al, 2012). However, 
different from other Fc receptors the FcµR lacks a conventional ITAM or ITIM, but the 
cytoplasmic tail contains three other conserved tyrosine residues. The most C terminal tyrosine 
constitutes a putative phosphorylation motif (DYIN) which matches the ITT motif (DYXN) present 
in membrane IgG/E and thereby is a potential docking site for Grb2 (Kubagawa et al, 2009). Thus, 
it is conceivable that the FcµR mediates signal integration via the ITT-like motif by the 
recruitment of Grb2 which due to several interaction partners provides multiple possibilities to 
interfere with signal transduction. Examination of the FcµR-ITT-like motif as a potential Grb2 
membrane anchor has been part of this thesis. 
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1.3 Aims of this study 
My PhD thesis is divided into three parts addressing the following issues: 
1 Investigation of regulation of intracellular B cell antigen receptor signaling events by a 
recombinant soluble FcγIIB receptor 
The recombinant soluble human FcγRIIB as a new treatment option for Ig mediated autoimmune 
diseases is proposed to have a dual mode of function: On the one hand it prevents binding of 
immune complexes to membrane bound FcγRs. On the other hand, it could also interact with 
membrane bound IgG as part of the BCR on memory B cells and thus interfere with the 
formation of antibody producing plasma cells. Here, I addressed whether the soluble FcγRIIB is 
able to bind to the IgG-BCR and affects BCR signaling events in vitro. 
2 Investigation of the Erk signaling pathway following BCR activation in human B cells 
The activation of Erk following BCR activation is a critical determinant in B cell development and 
differentiation. Studies addressing the mechanisms of Erk activation were mainly performed in 
chicken cells and mice suggesting a neglectable role of Grb2 in Erk activation. However, 
stimulation of B cells with FcγRIIB suggested an alternative route for BCR mediated Erk activation 
in humans independent of PLCγ2 activity and Ca2+ mobilization. I analyzed activation of Erk 
following BCR stimulation with regard to the role of Grb2 in human B cells.  
3 Elucidation of the molecular characteristics and signaling properties of the FcµR 
The adapter protein Grb2 was shown to be recruited to several (co)receptors upon ligation and 
phosphorylation of the latter. Thereby it contributes to negative and positive regulation of BCR 
signaling. The recently discovered FcµR carries a putative Grb2 docking site (ITT-like motif) in its 
cytoplasmic domain but lacks conventional signaling motifs. Here, I examined the putative ITT-
like motif of the FcµR in terms of Grb2 recruitment and signaling properties. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Instruments 
Table 1. Instruments used in this thesis. 
Instrument/Application Manufacturer 
Agarose Gelelectrophoresis System Peqlab 
Balance BP61 Sartorius 
Balance H95 Sartorius 
BioPhotometer Eppendorf 
BD FACSCaliburTM Becton Dickinson 
Cell culture incubator HeraCell 150 CO2 Heraeus 
Centrifuge RC 3B Plus Sorvall® 
Chemi Lux Gel Imager Intas Science Imaging 
Electrophoresis power supply EPS 301 Amersham 
Electrophoresis system Agarose gels Peqlab 
Electrophoresis system Hoefer SE600 Amersham 
Flow cytometer LSR II Becton Dickinson 
Freezer HERAfreeze Heraeus 
Freezer Platilab 340 Angelantoni life science 
Ice machine Ziegra 
Incubation shaker Unitron Infors 
Incubator Kelvitron t Heraeus 
Laminar flow cabinet HERA safe Heraeus 
Light microscope TELAVAL 31 Zeiss 
Magnetic stirrer M21/1 Framo® Gerätetechnik 
Mastercycler epgradient Eppendorf 
Microcentrifuge 5415D Eppendorf 
Microcentrifuge 5417R Eppendorf 
Mini PROTEAN Tetra Cell Electrophoresis system Biorad 
Multifuge 3SR Heraeus 
NanoDrop 2000 Thermo scientific 
Neubauer improved cell counting chamber Laboroptik 
NucleofectorTM II Device  Amaxa/Lonza 
pH-Meter inoLab ® WTW 
Rocking shaker Neolab 




Semiphor Transphor Unit TE77 Amersham 
Shaker 3006 GFL 
Ultrasonic device Sonoplus Bandelin  
Thermomixer comfort Eppendorf 
UV illuminator Intas systems 
Vortex Genie 2 Scientific industries 
Water purification system arium 611 Sartorius 
Water bath  Schütt Labortechnik 
 
2.1.2 Consumables 
Table 2. Consumables used in this study. 
Name Manufacturer 
1.5 ml, 2 ml reaction tubes Greiner bio-one 
10 ml Syringes BD Bioscience 
14 ml reaction tubes Greiner bio-one 
15 ml, 20 ml reaction tubes Greiner bio-one 
2 ml, 5 ml, 10 ml, 25 ml serological pipettes Greiner bio-one 
5 ml flow cytometry tubes Sarstedt 
60 mm, 100 mm, 145 mm dishes Greiner bio-one 
96 well suspension culture plates Greiner bio-one 
Cryo tubes Greiner bio-one 
Filter tips Greiner bio-one 
Nitrocellulose membrane Hybond ECL Amersham biosciences 
Parafilm American national can 
PCR tubes 0.2 ml Sarstedt 
Photometer cuvettes Roth 
Pipette tips Greiner bio-one 
Pipette tips Greiner bio-one 
Sterile filter Filtropur, S 0.2, S 0.45 Sarstedt 
Whatman filter paper GE Healthcare 
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2.1.3 Chemicals and reagents 
Table 3. Chemicals and reagents used in this study 
Name Manufacturer 
Acrylamide Rotiphorese Gel 30 Roth 
Agar-Agar Roth 
Agarose Peqlab 
Ammonium persulfate (APS) Roth 
Ampicillin Roth 
L-Arginine:HCl (13C6) Cambridge Isotope Lab 
Bovine serum albumin Serva 
Brom-chlor:indoxyl-β-D-galactosid (X-gal) Roth 
Bromphenol blue Merck 
100x Bovine serum albumin (BSA) NEB 
Calcium chloride (CaCl2) Merck 
Coomassie Brillant Blue R-250 Roth 
Cytofix™ Fixation Buffer Becton Dickinson 
Dimethyl sulfoxide (DMSO) Roth 
DNA ladder GeneRuler 1 kb Fermentas 
Deoxynucleoside triphosphpate (dNTP) mix NEB 
Dithiothreitol (DTT) Roth 
Ethylendiaminetetraacetic acid (EDTA) Roth 
Ethanol Roth 
Ethidium bromide Roth 
Fetal calf serum (FCS), dialyzed  PAN biotech  




Hydrogen peroxide (H2O2) Roth 
Hydrochloric acid (HCl) Roth 
4-(2-hydroxyethyl)-1-piperazineethansulfonic acid (HEPES) Roth 
Hexadimethrine bromide (polybrene) Sigma Aldrich 
Igepal CA-630 (NP40) Sigma Aldrich 
Indo-1 AM Life technologies 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Roth 
Isopropanol Roth 
Kanamycin Roth 
Luminol Sigma Aldrich 




L-Lysine:2HCl (4,4,5,5-D4)  Cambridge Isotope Lab 
Magnesium chloride (MgCl2) Roth 
Methanol (MeOH)  Roth 
NEBuffer 1, 2, 3, 4, Cutsmart NEB 
NuPAGE LDS sample buffer Invitrogen 
NuPAGE sample reducing agent Invitrogen 
p-Coumaric acid Sigma Aldrich 
Penicillin Sigma Aldrich 
Phosflow™ Perm/Wash Buffer I, 10x Becton Dickinson 
Phusion HF reaction buffer NEB 
Phusion GC reaction buffer NEB 
Pluronic F-127 Life technologies 
Potassium chloride (KCl) Roth 
Potassium dihydrogen phosphate (KH2PO4) Merck 
Prestained protein marker broad range NEB 
Protease Inhibitor Cocktail P2714 Sigma Aldrich 
Puromycin InvivoGEN 
Sodium azide (NaN3) Roth 
Sodium chloride (NaCl) Roth 
Sodium dodecyl sulfate (SDS) Roth 
di-Sodium hydrogen phosphate (Na2HPO4) Roth 
Sodium orthovanadate (Na3VO4) Sigma Aldrich 
Streptomycin Sigmal Aldrich 
T4 DNA Ligase buffer NEB 
Tetramethylethylenediamine (TEMED) Roth 
Trans-IT® 293 transfection reagent Mirus 
Tris (hydroxymethyl)-aminomethane (Tris) Roth 
Triton X-100 Roth 
Trypsin Gibco 
Trypton/Pepton Roth 
Tween 20  Roth 
Yeast extract Roth 
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2.1.4 Buffers and solutions 
Table 4. Buffers and solutions 
Name Composition 
Antibody dilution solution 1 % BSA, 0.01 % NaN3 in TBS-Tween 
Blotting buffer 48 mM Tris, 39 mM glycine, 0.0375 % SDS, 0.001 % NaN3, 
20 % MeOH, ddH2O  
Coomassie staining solution 40 % MeOH, 10 % HOAc, 0.1 % Coomassie Brilliant Blue 
R250 in ddH2O 
Coomassie destaining solution 40 % MeOH. 10 % 10 % HOAc, in ddH2O 
6x DNA loading buffer 60 mM EDTA, 10 mM Tris/HCl, 60 % glycerol, 0.03 % 
bromophenol blue, pH7.6, in ddH2O 
ECL solution 4 ml ECL solution A, 400 µl ECL solution B,  
1.2 µl H2O2 (30 %) 
ECL Solution SA 100 mM Tris/HCl, 0.28 mM Luminol, pH 8.6, in ddH2O 
ECL solution SB 6.7 mM p-coumaric acid in 100 % DMSO 
Krebs-Ringer solution  140 mM NaCl, 10 mM D-Glucose, 10 mM HEPES, 4 mM KCl, 
1 mM MgCl2 (1 mM CaCl2), in ddH2O 
4x Laemmli loading buffer  250 mM Tris/HCl (pH 6.8), 8 % SDS, 35 % Glycerol, 0.04 % 
bromophenol blue, 0.3 M DTT in ddH2O 
NP-40 Lysis buffer 137 mM NaCl, 50 mM Tris/HCl (pH 7.8), 0.5 mM EDTA (pH 
8), 10 % Glycerol, 1 % NP-40; added freshly: 1:50 protease 
inhibitor cocktail, 1 mM Sodium orthovanadate (Na3VO4), 
in ddH2O 
PBS 137 mM NaCl, 2.4 mM KCl, 4.3 mM Na2HPO4, 1.4 mM 
KH2PO4. pH 7.4, in ddH2O 
SDS-PAGE buffer 192 mM glycine, 25 mM Tris, 0.1 % SDS, in ddH20 
Resolving gel buffer 1.5 M Tris, pH 8.8, in ddH2O 
Stacking gel buffer 0.5 M Tris (pH 6.8), in ddH2O 
TAG lysis buffer 10 mM Tris (pH 8), 50 mM KCl, 0.45 & NP40, 0.45 % 
Tween 20 in in ddH2O 
TAE buffer 40 mM Tris/HOAc, 10 mM NaOAc, 1 mM EDTA, pH 7.8, in 
ddH2O 
TBS-T 137 mM NaCl, 20 mM Tris, 0.1 % Tween20, pH 7.6, in 
ddH2O 
Western blot blocking solution 5 % BSA, 0.01 % NaN3 in TBS-T 
 




Table 5. Oligonucleotides used in this study 
Oligonucleotides Sequence Application 
EcoRI GRAPEx2_fwd ATAGAATCCGCACTGAGGAACGAGGGCTT Cloning 
EcoRI GRAPEx2_rev GTACTTAAGTGGCTCACGTCCTCAGTGT Cloning 
EcoRI_PLCy1_fwd ATAGAATTCTGGCGGGCGCCGCGTCCCCTTGC Cloning 
EcoRI_PLCy1_rev ATAGAATTCCTAAAGGCGGTTGTCTCCATTGACCCG Cloning 
EcoRI-p46SHC1 fwd ATAGAATTCTGGCTGCATCCCAACGACAAAGTC Cloning 
EcoRI-p52SHC1 fwd ATAGAATTCCATGAGGCCCTGGACATGAACA Cloning 
EcoRI-PLCy1fwd ATAGAATTCCTGGCGGGCGCCGCGTCCCCTTGC Cloning 
EcoRI-PLCy1fwd ATAGAATTCCTGGCGGGCGCCGCGTCCCCTTGC Cloning 
EcoRI-PLCy1rev ATAGAATTCGGAAGGCCGCCACAGGGGGCTGC Cloning 
EcoRI-PLCy1rev ATAGAATTCGGAAGGCCGCCACAGGGGGCTGC Cloning 
EcoRI-SHC1rev ATAGAATTCTCACAGTTTCCGCTCCACAGGTTG Cloning 
FcmR ITT_fwd CAGCAGACGATCTCCGATGACTACATAAACGTGCCTGGGCAGGGAGCCTC Mutagenesis 
FcmR ITT_rev GAGGCTCCCTGCCCAGGCACGTTTATGTAGTCATCGGAGATCGTCTGCTG Mutagenesis 
g2aFcmR ITT (YF)_fwd CGATCTCCGATGACTTCATAAACGTGCCTGG Mutagenesis 
g2aFcmR ITT (YF)_rev CCAGGCACGTTTATGAAGTCATCGGAGATCG Mutagenesis 
GRAPEx2_fwd GCACTGAGGAACGAGGGCTT Cloning 
GRAPEx2_rev GTGGCTCACGTCCTCAGTGT Cloning 
GRB2 R86K fwd  GATGGGGCCTTTCTTATCAAAGAGAGTGAGAGCGCTC Mutagenesis 
GRB2 R86K rev  GAGCGCTCTCACTCTCTTTGATAAGAAAGGCCCCATC Mutagenesis 
GRB2 SH2 R86L_fwd GGCCTTTCTTATCCTAGAGAGTGAGAGCG Mutagenesis 
GRB2 SH2 R86L_rev CGCTCTCACTCTCTAGGATAAGAAAGGCC Mutagenesis 
GRB2 W193K fwd  GATAACTCAGATCCCAATAAGTGGAAAGGGGCCTGCC Mutagenesis 
GRB2 W193K fwd  GGCAGGCCCCTTTCCACTTATTGGGATCTGAGTTATC Mutagenesis 
GRB2 W36K fwd  CGAAGAATGTGATCAGAACAAGTACAAGTACAAGGCAGAGCTTAATG Mutagenesis 
GRB2 W36K rev  CATTAAGCTCTGCCTTGTACTTGTTCTGATCACATTCTTCG Mutagenesis 
hFcmRcyt_fwd ATAAGGGTACCGGCCGTTGAAAGGAGGAAA Cloning 
hFcmRcyt_rev GTAGGATCCGAATTCTCAGGCAGGAACATTGATGTAG Cloning 
hFcmRYF_fwd ATTCAGATGACTTCATCATGTTCCTG Mutagenesis 
hFcmRYF_rev CAGGAACATTGATGAAGTCATCTGAAT Mutagenesis 
IGHG_fwd ATGGACTGGACCTGGAGGATC Cloning 
IGHG1 TAG-TGG_fwd CTTCTTCAAGGTGAAGTGGATCTTCTCCTCGGTGG Mutagenesis 
IGHG1 TAG-TGG_rev CCACCGAGGAGAAGATCCACTTCACCTTGAAGAAG Mutagenesis 
IGHG1 Xho1_fwd GCTGGAATTCGCCCTTACTCGAGTCCACCAAGGGCCCATC Cloning 
IGHG1 Xho1_rev GATGGGCCCTTGGTGGACTCGAGTAAGGGCGAATTCCAGC Cloning 
IGHG1_rev ATAGAATTCCTAGGCCCCCTGTCCGATCATGTT Cloning 
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Oligonucleotides Sequence Application 
IgMG Xho1_fwd GTCTTCCCCCTCGAGTCCTGCGAGAGCC Cloning 
IgMG Xho1_rev GGCTCTCGCAGGACTCGAGGGGGAAGAC Cloning 
PLCy2 Ex2 EcoRI fw ATA GAA TCC CGA TTC CTT CCT TCT CC  Cloning 
PLCy2 Ex2 EcoRI rev GTA CTT AAG CTA TGA GTT TCT GCA GGC Cloning 
PLCy2 Ex2001 fwd TCCCGATTCCTTCCTTCTCC Cloning 
PLCy2 Ex2001 rev AGCTATGAGTTTCTGCAGGC Cloning 
SHC1Ex5TV2fwd GGTGCTAAGGGGAGATCTAG Cloning 
SHC1Ex5TV2rev TGATTCACAGGGTCTTTGGC Cloning 
SHC1Guide#5fwd CACCGCAAATGAGATAGATTGCATG CRISPR  
SHC1Guide#5rev AAACCATGCAATCTATCTCATTTGC CRISPR  
 
2.1.6 Enzymes 
Table 6. Enzymes used in this study 
Enzymes Company 
Calf intestine phosphatase (Cip) NEB 
Dpn1 NEB 
Phusion® DNA polymerase NEB 
Plasmid-SafeTM Biozym 
Restriction endonucleases NEB 
Taq DNA polymerase NEB 
T4 DNA Ligase NEB 
 
2.1.7 Reaction systems (Kits) 
Table 7. Ready-to-use reaction systems.  
Kit Company 
CD19 pluriBead® Cell separation kit pluriselect 
First strand cDNA synthesis Kit Fermentas 
Human B cell nucelofector® Kit Lonza 
Invisorb® spin plasmid mini two Invitek 
NucleoSpin® RNA  Macherey-Nagel 
The original TA cloning® kit Invitrogen 
Wizard® SV Gel and PCR clean up kit Promega 




Table 8. Cloning vectors 
Vector cDNA Source  
pBluescript IgG/M N. Engels 
pBluescript IgG/M_Xho1 This thesis 
pBluescript VH-IGHG1 This thesis 
pBluescript VH-IGHG1 TAG-TGG This thesis 
pCR 2.1 hFcmR-Cyt This thesis 
pCR TOPO IGHG1 This thesis 
pCR TOPO IGHG1_Xho1 This thesis 
pCR2.1 CD8/hFcmR-Cyt This thesis 
pCR2.1 CD8/hFcmR-Cyt (Y385F) This thesis 
pCR2.1 CD8/αITT N. Engels 
pCR2.1 g2a wt N. Engels 
pCR2.1 g2a-(ITT-Fcmr) This thesis 
pCR2.1 g2a-(ITT-Fcmr) YF This thesis 
pCR2.1 g2a-DAP10 N. Engels 
PCR2.1 g2aFcmR (Y385F) This thesis 
PCR2.1 g2aFcmR WT This thesis 
pCR2.1 GRAP N. Engels 
PCR2.1 hFcmRcyt (Nhe1) This thesis 
pCR2.1 mGrb2 R86K L. König 
pCR2.1 mGrb2 W193K L. König 
pCR2.1 mGrb2 W36K L. König 
pCR2.1 mGrb2 W36K R86L W193K This thesis 
pCR2.1 mGrb2 wt L. König 
pCR2.1 SHC1 p46 This thesis 
pCR2.1 SHC1 p52 This thesis 
pCR-Blunt II TOPO hFcmR(Y385F) This thesis 
pCR-Blunt II TOPO human FcµR H. Kubagawa 
pCR-XL-TOPO PLCy1 Dharmacon 
p-OTB7 SHC1 p52 complete cDNA Dharmacon 
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Table 9. Retroviral expression vectors 
Construct Description Source  
pMSCV-puro CD8/hFcmR-Cyt This thesis 
pMSCV-puro CD8/hFcmR-Cyt (Y385F)   This thesis 
pMSCV-puro g2a wt This thesis 
pMSCV-puro g2a YF This thesis 
pMSCV-puro g2a-(ITT-Fcmr) This thesis 
pMSCV-puro g2a-(ITT-Fcmr) YF This thesis 
pMSCV-puro g2aFcmR (Y385F) This thesis 
pMSCV-puro g2aFcmR wt This thesis 
pMSCV-puro GFP K. Schulz 
pMSCV-puro GRAP This thesis 
pMSCV-puro hFcmR This thesis 
pMSCV-puro hFcmR (Y385F) This thesis 
pMSCV-puro mGrb2 R86K This thesis 
pMSCV-puro mGrb2 W193K This thesis 
pMSCV-puro mGrb2 W36K This thesis 
pMSCV-puro mGrb2 W36K R86L W193K This thesis 
pMSCV-puro mGrb2 wt This thesis 
pMSCV-puro RasGRP3-HA K. Gronke 
pMSCV-puro VH-IGHG1 This thesis 
pMSCV-puro VH-IGHG1 TAG-TGG This thesis 
pMSCV-puro/monomeric GFP/T7 tag PLCy2 N. Engels 
pMSCVpuro-IE - C. Hitzing 
pMSCVpuro-pCitrine PLCγ1 This thesis 
 
Table 10. GST expression vectors 
Vector Insert Source 
pGEX-4T1 Grb2-SH2 N. Engels 
pGEX-4T1 Grb2-SH2 R86L N. Engels 
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Table 11. TALEN and CRISPR/Cas cloning vectors 
Vector Source 
pTAL4Titanium C. Hitzing 
pFusA5A C. Hitzing 
pFusA5B C. Hitzing 
pFusA5C C. Hitzing 
pFusB1B C. Hitzing 
pFusB2B C. Hitzing 
pFusB3B C. Hitzing 
pFusB4B C. Hitzing 
pFusB4 C. Hitzing 
pSpCas9(BB)-2A-GFP Addgene 
 
Table 12. Transient expression vectors for gene targeting 
Vector Insert Source 
pmaxKS IRES EGFP GRAP Ex2 TAL1 This thesis 
pmaxKS IRES EGFP PLCG1 Ex2-3 TAL1 K. Vanshylla 
pmaxKS IRES EGFP PLCG2 Ex2 TAL1 This thesis 
pmaxKS IRES tagRFP  GRAP Ex2 TAL2 This thesis 
pmaxKS IRES tagRFP PLCG1 Ex2-3 TAL2 K. Vanshylla 
pmaxKS IRES tagRFP PLCG2 Ex2 TAL2 This thesis 
pSpCas9(BB)-2A-GFP SHC1 Ex5 This thesis 
 
2.1.9 Software and data bases 
Table 13. Software 
Application Name Manufacturer 
Flow cytometer data acquisition  FACSDiva BD Bioscience 
Flow cytometer data analysis Flowjo Treestar 
Image processing ImageJ W. Rasband 
Sequence data analysis Clone manager Sci-Ed software 
Sequence data analysis Finch TV Geospiza 
Text processing Microsoft office  Microsoft 
Western blot documentation Chemostar professional Intas 
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Table 14. Data bases 
Program Application 
http://crispr.mit.edu/ CRISPR design 
http://web.expasy.org/translate/ DNA-Protein translation 
http://www.ensembl.org/index.html Genomic blast 
http://www.ncbi.nlm.nih.gov/ Genomic blast 
http://bioinfo.ut.ee/primer3-0.4.0/ Primer design 
http://www.uniprot.org/ Protein information  
http://multalin.toulouse.inra.fr/multalin/ Sequence alignment 
https://tale-nt.cac.cornell.edu/node/add/talen TALEN design 
 
2.1.10  Antibodies and B cell stimulation reagents 
Table 15. Antibodies and reagents used for cell stimulation.  
Antibody/reagent Company 
dimeric soluble FcγRIIB provided by SuppreMol, part of Baxalta (now part of Shire) 
goat F(ab’)2 α-human IgG  Jackson Immuno Research 
goat F(ab’)2 α-human IgM  Jackson Immuno Research 
goat F(ab’)2 α-mouse IgG  Jackson Immuno Research 
goat-α-mouse IgG-BIOT Southern biotech 
monomeric soluble FcγRIIB provided by SuppreMol, part of Baxalta (now part of Shire) 
monomeric soluble FcγRIIB-bio provided by SuppreMol, part of Baxalta (now part of Shire) 
streptavidin Jackson Immuno Research 
 
Table 16. Primary antibodies for Western blot analysis. Primary antibodies were diluted according to the 
manufacturer’s instructions in 1% BSA/TBS-T and 0.01 % NaN3  
Primary antibody Isotype Company 
α-Actin rabbit Sigma Aldrich 
α-Actin mouse IgG2b CST 
α-BLNK mouse IgG2a Becton Dickinson 
α-BTK rabbit CST 
α-CD79a (EP3618) rabbit Abcam 
α-Erk mouse IgG2a Becton Dickinson 
α-FYB/SLAP130 mouse IgG1 Becton Dickinson 
α-GRAP rabbit ATLAS antibodies 
α-Grb2 (3F2) mouse IgG1 Millipore 
α-pAkt (Ser473) (D9E) rabbit CST 
α-pBLNK (Tyr96) rabbit CST 
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Primary antibody Isotype Company 
α-pErk (E10) mouse IgG1 CST 
α-PLCγ1 rabbit Santa Cruz 
α-PLCγ2 rabbit Santa Cruz 
α-RasGRP1 mouse IgG1 Santa Cruz 
α-RasGRP2 rabbit Abcam 
α-RasGRP3 mouse IgG1 Santa Cruz 
α-SHC (HPA046595) rabbit Abcam 
 
Table 17. Secondary antibodies for Western blot analysis. Secondary antibodies were diluted 1:10000 in TBS-T 
Secondary antibody Isotype Company 
α- mouse IgG1-HRP goat Southern biotech 
α-mouse IgG2a-HRP goat Southern biotech 
α-mouse IgG2b-HRP goat Southern biotech 
α-mouse IgG-HRP goat Southern biotech 
α-rabbit IgG-HRP goat Southern biotech 
 
Table 18. Antibodies for FACS analysis 
Antibody Fluorochrome Isotype Company 
α-human IgM FITC goat F(ab’)2 Southern biotech 
α-CD19  PE-Cy7 mouse Becton Dickinson 
α-human IgG FITC goat Southern biotech 
α-mouse IgG2a Cy5 goat Southern biotech 
α-pErk (Thr202/Tyr204)  ALEXA Fluor® 647 mouse IgG1 Becton Dickinson 
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2.1.11  Media  
Table 19. Media for eukaryotic cell lines 
Medium Company Cell type Supplements 
DMEM  Merck Millipore Plat E 10 % FCS 
1 % Penicillin/Streptomycin 
1 mM L-Glutamine  




10 % FCS 
1 % Penicillin/Streptomycin 
1 mM L-Glutamine 
SILAC RPMI 1640 Thermo scientific  10 % dialyzed FCS,  
0.12mM L-arginine (13C6) (+6), 
0.27mM L-lysine (4,4,5,5-D4) 
(+4), 1 % Penicillin/Streptomycin 
 
Table 20. Media for bacteria. LB medium was used for E.coli Top10F’ or gene hogs; YT medium was used for protein 
expression in E.coli BL21. Before use, media were autoclaved for 30 min at 121°C, 1.25 bar. For selection, media were 
supplemented with the respective antibiotics: 100 µg/ml Ampicillin, 50 µg/l Kanamycin, 50 µg/ml Spectinomycin, 10 
µg/ml Tetracyclin. 
Medium Ingredients 
LB medium 10 g/l tryptone 
5 g/l yeast extract 
5 g/l NaCl 
pH 7  
YT medium 16 g/l tryptone 
15 g/l yeast extract 
5 g/l NaCl 
pH7 
 
2.1.12  Bacteria 
Table 21. Bacterial strains used in this study. TOP10F’ were  
Strain Manufacturer 
One Shot TOP10F’ chemically competent E.coli Invitrogen 
One Shot BL21 (DE3) chemically competent E.coli Invitrogen 
ElectrocompTM GeneHogs® E Invitrogen 
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2.1.13  Eukaryotic cell lines 
DG75 (DSMZ-No: ACC 83) 
Human burkitt lymphoma cell line derived from a pleural effusion of a 10-year old boy with 
Burkitt lymphoma (refractory, terminal) in 1975. Epstein-Barr virus (EBV)-negative suspension cell 
line that expresses IgM paired with a κ light chain (membrane bound and secreted) (Gabay et al, 
1999). In this work DG75 EB (EcoBlast) cells (generated by L. König) transduced with an ecotropic 
receptor were used to enable efficient retroviral transduction with ecotropic viruses 
Table 22. Knock-out cell lines derived from DG75. 
Genetic background Source 
BTK-/- W. Schulze (Engels et al, 2014) 
GRAP-/- This work 
GRB2-/- J. Lutz (Engels et al, 2014) 
GRB2/GRAP-/- This work 
PLCG1-/- K.Vanshylla, unpublished 
PLCG1/2-/- This work 
PLCG2-/- This work 
SHC1-/- This work 
SLP65-/- C. Hitzing (PhD thesis 2015) 
 
DOHH-2 
Non-Hodgkin’s lymphoma derived, EBV-negative B cell line expressing surface IgG paired with a 
λ light chain (Kluin-Nelemans et al, 1991)  
HF-1 
Phenotypically mature EBV-negative B cell line derived from a patient with follicular lymphoma 
expressing surface IgG paired with a κ light chain (Eray et al, 1994). 




SUDHL (Southwestern University Diffuse Histiocytic Lymphoma) 4 is a diffuse histiocytic 
lymphoma cell line expressing surface IgG paired with a κ light chain. (Epstein & Kaplan, 1979) 
Raji 
Burkitt’s lymphoma derived EBV-positive B cell line expressing surface IgM with κ light chain 
(Epstein et al, 1966). 
Ramos 
Burkitt’s lymphoma derived EBV-negative B cell line expressing surface IgM with λ light chain 
(Klein et al, 1975). 
JURKAT 
Immortalized T cell line isolated from peripheral blood of a boy with T-cell leukemia (Schneider 
et al, 1977). 
Platinum-E (PlatE) 
HEK 293T-derived retroviral packaging cell line stably transfected with the structural genes gag, 
pol and env of the moloney murine leukemia virus (MMLV) for generation of viral particles used 
for retroviral transduction (Morita et al, 2000). 
2.2 Methods 
2.2.3 Molecular Biology 
2.2.3.1  Isolation of genomic DNA 
To isolate genomic DNA from human B cell lines, cells were collected and washed in PBS. 1x106 
cells were resuspended in 200 µl Tag lysis buffer plus 1 µl proteinase K and incubated at 55°C for 
3 h, following a 15 min incubation step at 95°C. Lysates were either directly used for polymerase 
chain reaction (PCR) or stored at -20°C until further use.  
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2.2.3.2  Generation of cDNA libraries 
Isolation of mRNA 
Isolation of mRNA was performed by using a NucleoSpin® RNA reaction kit (Macherey-Nagel) 
according to the manufacturer’s recommendations. mRNA concentrations were measured by the 
NanoDrop 2000 (Thermo scientific). mRNA was directly used for transcription to cDNA or stored 
at -80°C until further use.  
Reverse transcription of mRNA 
For reverse transcription of mRNA into cDNA the First strand cDNA synthesis Kit (Fermentas) was 
used following the manufacturer’s instructions regarding single strand cDNA synthesis. cDNA 
was directly used for PCR or stored at -20°C until further use.  
2.2.3.3 Polymerase chain reaction (PCR) 
Primer design 
Primers were designed by using the web based program primer 3 (http://primer3.ut.ee/) 
considering the following guidelines (Primer guidelines, Howard Judelson, 10.06, p. 1):  
1. Melting temperature (Tm) between 55 and 65°C (usually corresponds to 45-55% G+C for 
a 20-mer) 
2. Absence of dimerization capability 
3. Absence of significant hairpin formation (usually >3 bp) 
4. Lack of secondary priming sites in the template 
5. Low specific binding at the 3' end, to avoid mispriming 
Primers were ordered and synthesized from eurofins MWG.  
PCR sample preparation and amplification program 
Amplification of DNA fragments from cDNA templates or genomic DNA was performed by using 
PCR. Therefore, in general Phusion® DNA polymerase was used. Samples were prepared 
according to the protocol supplied with the polymerase as depicted in the following table (table 
23). 
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Table 23. Composition of the PCR reaction mix  
Vol [µl] Reagent Final Concentration 
10 5x Phusion® HF buffer or GC buffer(*) 1x 
1 dNTPs (10 mM, New England Biolabs) 200 µM 
2.5 Forward primer (10 µM) 0.5 µM 
2.5 Reverse primer (10 µM) 0.5 µM 
1.25 DMSO (optional) 2,5% 
1 Template 50–250 ng/µl 
0.5 Phusion® polymerase (2,000 units/ml); New England Biolabs) 1 Units/50 µl PCR 
 ddH2O (to 50 µl)  
(* GC buffer was used for DNA templates with high GC content) 
The PCR was carried out following the protocol supplied with the Phusion® polymerase (New 
England Biolabs) as designated in the subsequent table (table 2). Annealing temperature was 
adjusted to ca. 3 -5°C below the melting temperature of the primers (Tmprimer). Elongation time 
was chosen according to the size of the template (30 sec/kb). 
Table 24. Standard PCR program  
 Step Temperature Time 
 Initial denaturation 98°C 5 min 
35 
cycles 
Denaturation 98°C 30 sec 
Annealing x °C (*) 10 sec 
Elongation 72°C 30 sec/kb 
 Final Elongation 72°C 10 Min 
 Stop 11°C ∞ 
* Annealing temperature = Tmprimer – 3-5°C 
PCR products were separated and analyzed by agarose gel electrophoresis. For further use the 
DNA was extracted from the gel by using the Promega Wizard® SV Gel and PCR Clean-Up 
System 
2.2.3.4  Site directed mutagenesis 
In order to change single bases within a cDNA-containing plasmid to achieve the exchange of 
single amino acids within the respective protein, PCR site-directed mutagenesis (SDM) was 
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performed. Thereby, the whole plasmid serves as a template and needs to be amplified. To this 
end, complementary primers with the desired mutation were designed and analyzed by using 
the web-based program primer x (http://www.bioinformatics.org/primerx/) considering the 
following guidelines. 
 1. Primer length: between 25 and 45 bases  
2. Melting temperature ≥ 78°C (considering the percentage of mismatch) 
3. The desired mutation should be in the middle of the primer with ~10-15 bases of correct 
sequence on both sides 
4. GC content: at least 40 % 
5. Primer should terminate in one or more C or G bases 
PCR reaction mix and PCR program were chosen as described in the previous section (table 23 & 
24). Following PCR, the PCR product was incubated with 1 µl of Dpn1 for 1 h at 37°C in order to 
enzymatically remove the original plasmid. Amplification of the plasmid and digest of the 
original plasmid by Dpn1 were analyzed by agarose gel electrophoresis. After Dpn1 treatment, 
2 µl of the reaction mix were used for transformation of competent bacteria (Top10’).  
2.2.3.5 Restriction enzyme digest 
Preparative digest 
Preparative digest of DNA was performed in order to prepare for ligation of DNA fragments; 
usually for ligation of an insert into another vector backbone. Therefore, 2-3 µg of DNA were 
incubated with the respective restriction enzyme(s) (NEB) and the appropriate buffer 
composition according to the manufacturer’s instructions for 2-3 h at 37°C. If only one enzyme 
was used for restriction digest, the vector backbone had to be additionally treated with Calf 
intestinal alkaline phosphatase (Cip; NEB) for at least 45 min to prevent re-ligation of the vector 
backbone due to self-compatible ends. DNA fragments were separated by agarose gel 
electrophoresis followed by gel extraction.  




For analytical digest the reaction mix was assembled as above-mentioned according to the 
manufacturer’s instructions regarding the respective enzyme. Incubation was performed for 1 h 
at 37°C. The digest was analyzed by agarose gel electrophoresis.  
2.2.3.6 Agarose gel electrophoresis 
The agarose gel was prepared by dissolving the appropriate amount of 0.7-2% agarose (Peqlab) 
in TAE buffer and heating of the suspension to near-boiling point. After cooling of the melted 
agarose to ∼50°C, 0.1 % (v/v) ethidium bromide were added and the agarose was poured into a 
horizontal casting tray with a comb to create the sample wells. Once the gel has set completely, 
the gel was transferred to the agarose gel electrophoresis chamber (Peqlab) and covered with 
TEA buffer. The comb was removed and the samples were loaded after addition of 6x DNA 
loading buffer. Agarose gel electrophoresis was performed at 220 mA and 100 V for 30-45 min. 
2.2.3.7 Purification of DNA from agarose gel  
DNA fragments were extracted from agarose gels by using the Promega Wizard®SV Gel and 
PCR Clean-Up System. Therefore, the bands corresponding to the size of the product were cut 
out and extracted following the manufacturer’s instructions. DNA was eluted with 40 µl of 
nuclease free H2O.  
2.2.3.8 TA cloning 
Cloning of PCR products into the pCR2.1 vector via TA cloning requires the addition of a 
3’-adenine overhang at each end of the PCR product. Therefore, PCR products were run on 
agarose gel and purified as described in section 2.2.3.7. After purification, DNA was eluted in 20 
µl nuclease free water instead of 40 µl. For the reaction 2 µl of Taq buffer, 1 mM of dATPs and 
0.2 µl of Taq polymerase were added and the mix was incubated at 72°C for 20 min. Afterwards, 
the DNA fragment was ligated into pCR2.1 topo as described in the following section and used 
for bacterial transformation. Blue-white selection was used to check for success of ligation. 
Therefore, transformed bacteria were plated along with 40 µl Brom-chlor:indoxyl-β-D-galactosid 
(XGal; 50 mg/ml in DMF) and 40 µl 0.1 M Isopropyl-β-D-thiogalactopyranoside (IPTG). Bacteria 
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that incorporated a plasmid with inserted DNA fragment formed white colonies, while Bacteria 
carrying a plasmid without insert formed blue colonies.  
2.2.3.9 Ligation of DNA fragments 
Following purification from agarose gel (section 2.2.3.7), DNA fragments were ligated according 
to the protocol supplied by NEB. Therefore, 4 µl of DNA insert were mixed with 0.5-1 µl of the 
respective vector, 0.5 µl T4-DNA ligase, and 1 µl 10x ligase buffer. The total volume was adjusted 
to 10 µl with ddH2O. The ligation mix was incubated either for 1 h at room temperature or 
overnight at 16°C. Afterwards, ligation mix was ready for transformation of bacteria.  
2.2.3.10 Transformation of chemically competent bacteria 
For transformation, 2-5 µl of plasmid DNA were added to an aliquot of chemically competent 
bacteria (TOP10F’, GeneHog or BL21). After 30 min incubation on ice the bacteria were incubated 
at 42°C for 30 s, followed by a 2 min incubation step on ice. Bacteria transformed with plasmids 
carrying an ampicillin resistance were plated directly on selective LB agar plates. Bacteria 
transformed with kanamycin-resistance plasmids required a further incubation step in 1 ml of 
antibiotic-free LB medium at 37°C for at least 30 min. Plated bacteria were incubated at 37°C for 
12-16 hours maximum. 
2.2.3.11 Preparation of Plasmid DNA 
In order to expand bacteria for isolation of Plasmid DNA, 4 ml of selective LB medium were 
inoculated with single clones from plated bacteria and incubated at 37°C for 12-16 hours. 
Preparation of plasmid DNA was performed using the Invisorb® Spin Plasmid Mini Two 
preparation kit (Invitek) according to the manufacturer’s instructions. Different from the protocol, 
elution of DNA was done in 40 µl nuclease free water instead of 50 µl of the supplied elution 
solution.  
2.2.3.12 Sequencing of DNA 
Sequence validation of PCR products or plasmids was performed by the DNA sequencing service 
of the company Seqlab (Sequence Laboratories, Goettingen). In preparation for the 
sequencing 1.2 µg of the DNA sample were added to a total volume of 15 µl (filled up 
  Materials and Methods 
40 
 
with ddH2O). Sequencing primers were either added directly to the mix in a total concentration 
of 30 pmol or chosen from the Seqlab standard primer list. 
2.2.4 Genome editing techniques 
In order to generate constitutive knock-out cell lines, two techniques, namely the Transcription 
Activator-like Effector Nuclease (TALEN) -based or the Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR)/Cas-based genome editing technique were applied. Both 
techniques are useful tools to target distinct DNA sequences in order to modify genes of interest 
by introduction of double strand breaks. The cell’s DNA repair mechanisms induce errors leading 
to an incomplete or unfunctional gene product (Pu et al, 2015). 
Transcription activator-like effector nucleases (TALEN) are composed of a TAL effector DNA 
binding domain (TALE) that can be engineered to bind any DNA sequence and a nuclease (FokI) 
(figure 5 a). The tandemly arranged modules of the DNA binding domain consist of 34 amino 
acids, which are almost identical for each repeat; except for two amino acids at position 12 and 
13 termed repeat variable diresidue (RVD). Four different variants of RVDs that either bind G, A, T 
or C, establish the DNA binding specificity of the DNA binding domain. Since the FokI activity 
requires dimerization, a TALEN pair needs to be generated recognizing DNA sequences to the 
left and to the right site of the intended cut site (Pu et al, 2015). Assembly of the tandem repeats 
of the DNA binding domain specific for a desired target requires several steps of cloning. The 
CRISPR/Cas genome editing technique uses a so called guide RNA (gRNA), which specifically 
binds to the target DNA, to direct the nuclease (Cas9) to the desired cut site (figure 5b). 
Furthermore, for efficient DNA binding, the Cas9 requires a protospacer adjacent motif (PAM) 
adjacent to the 5’ end of the targeted DNA region. The Cas9 introduces double-strand breaks 
(DSBs) ∼3 bp upstream of the PAM sequence (Ran et al, 2013, Pu et al, 2015). In contrast to the 
TALEN-technique the CRISPR/Cas system only requires a single step of cloning which makes the 
design of constructs much easier.  




Figure 5. Genome editing by TALEN- and CRISPR/Cas sytems. (a) TALEN-based genome editing. Tandem repeats of 
the DNA-binding domains (TALE) depicted in blue, green, red and purple spheres bind to the target sequences 
(orange; N being any nucleotide) in order to induce dimerization of the nuclease FokI (grey) leading to induction of a 
double strand break (DSB). (b) CRISPR/Cas-based genome editing. Guide RNA (gRNA) pairs with the nuclease Cas9 
(red) and together with the protospacer adjacent motif (PAM) guides it to the target sequence (orange; N being any 
nucleotide) in order to induce a DSB (modified from Pu et al, 2015) 
 
2.2.4.1 TALEN-based genome editing  
TALEN design and Golden Gate TALEN assembly 
TALEN constructs were planned by using the web based program “TAL Effector Nucleotide 
Targeter 2.0” (https://tale-nt.cac.cornell.edu/). Thereby, the TALEN cut site was chosen to lie 
within a suitable restriction site for later activity tests. TALEN assembly was performed following 
the protocol supplied with the Golden Gate TALEN and TAL Effector Kit 2.0 (addgene; modified; 
see also PhD thesis, C. Hitzing). After TALEN assembly, the two constructs encoding the TALEN 
pair were subcloned into two different pMAX vectors carrying a red fluorescent protein (RFP) or 
green fluorescent protein (GFP) expression cassette, respectively. Both constructs were 
introduced simultaneously into DG75 B cells by nucleofection as described in section 2.2.6.4. RFP 
and GFP expressing, double positive cells were enriched by flow cytometry based cell sorting as 
a 
b 
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described in section 2.2.6.7 48 h after electroporation. Once the cells have recovered from the 
cell sorting procedure, they were subcultured by seeding one cell per well in 96 well plates.  
Activity test 
To test the activity of the TALEN constructs, genomic DNA was isolated from the population by 
cell sorting. Following, the exon targeted by the TALEN constructs was amplified by PCR. The 
PCR product was separated on agarose gel and extracted from the gel. Different from the gel 
extraction protocol, the DNA was eluted in 20 µl instead of 40 µl. The purified PCR product was 
incubated with the appropriate restriction enzyme according to the manufacturer’s instructions. 
The digested PCR product was analyzed by agarose gel electrophoresis. TALEN constructs could 
be confirmed as active, once the restriction site was no longer intact, leading to an incomplete 
digest of the PCR product. 
Screening of potential knock out clones 
Single cell clones were expanded and analyzed for deficiency of the respective protein by 
Western blot analysis (2.2.5.7). Single cell clones that displayed low expression or a complete lack 
of expression were subjected to sequence analysis of the exon to verify the defect on DNA level. 
Therefore, the exon targeted by the TALEN constructs was amplified by PCR from genomic DNA 
of the single cell clone. The PCR product was subcloned into pCR2.1 in order to get a single 
sequence of each allele of the exon. To confirm the exon sequence, at least seven exons were 
sent for sequencing. Cells were considered as knock-out cell lines, when both alleles of an exon 
showed a deletion, leading to an early stop codon. 
2.2.4.2 CRISPR/Cas–based genome editing  
For cloning of CRISPR/Cas-based genome editing constructs I used a pSpCas9(BB)-2A-GFP 
vector (gift from the Zhang lab; addgene plasmid #48138), which encodes all necessary elements 
on one vector. Design of guide RNA was performed by using the CRISPR/Cas Design software 
(http://crispr.mit.edu/). Guide RNAs were selected that had a high score, which corresponds to 
low numbers of off-targets and that overlapped with a restriction site for later activity tests. 
Phosphorylated oligonucleotides encoding the guide RNA were ordered from eurofins MWG. 
Assembly of the CRISPR/Cas construct was performed according to the protocol of the Zhang 
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lab (Ran et al, 2013). Following steps including nucelofection, activity test and screening of 
potential knock-out clones were conducted as described for the TALEN-based genome editing 
method (2.2.4.1). 
2.2.5 Biochemistry  
2.2.5.1  Stimulation of the B cell receptor for signaling analysis 
Cells were harvested by centrifugation (300 rcf, 4 min) and washed 1x with PBS. Subsequently, 
cells were starved in R0 medium (RPMI w/o FCS) at 37°C for 30 min in order to reduce 
stimulatory effects due to the FCS. For expression and phosphorylation studies 1-2x106 cells per 
sample were reconstituted in 100 µl R0, while for interaction studies (affinity purification or 
immunoprecipitation) 3-4x107  cells per sample were reconstituted in 1 ml of R0. Following 
starvation, the cells were stimulated via the BCR with 10 µg/ml anti (α)-IgM F(ab’)2 or  α-IgG 
F(ab’)2, depending on the Ig isotype of the respective cell type. Stimulation was performed at 
37°C and stimulation times were chosen according to the type of experiment. In order to stop 
the stimulation process, cells were pelleted quickly by a short run of centrifugation and washed 
once with ice cold PBS (300 rcf, 4°C). Subsequently, cells were lysed as described in the next 
section (2.2.5.2). 
2.2.5.2 Preparation of cleared cellular lysates  
For preparation of cleared cellular lysates (CCL), cells were resuspended in 20 µl of 0.1% NP40 
lysis buffer per 1x106 cells and incubated on ice for at least 15 min. For lysis of higher cell 
numbers, incubation was performed at 4°C under mild rotation. Following lysis, the cytosolic 
fraction was cleared from nuclei and cell debris by centrifugation at 16000 rcf, 4°C for 15 min. 
The supernatant was transferred to a fresh 1.5 ml Eppendorf tube and supplemented with 
one-fourth volume of 4x Laemmli loading buffer in preparation for the SDS-PAGE. Samples were 
boiled at 95°C for 3 min and stored at -20°C until further use. 
2.2.5.3 Immunoprecipitation  
For immunoprecipitation (IP) 35x106 cells were stimulated and lysed as described before (2.2.5.2). 
For mIgG-IP cells were directly stimulated with 10 µg/ml of the precipitating antibody 
(biotinylated- goat-α-mouse IgG; Southern biotech) instead of  α-IgG F(ab’)2. In order to 
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precipitate the IgG-BCR, lysates were incubated with Streptavidin Sepharose® Bead Conjugate 
(CST) for 1 h at 4°C under mild rotation. Following, the beads were washed 3x with NP-40 lysis 
buffer, resuspended in 30 µl 4x Laemmli buffer and boiled at 95°C. Lysates were either stored at -
20°C until further use or analyzed directly on SDS-PAGE/Western Blot.  
2.2.5.4 Affinity purification  
Expression and purification of GST fusion proteins 
GST fusion proteins for affinity purification were produced in the E.coli strain BL21. Therefore, 
bacteria were transformed with the respective cDNA cloned into the bacterial expression vector 
pGEX as described before (2.2.3.10) Single colonies were transferred to 4 ml 2YT medium, grown 
over night at 37°C under mild agitation (300 rcf) and transferred to a 50 ml culture the next day. 
Cell expansion was controlled by measuring the optical density (OD) at 600 nm. Protein 
expression was induced at an OD600 = 0.6 with 100 µM IPTG at 37°C and mild agitation for 3-5 h. 
Expression of the construct coding for GST-Grb2-SH2 R86L required incubation at 25°C instead 
of 37°C in order to increase protein yield. Afterwards, cells were pelleted by centrifugation (3000 
rcf, 30 min) and the supernatant discarded. At this point cells were either stored at -80°C until 
further use, or directly resuspended in 2 ml PBS plus proteinase inhibitor (50x). Cells were lysed 
by sonication (3x 30 sec, 1 cycle, 50 %) on ice. Subsequently, lysates were supplemented with 
0.25 % of 10 % TritonX-100 and incubated on ice for 30 min. Afterwards, lysates were cleared by 
centrifugation at 6000 rcf and 4°C for 20 min. 100 µl Glutathione Sepharose 4B (GE healthcare) 
were washed once in PBS in order to remove containing ethanol and added to the cleared 
lysates. Samples were incubated for 2 h at 4°C under mild agitation. Following, beads were 
washed twice with PBS and reconstituted in 100 µl PBS for storage. Purification yield of the 
samples was determined by running 2 µl of the sample along with a BSA standard on SDS-PAGE 
following Coomassie staining.  
GST-pulldown assay 
For GST-pulldown assay, 35x106 cells per sample were stimulated via the BCR and lysed as 
described before (2.2.5.2). After clearance of lysates by centrifugation, lysates were mixed with 
∼10 µg of GST-fusion protein (equal ca. 25-30 µl of bead slurry) and incubated for 1h at 4°C 
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under mild rotation. Subsequently, beads were washed 3x with NP-40 lysis buffer by 
centrifugation (500 rcf, 4°C) and proteins were eluted by adding 30 µl of 4x Laemmli buffer 
boiling at 95°C for 3 min. Afterwards, samples were directly analyzed by SDS-PAGE and Western 
Blot or stored at -20°C until further use. 
2.2.5.5 SDS polyacrylamide gel electrophoresis 
For separation of proteins from CCLs, affinity purification or IP samples, discontinuous SDS-PAGE 
(sodium dodecyl sulfate polyacrylamide gel electrophoresis) was used, as originally established 
by U. Laemmli. SDS-PAGE facilitates separation of proteins according to their electrophoretic 
mobility (size, conformation and charge) under denaturing conditions (Laemmli, 1970). 
Discontinuous polyacrylamide gels consist of a stacking gel for initial concentration of the 
proteins and a resolving gel for separation of proteins. Solution for each, stacking and resolving 
gel, were prepared as depicted in the following table (table 25)  
Table 25. Composition of Resolving and Stacking gel for SDS polyacrylamide gel electrophoresis 
Reagent Resolving gel Stacking gel 
1.5 M Tris/HCL (pH 8.8) 375 mM - 
0.5 M Tris/HCL (pH 6.8)  125 mM 
Acrylamid 10 % 4.8 % 
TEMED* 0.1 % 0.1 % 
10 % APS*  0.1 % 0.1 % 
ddH2O To final volume To final volume 
*TEMED and APS were added directly before polymerization 
First, the resolving gel was polymerized between two glass plates before the stacking gel was 
casted on top with a comb to form sample wells. After polymerization, samples were loaded 
along with a Prestained protein marker broad range (NEB). Gel electrophoresis was performed by 
using either the Mini PROTEAN system (Biorad) at a current of 15-25 mA or the electrophoresis 
system Hoefer SE600 (Amersham) at a current of 7-10 mA (o/n) or 20-40 mA (by day). Following 
SDS-PAGE, the gel was either subjected to Coomassie staining or Immunoblot. 
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2.2.5.6 Coomassie staining 
For unspecific visualization of proteins separated on SDS-PAGE the dye Coomassie Brilliant Blue 
R-250 was used. Therefore, the gel was stained in Coomassie Brilliant Blue for 10-20 min at RT. 
Following, the gel was incubated in Coomassie destaining solution for 20 min or in ddH2O o/n at 
RT in order to destain the polyacrylamide gel and visualize the proteins.  
2.2.5.7 Western blot 
For specific analysis of proteins by immunoblot the cellular lysates separated on SDS PAGE were 
transferred from the gel to a nitrocellulose membrane by using the semi dry western blot 
technique (Towbin et al, 1992). Therefore, the nitrocellulose membrane, the gel and two pieces 
of Whattman paper were equilibrated in 1x blotting buffer. To facilitate transfer of negatively 
charged proteins to the nitrocellulose membrane, the components were assembled in the 
following order from the bottom to the top: [Cathode] – bottom Whattman paper – 
nitrocellulose membrane – SDS gel – upper Whattman paper - [Anode]. Transfer was performed 
with constant amperage of 1 mA/cm² for 70 min. Voltage was restricted to 16 V. Following 
transfer, the membrane was incubated in blocking solution (5% BSA in TBS-
Tween + 0.1 % NaN3).  
Incubation with primary antibody was performed at 4°C o/n or at RT for 1h. Afterwards, the 
membrane was washed with TBS-Tween three times for 20 min before it was incubated with a 
HRP-labeled secondary antibody (1:10 000 in TBS-T) for 1 h at RT. Following, the membrane was 
washed again three times for 20 min with TBS-T. The immobilized proteins were visualized by 
adding ECL solution to the membrane. The emitted chemiluminescence resulting from the 
reaction of the HRP with the ECL solution was recorded by the Chemi Lux Gel Imager (Intas).  
2.2.6 Cell Biology 
2.2.6.2 Cell culture and maintenance  
All human B cell lines were cultured in RPMI supplemented with 10% FCS, 1 % 
Penicillin/Streptomycin and 1 mM L-Glutamine (further referred to as R10 medium). For 
maintenance DG75 and SUDHL4, cells were splitted every second day in a 1:10 ratio, while HF1 
cells were splitted every second day in a 1:5 ratio. The retroviral packaging cell line Platinum-E 
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(PlatE) was cultured in DMEM medium supplemented with 10%FCS, 1 % Penicillin/Streptomycin 
and 1 mM L-Glutamine (further referred to as D10 medium). For maintenance PlatE cells were 
splitted every 2-3 days in a 1:10 ratio. 
2.2.6.3 SILAC labeling of human B cell lines 
The cells were cultured in SILAC RPMI-1640 medium containing 0.12 mM L-arginine (13C6) (+6) 
and 0.27 mM L-lysine (4,4,5,5-D4) (+4), 10 % dialyzed FCS and Penicillin/Streptomycin. To 
achieve a complete labeling, the cells were cultured at least for five to six passages in this 
medium. The unlabeled control cells were cultured in RPMI-1640 medium supplemented with 10 
% dialyzed FCS and Penicillin/Streptomycin. 
2.2.6.4 Amaxa ® Nucelofection  
Nucleofection of human B cell lines was performed by using the Amaxa® Human B Cell 
Nucleofector® Kit. To this end, cells were grown to a density of less than 1x106 cells/ml. On day 
of nucleofection, 3x106 cells per sample were harvested by centrifugation. The supernatant was 
removed completely. Subsequently, cells were resuspended in the nucleofection suspension, 
consisting of 82 µl Human B cell nucleofector solution, 18 µl of Supplement 1 and 2 µg of the 
respective DNA. The cell/DNA suspension was transferred to a cuvette supplied with the kit and 
inserted into the NucleofectorTM II device (Amaxa/Lonza). Transfection was accomplished by 
using program T-015. Afterwards, cells were seeded in a 5 cm culture dish in prewarmed R10.  
2.2.6.5 Retroviral transduction of human B cell lines 
Transfection of PlatE cells 
In preparation of the retroviral transduction of human B cell lines, the virus-packaging cell line 
PlatE was transfected with the respective plasmid DNA in order to produce virus particles. 
Therefore, PlatE cells were plated ca. 24 h before transfection on a 5 cm Petri dish in DMEM with 
a ratio of 1:5 in order to achieve around 70% confluence the next day. Transfection of PlatE cells 
was performed by using the TransIT transfection reagent (Mirus). For each sample 8 µl TransIT 
were added to 250 µl R0 medium and incubated at RT for 15 min. Subsequently, 3-5 µg of the 
respective plasmid DNA (and if required 1 µg of the VSV-G pMSCV plasmid) were added, mixed 
and again incubated at RT for 15-30 min. Meanwhile, the D10 medium was removed from the 
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PlatE cells and replaced by 2.5 ml of fresh prewarmed R10 medium. After incubation, the DNA 
mix was added dropwise to the PlatE cells. After 24 h the medium of the transfected PlatE cells 
was filled up to a total volume of 5 ml with R10 medium.  
Infection of B cell lines 
48 h after transfection of PlatE cells the virus containing supernatant (virus-supe) was collected 
and used for infection of B cell lines. Therefore, 5 ml of the virus-supe were supplemented with 
4 mg/ml Polybrene and centrifuged at 300 rcf for 4 min in order to remove detached PlatE cells. 
Meanwhile, 2x106 B cells were collected, resuspended in 500µl R10 medium, combined with the 
virus-supe and transferred to a 5 cm Petri dish. After 24 h the Polybrene was removed by 
centrifugation and the cells were reconstituted in fresh R10 medium. Once the cells had 
recovered from the infection process, cells expressing the transduced construct were selected by 
addition of the respective antibiotic to the culture.  
2.2.6.6 Isolation of human primary B cells from peripheral blood  
Isolation of human primary B cells from peripheral blood was performed by using the 
CD19 pluriBead® Cell separation kit (pluriselect) following the manufacturers protocol. Blood 
from healthy donors was collected and supplemented with 30 µl heparin per 50 ml blood to 
prevent coagulation. Different from the protocol, 5 µl of CD19 pluriBeads® were added to 1 ml 
blood. Purity of isolated B cells was checked by surface staining of CD19 after 30 min incubation 
in R10 at 37°C and 5 % CO2 or by surface staining of CD20. 
2.2.6.7 Flow cytometry 
Staining of cell surface proteins 
For detection of cell surface proteins/receptors 1x106 cells were harvested by centrifugation and 
washed 1x with PBS. Cells were reconstituted in 300 µl PBS and transferred to FACS tubes. The 
fluorescence-labeled antibodies used for surface staining were diluted according to the 
manufacturer’s recommendations. After 20 min incubation on ice, cells were washed 1x with ice 
cold PBS and reconstituted in 300 µl PBS for flow cytometric measurement.  
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Detection of phosphorylated protein by intracellular flow cytometry 
If required, cells were stimulated as described in section 2.2.5.1 Per sample, 0.5-1x106 
subconfluently cultured cells were harvested and washed once in PBS. Subsequently, cells were 
reconstituted in 100 µl R0 and starved for 20-30 min at 37°C. Following, cells were stimulated via 
the BCR either with 10 µg/ml α-IgM F(ab’)2 or α-IgG F(ab’)2 depending on the Ig isotype of the 
respective cell type for different time points. Reaction was stopped by adding an equal volume 
of Cytofix™ Fixation Buffer (Becton Dickinson) and cells were incubated for 10 more minutes at 
37°C for fixation. Afterwards, cells were centrifuged at 500 rcf for 8 min and the supernatant was 
discarded. For permeabilisation, cells were reconstituted in 400 µl 1x Phosflow™ Perm/Wash 
Buffer I, incubated for 20 min at room temperature and washed 1x with 400 µl 1x Perm/Wash 
Buffer I. Following, cells were reconstituted in 100 µl Perm/Wash buffer again and stained with 
the respective antibody for 30-60 min. Antibodies were applied as described by the 
manufacturer, expect for Alexa Flour® 647 Mouse Α-Erk1/2 (pT202/pY204); here, 10 µl per 1x106 
cells instead of 20 µl were used. Following staining, samples were filled up with 1 ml 1x 
Perm/Wash Buffer I, and again centrifuged for 8 min at 500 rcf. The supernatant was discarded 
and cells were reconstituted in 300 µl Perm/Wash buffer for flow cytometric measurement.   
Ca2+ mobilization assay 
Mobilization of Ca2+ is a key event in BCR signaling. Intracellular Ca2+ concentration can be 
measured by using Indo-1-AM, a Ca2+ sensitive, cell-permeable, ratiometric dye, which shifts its 
fluorescence emission wavelength upon Ca2+ binding from 475 nm (blue) to 400 nm (violet). For 
Ca2+ mobilization assays, cells were grown to a density less than 1x106 cells per ml in order to 
prevent preactivation caused by stress. 1x106 cells were harvested by centrifugation and 
transferred to light-opaque microcentrifuge tube. Cells were loaded with 1 µM Indo-1-AM in 
700 µl R10 medium supplemented with 0.015 % pluronic acid. Following incubation at 30°C for 
30 min, samples were filled-up with 750 µl of R10 medium and were incubated for another 
10 min at 37°C. Afterwards, cells were washed 2x by centrifugation (1.5 min, 300 rcf) with Krebs-
Ringer buffer supplemented with 1 mM CaCl2. Finally, 1x10
6 cells were reconstituted in 300 µl 
Krebs-Ringer buffer and incubated at 30°C for 15 min prior measurement in order to rest and 
minimize preactivation of cells. Measurement of Ca2+ flux was performed at the flow cytometer 
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LSR II (Becton Dickinson). Ca2+ flux was measured 30 s before stimulation in order to record a 
base line of resting cells and 4.5 min after stimulation via the B cell receptor. B cell receptor 
stimulation was performed by using 10 µg/ml α-IgM F(ab’)2 or α-IgG F(ab’)2. Data were analyzed 
using the FlowJo software. 
Cell sorting by Flow Cytometry 
Separation of cell populations with distinct characteristics from a heterogeneous population was 
done by Flow cytometry based cell sorting. This was performed by the Central Service Unit Cell 
Sorting at the University Medical Center in Göttingen. 
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3 Results  
3.1 Regulation of intracellular B cell antigen receptor signaling events by a 
recombinant soluble FcγIIB receptor 
The human recombinant soluble FcγRIIB has currently been tested in clinical trials for the 
treatment of ITP and SLE. The study results revealed a long-lasting therapeutic effect of human 
recombinant soluble FcγRIIB in ITP with a sustained increase in platelet counts after only a single 
cycle of treatment. Consequently, it was assumed that the soluble FcγRIIB has a dual mode of 
action: First, it can compete with membrane-bound Fcγ receptors for immune complex binding 
and hence prevents destruction of platelets and activation of immune cells via membrane FcγRs. 
Second, it is also suggested to interfere with memory B cell and/or plasma cell formation and 
thus with production of new autoantibodies which would explain the observed sustained effects 
in ITP patients. We hypothesized that the human recombinant soluble FcγRIIB interacts with 
membrane IgG (mIgG) as part of the BCR, thereby interfering with memory or plasma cell 
formation. In order to test the hypothesis, I functionally examined human recombinant soluble 
FcγRIIB and related molecules for their direct effects on the B cell response in vitro. 
3.1.1 Cellular system 
Due to the weak binding affinity of sFcγRIIB to IgG, it is not possible to directly prove binding to 
membrane IgG by using fluorescence-labelled sFcγRIIB-antibodies for FACS or 
fluorescence-labelled sFcγRIIB itself. Furthermore, human B cells express endogenous membrane 
FcγRIIB that would additionally complicate the proof of sFcγRIIB on the cell surface. Hence, I 
aimed to investigate the interaction of sFcγRIIB with membrane IgG indirectly by using functional 
read-out methods as Ca2+ mobilization and Western blot analysis of signaling effectors 
downstream of the BCR. Therefore, I compared expression of membrane IgG and the ability of 
BCR induced Ca2+ mobilization in three different IgG-positive human B cell lines, namely the 
follicular lymphoma B cell line HF1, non-Hodgkin’s lymphoma B cell line DOHH-2 and the diffuse 
histiocytic lymphoma cell line SUDHL4. Surface staining of mIgG with FITC-labeled α-human IgG 
on HF-1, DOHH-2 and SUDHL-4 cells (figure 6 a) revealed similar mIgG expression levels, 
whereas Ca2+ mobilization upon stimulation via mIgG was different (figure 6 b). While HF-1 cells 
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(figure 6 b; red line) exhibited the highest mobilization of Ca2+, the Ca2+ profile in DOHH-2 cells 
initially had a similar strength but was not as sustained as compared to HF-1 cells. SUDHL4 cells 
had a low potential to mobilize Ca2+ compared to HF-1 and DOHH-2. Thus, I chose the HF-1 cell 
line as a representative model to investigate signaling induced by sFcγRIIB. 
 
3.1.2 Dimeric and tetrameric sFcγRIIB induce BCR signaling events on IgG expressing B cells 
3.1.2.1  Dimeric sFcγRIIB dose-dependently induces Ca2+ mobilization in IgG+ B cells 
To assess whether the soluble FcγRIIB has an impact on BCR signaling of IgG-positive B cells, I 
stimulated HF-1 cells with different concentrations of monomeric or dimeric sFcγRIIB while Ca2+ 
mobilization was monitored by flow cytometry using the ratiometric Ca2+ sensitive dye Indo-1. 
The human Burkitt lymphoma B cell lines DG75 and Ramos expressing membrane IgM served as 
negative controls. Additionally, I treated the cells with the solvent only, serving as placebo. As an 
internal control, I additionally stimulated the cells via their endogenous IgG- or IgM-BCR by 
using F(ab’)2 α-IgM or F(ab’)2 α-IgG, respectively, in order to test Ca2+ mobilization capacity in 
general. Treatment of the IgG-negative cell lines Ramos and DG75 with either monomeric 
sFcγRIIB or dimeric sFcγRIIB did not induce any Ca2+ mobilization, although Ca2+ mobilization 
following stimulation via the BCR with F(ab’)2 α-IgM was normal (figure 7 a & b). Whilst 
stimulation with monomeric sFcγRIIB did not lead to Ca2+ mobilization in the IgG expressing 
HF-1 cells (figure 7 c; blue lines), stimulation of these cells with dimeric sFcγRIIB induced Ca2+ 
a 
b 
Figure 6. Analysis of potential model IgG-B cell lines. 
a) Surface expression of membrane IgG on the human 
IgG
+
 B cell lines HF-1 DOHH-2 and SUDHL-4. Cells 
were incubated with a fluorescence-labelled antibody 
against hIgG and analyzed for IgG surface expression 
by flow cytometry. b) Different qualities of Ca
2+
 
mobilization of IgG+ cell lines. Cells were stimulated 
with 10 µg/ml α-IgG F(ab’)2 fragments. Ca2+ 
mobilization was monitored for 300 s by flow cytometry 
using the Ca
2+
 sensitive dye Indo-1.  
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mobilization in a dose dependent manner (figure 7 d; red lines). However, the signal induced by 
dimeric sFcγRIIB was weaker but more sustained compared to IgG-stimulation with F(ab’)2 α-
IgG, thus is of different quality. Thus, I assumed that sFcγRIIB is capable of binding to membrane 
IgG. However, monomeric sFcγRIIB that comprises only one binding site for IgG was not 
sufficient to induce signaling events in IgG-positive B cells. Hence, I concluded that sFcγRIIB can 
induce BCR signaling only when it is multimeric, at least dimeric, by cross-linking two or more 
IgG molecules on the cell surface.  
 
 
Figure 7. Dose dependent effects of msFcγRIIB and dsFcγRIIB on Ca
2+
 mobilization in IgG
+




 B cells (DG75 




 B cells (HF-1; c & d) were stimulated via their BCR with 10 µg/ml F(ab’)2 α-IgM or α-IgG or 
different concentrations of msFcγRIIB and dsFcγRIIB. Mobilization of the second messenger Ca
2+
 was monitored by flow 
cytometry for 300 sec using the Ca
2+
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3.1.2.2  Multimeric sFcγRIIB induces BCR signaling events in B cells 
To further test, whether only multimeric sFcγRIIB is able to induce BCR signaling in IgG-positive 
B cells, I used biotin-labeled monomeric sFcγRIIB (sFcγRIIB-bio) that upon interaction with 
streptavidin (SA) forms a stable tetramer. Stimulation with the preformed complex of 
20 µg/ml msFcγRIIB-bio and 1 µg SA induced Ca2+ mobilization in IgG-positive HF-1 cells (figure 
8 a) while stimulation with monomeric sFcγRIIB or SA alone was not sufficient to induce any Ca2+ 
signal. Dose reduction of msFcγRIIB and SA (2 µg/ml + 0.1 µg) correspondingly led to less 
mobilization of Ca2+ in HF-1 cells. Stimulation of IgG-negative DG75 control cells does not 
induce Ca2+ mobilization (figure 8 b).  
To check whether effector proteins downstream of Ca2+ mobilization get activated upon 
stimulation with dimeric and tetrameric sFcγRIIB, I analyzed phosphorylation of Akt and Erk 
kinases (figure 8 c). Therefore, I stimulated HF-1 or DG75 cells with monomeric or tetrameric 
sFcγRIIB (20 µg/ml msFcγRIIB-bio + 1 µg SA). Besides, cells were stimulated via the BCR F(ab’)2 
α-IgM or F(ab’)2 α-IgG as a positive control. Cells were lysed and analyzed by Western blot, 
probing for phosphorylated Akt, SLP65 or Erk. 
The data acquired from the Western blot analysis corresponded to the Ca2+ mobilization data 
regarding Akt and Erk activation. Stimulation with dimeric and tetrameric sFcγRIIB led to 
phosphorylation of Akt and Erk in HF-1 cells, but not in the DG75 control B cells (figure 8 c). The 
activation levels were comparable with Akt- and Erk- phosphorylation following BCR activation 
with F(ab’)2 α IgG. However, stimulation with either dimeric sFcγRIIB or tetrameric sFcγRIIB was 
not sufficient to induce SLP65 (figure 8 d) activation which occurs upstream of Ca2+ mobilization 
and Akt and Erk activation (reviewed in Kurosaki, 1999).  
Taken together, these data reveal that multimeric variants of the sFcγRIIB but not the monomeric 
sFcγRIIB can induce BCR signaling in IgG-positive human B cells with different strength and 
quality compared to conventional BCR activation regarding Ca2+ mobilization and 
phosphorylation of downstream effectors. 
  




Figure 8. Dimeric and tetrameric sFcγRIIB induce signaling events in IgG-positive B cells. HF-1 cells (a) were stimulated with 
10 µg/ml F(ab’)2 α-IgG, 20 µg/ml msFcγRIIB-bio + 1 µg SA, 2 µg/ml msFcγRIIB-bio + 0.1 µg SA, SA only or msFcγRIIB-bio 
only. DG75 cells (b) were stimulated with 10 µg/ml F(ab’)2 α-IgM or 20 µg/ml msFcγRIIB-bio + 1 µg SA (arrow indicates time 
point of stimulation). Ca
2+
 mobilization was monitored for 250 seconds by flow cytometry using the Ca
2+
 sensitive dye Indo-
1. For Western blot analysis (c & d) cells were stimulated with the before mentioned reagents for 3 min. Activation of 
downstream effector proteins as Akt kinase, the adapter protein SLP65 or Erk kinase was analyzed by Western blot, probing 
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3.1.3 Activation of BCR signaling by multimeric sFcγRIIB is IgG-BCR specific 
To test whether the BCR signaling in human IgG-positive B cells induced by treatment with 
multimeric variants of sFcγRIIB is due to specific binding to the IgG-BCR, I exogenously 
expressed the heavy chain of IgG1 in IgG negative DG75 B cells. Once expressed the IgG1 heavy 
chain pairs with the endogenous κ-light chain and forms a functional BCR complex together with 
the endogenous Igα/Igβ heterodimer. The IgG expressing DG75 B cells were termed DG75-hIgG. 
Stimulation of DG75-hIgG with F(ab’)2 α-IgG induced Ca2+ mobilization with exactly the same 
strength as in DG75-hIgG B cells stimulated F(ab’)2 α-IgM (figure 9 a), whereas the control cells 
(DG75 wild type; wt) as expected did not respond to stimulation with F(ab’)2 α-IgG (figure 9 b). 
Correspondingly, Erk and Akt phosphorylation reached the same strength upon stimulation of 
DG75 hIgG cells with F(ab’)2 as compared to stimulation via the endogenous IgM-BCR (figure 9 
c). Upon stimulation with dimeric and tetrameric sFcγRIIB, DG75-hIgG cells exhibited a delayed 
mobilization of Ca2+ compared to stimulation with F(ab’)2 α-IgG with around 40 % of the 
signaling strength (figure 9 a), while in DG75 wt cells stimulation with sFcγRIIB did not induce a 
Ca2+ signal (figure 9 b). However, Akt kinase exhibited only a weak activation after stimulation of 
DG75 hIgG cells with dimeric and tetrameric sFcγRIIB, whilst Erk kinase did not show any 
phosphorylation (figure 9 c). To sum up, the analysis of IgG-positive DG75 transfectants and 
DG75 parental cells treated with multimeric variants of sFcγRIIB confirmed IgG-specific BCR 
signal induction with sFcγRIIB, which is most probably mediated by the interaction of multimeric 
sFcγRIIB with the IgG BCR. 




Figure 9. IgG-BCR-specific stimulation of DG75 B cells retrovirally transduced with hIgG. The IgM expressing human B cell line 
DG75 was retrovirally transduced with the heavy chain of human IgG in order to form an IgG-BCR complex on the cell 
surface. DG75 wt cells served as negative control. For Ca2+ mobilization IgM/IgG double positive DG75 hIgG (a) and DG75 
wt cells (b) were stimulated with 10 µg/ml F(ab’)2 α-IgM, 10 µg/ml F(ab’)2 α-IgG, 40 µg/ml m sFcγRIIB, 20 µg/ml dimeric 
sFcγRIIB or tetrameric sFcγRIIB (25 µg/ml sFcγRIIB-bio + 2 µg SA). Stimulation with 2 µg SA only served as negative control. 
Arrows indicate time point of stimulation Ca
2+
 mobilization was monitored for 250 seconds by flow cytometry using the Ca
2+
 
sensitive dye Indo-1. For Western Blot analysis (c) cells were stimulated with the same reagents as for the Ca
2+
 measurement 
for 3 min. Activation of downstream effector proteins as Akt kinase or Erk kinase was analyzed by Western blot, probing with 
phospho-specific antibodies for the respective protein (p-Erk and p-Akt). Probing for Actin served as loading control.  
 
Here I could show by functional assays that multimeric but not monomeric sFcγRIIB binds to the 
IgG-BCR and induces BCR-specific signaling events. Signaling could only be induced when using 
multimeric variants of FcγRIIB. Although I did not observe signaling, I cannot exclude that the 
monomeric sFcγRIIB does not bind to mIgG. Once multimerized by streptavidin also the 
monomeric variant induces IgG-BCR specific signaling, though with different quality as 
compared to direct BCR stimulation by BCR specific F(ab’)2 Ca2+ mobilization induced by 
multimeric sFcγRIIB was delayed and about 40-70 % weaker than the Ca2+signal induced by BCR 
a b 
c 
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specific F(ab’)2. Although I could observe Ca2+ mobilization, SLP65 activation was not detectable. 
SLP65 is important for the formation of the trimolecular Ca2+ mobilization complex. 
3.2 BCR mediated activation of extracellular signal regulated kinase Erk 
Ligation of the BCR leads to the activation of a wide variety of pathways regulating gene 
expression and hence the fate of B cells. One pathway that gets activated upon BCR ligation is 
the mitogen-activated protein kinase (MAPK)/Erk-pathway resulting in activation of the 
extracellular signal regulated kinase Erk. Erk promotes cell cycle progression, cell survival and 
plays a role in B cell development and differentiation into plasma cells (Yasuda & Kurosaki, 2008; 
Yasuda et al, 2011). Data from DT40 chicken B cells and mouse models revealed that 
BCR-induced activation of Erk in these systems is mediated via RasGRP3 and DAG. RasGRP3 
activity is dependent of the activity of PLCγ2 and thus is accompanied by the mobilization of the 
second messenger Ca2+ (Oh-hora et al, 2003; Coughlin et al, 2005). With the sFcγRIIB I found a 
new tool to stimulate BCR activation only by binding to the Fc portion of the mIgG. However, my 
results showed that stimulation with the sFcγRIIB induces strong activation of Erk independent of 
SLP65 activation, which is important for the formation of the Ca2+ initiation complex and thus for 
the mobilization of Ca2+. From that I hypothesized, that activation of the MAPK/Erk pathway in 
human B cells, different from chicken B cells, occurs independently of Ca2+ mobilization, 
indicating species specific differences between chicken, mice and human B cells. Thus, I revisited 
the BCR signaling pathway with regard to the activation of Erk in the human B cell line DG75 and 
different DG75-derived sublines deficient for various candidates of the BCR pathway.  
3.2.1 Erk activation is independent of mobilization of the second messenger Ca2+  
Activation of PLCγ2 requires the formation of the Ca2+ initiation complex consisting of SLP65, Btk 
and PLCγ2. To investigate the relevance of Ca2+ mobilization in Erk activation in human B-cells, I 
compared Ca2+ mobilization and Erk activation in DG75-sublines deficient for SLP65 (SLP65-/-) or 
Btk (BTK-/-; kindly provided by C. Hitzing and W. Schulze,). Furthermore, I included DG75 B cells 
deficient for the adapter protein Grb2 (GRB2-/-, kindly provided by J. Lutz) in this analysis. Due to 
its permanent association with the guanine nucleotide exchange factor Sos Grb2 was suggested 
to be involved in activation of the MAPK/Erk pathway following BCR stimulation as it was 
described for the EGFR pathway (Lowenstein et al, 1992). 
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For analysis of Erk phosphorylation the different DG75 sub-cell lines were stimulated via the BCR 
and analyzed for Ca2+ mobilization by flow cytometry (figure 10 a) and for phosphorylation of 
Erk by Western blot (figure 10 b) or intracellular staining (ICS) for flow cytometry (figure 10 c & 
d) using phospho-specific antibodies. The relative median fluorescence intensity (MFI) of three 
independent experiments was plotted in a bar diagraph (figure 10 d).  
In accordance to published data, Ca2+ mobilization (figure 10 a) in DG75 B cells deficient for 
SLP65 (SLP65-/-) and Btk (BTK-/-) was up to 50 % diminished compared to parental cells (wt) 
whereas the lack of Grb2 did not have any effect on Ca2+ mobilization. In contrast, both, Western 
blot analysis (figure 10 b) and ICS for phosphorylated Erk (figure 10 c & d) showed a remarkable 
decrease in Erk activation upon 3, 10 and 20 min BCR stimulation in Grb2-deficient DG75 
(GRB2-/-) compared to parental cells (wt), while Erk activation in SLP65- (SLP65-/-) and Btk- (BTK-/-) 
deficient DG75 was not affected. Quantification of ICS data revealed a 50 % decrease of Erk 
phosphorylation in Grb2 deficient DG75 (GRB2-/-) compared to parental cells (wt) (figure 10 d). In 
summary, these results reveal that Erk activation in the human B cell line DG75 does not depend 
on SLP65 or Btk and hence is independent of Ca2+ mobilization. This is in contrast to the 
observations made in the chicken B cell line DT40, which requires Ca2+ mobilization for sufficient 
activation of Erk following BCR induction (Oh-hora et al, 2003). Instead, the adapter protein Grb2 
plays an important role in BCR mediated Erk activation in human B cells.  






independent activation of Erk in human B cells. 
 
(a) Mobilization of Ca
2+





), or Grb2 (GRB2
-/-
) or DG75 parental cells (wt). Cells were loaded with the ratiometric dye Indo-1. 
Baseline was recorded for 30 s before cells were stimulated with 10 µg/ml F(ab’)2 α-IgM. Ca
2+
 mobilization was monitored 
for 300 s by flow cytometry. (b) Western blot analysis of phosphorylated Erk. Cells were stimulated with 10 µg/ml F(ab’)2 α-
IgM for 0, 3, 10 or 20 min, lysed and analyzed by Western blot probing for phosphorylated Erk (α-pErk). Expression of total 
Erk, Grb2, Btk and SLP65 was verified with respective antibodies. Actin served as loading control. (c & d) Intracellular staining 
for phosphorylated Erk. Cells were stimulated with 10 µg/ml F(ab’)2 α-IgM for 0, 3, 10 or 20 min, fixed and permeabilized, 
stained with α-pErk-Alexa 647 and analyzed by flow cytometry. (c) Representative histograms of Erk phosphorylation in 
different DG75 sub-cell lines. (d) fold change of median fluorescence intensity (MFI)/Erk phosphorylation in DG75 sub-cell 
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3.2.2 PLCy is dispensable for the activation of Erk 
Having shown that Erk activation following BCR activation occurs independently of the 
mobilization of Ca2+, I aimed to analyze the role of PLCγ in Erk activation directly. To this end, I 
generated a DG75 sub-cell line deficient for PLCγ2 (PLCG2-/-) and a sub-cell line deficient for 
both, PLCγ1 and 2 (PLCG1/2-/-) using the TALEN-based genome editing technique. PLCγ2 is a key 
molecule in BCR signaling, since it generates the second messenger DAG. Thus, it is 
indispensable for the activation of RasGRP3 and Erk in chicken B cells and mice. PLCγ1 is the 
structural homologue to PLCγ2 and its functional analogue in T cells (Oh-hora et al, 2003; Bell et 
al, 2004; Kane et al, 2000).  
3.2.2.1  Generation of a PLCγ2 deficient cell line  
For targeting the PLCG2 gene by TALEN, I chose exon 2 which according to the ensembl.org 
database is present in all transcript variants (figure 11 a). TALEN constructs were planned by 
using the web based program “TAL Effector Nucleotide Targeter 2.0”. For later activity tests, I 
chose a TALEN pair that locates the nuclease (FokI) to a BsrBI restriction site. In case of a 
functional TALEN pair the restriction site is damaged and cannot be cut by the respective 
restriction enzyme anymore. The two TALEN constructs were cloned in a pMAX vector each, 
carrying either IRES-RFP- or IRES-GFP expression cassette and simultaneously introduced into 
the target cells by nucleofection as described in section 2.2.6.4. Afterwards, RFP+ GFP+ cells were 
enriched by cell sorting. In order to test the activity of the TALEN pair, I amplified exon 2 of 
PLCG2 from DG75 parental cells (wt) or from cells transfected with the TALEN pair by PCR, 
treated the product with BsrBI and analyzed it by agarose gel electrophoresis (figure 11 b). 
Treatment of exon 2 derived from the parental cells (wt) led to cleavage of the exon to a 
fragment of ca. 500 bp and a fragment of around 100 bp (not detectable), while the PCR product 
of exon 2 derived from cells transfected with the TALEN pairs was intact following BsrBI 
treatment (figure 11 b). Thus, the PLCG2-TALEN pair was considered as active. For clonal 
expansion of single-cell clones from the sorted cell population, the cells were diluted and 
subcultured in 96 well plates. After expansion of single-cell clones, PLCγ2 expression was 
analyzed by Western blot. In total, six out of 59 analyzed clones exhibited a PLCγ2 deficiency on 
protein level (figure11 c). Figure 11 d exemplarily shows lack of PLCγ2 expression in clone #33 on 
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Western blot. Three (clone #16, #33 and #45) out of six clones were analyzed by Sanger 
sequencing in order to confirm mutation on genomic level. Therefore, genomic DNA from each 
clone was isolated; Exon 2 was amplified by PCR and cloned into pCR2.1 vector in order to 
sequence both alleles of the exon separately. Subclone #33 was confirmed to carry a 7 bp 
deletion on allele 1 and a 4 bp deletion on allele 2 resulting in a premature stop codon (*) (figure 
11 e). For clone #16 only one allele with a 2bp deletion could be successfully sequenced, while 
clone #45 carries a 22 bp deletion on one allele and a 15 bp (multiple of three) deletion on the 
other allele (not shown). Therefore, clone #33 was used for further experiments, referred to as 
PLCγ2-deficient DG75 (PLCG2-/-).  




Figure 11. Generation of PLCγ2-deficient DG75 cells using TALEN. (a) Genomic organization of the PLCG2 gene. Exon 2 was 
chosen for targeting by TALEN constructs. Binding sites for left and right TALEN constructs are highlighted in orange. Cut site 
of the nuclease (FokI) is indicated by the red arrow. BsrBI restriction site for activity analysis is indicated in green. (b) TALEN 
activity test. Exon 2 was amplified from parental DG75 cells or TALEN-nucleofected cells and treated with BsrBI. Treated PCR 
product was analyzed by agarose gel electrophoresis. (c) Statistics of single-cell clone analysis. Single-cell clones were 
analyzed by Western blot. Clones lacking PLCγ2 expression were further analyzed by Sanger sequencing to verify mutation 
on genomic level. (d) Exemplary Western blot analysis of DG75 PLCG2
-/-
 subclone #33. (e) Genomic DNA sequence and 
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3.2.2.2  Ca2+mobilization in PLCγ2-deficient cells is impaired but not completely abolished 
According textbook knowledge, PLCγ2 is of central importance in mediating the mobilization of 
the second messenger Ca2+ in B cells (Engelke et al, 2007). Hence, I first tested the newly 
generated PLCγ2-deficient DG75 sub-cell line (PLCG2-/-) for its ability to mobilize Ca2+ (figure 12 
a). All clones tested PLCγ2-negative on Western blot exhibited 50 % decrease in Ca2+ 
mobilization compared to parental cells (wt) upon BCR stimulation. Ca2+ profiles of subclone #16, 
#33 and #45 were plotted representatively in figure 12 a. IgM-BCR expression of PLCγ2-deficient 
clones was similar to IgM expression of parental cells (wt), excluding the possibility of low Ca2+ 
mobilization due to low IgM expression (figure 12 b). To test PLCγ2 independent off-target 
effects, I reconstituted PLCγ2-deficient DG75 with EGFP-tagged PLCγ2 and repeated the Ca2+ 
mobilization assay. Reconstitution of PLCγ2-deficient DG75 (PLCG2-/- EGFP-PLCγ2) could restore 
the ability to mobilize Ca2+ entirely and hence rule out unwanted off-targets (figure 12 c & d). 
Nevertheless, considering the role of PLCγ2 it is surprising that the capability of Ca2+ 
mobilization is not completely abolished in these cells. This could be due to other PLC isoforms 
that are expressed in B cells and compensate for the loss of PLCγ2. One candidate is the 
functional analogue of PLCγ2 in T cells, namely PLCγ1, which is also highly expressed in B cells.  




Figure 12. Impaired Ca
2+
 mobilization in PLCγ2-deficient cells. (a) Ca
2+
 mobilization analysis of three representative PLCγ2-
deficient subclones (#16, #33, #45). Baseline was recorded for 30 s before cells were stimulated via the IgM-BCR (time point 
of stimulation is indicated by the arrow). Ca
2+
 mobilization was monitored for 250 s in total by flow cytometry using the 
ratiometric Ca
2+
 sensitive dye Indo-1. (b) IgM-BCR expression level in PLCγ2-deficient clones. 1x10
6
 cells were stained with a 
FITC-labelled α-IgM antibody and analyzed by flow cytometry. (d) Ca
2+
 mobilization assay of PLCγ2-deficient cells 
reconstituted with N-terminally EGFP-tagged PLCγ2 (PLCG2
-/-
 EGFP-PLCγ2), compared to DG75 parental cells (wt) 
transduced with EGFP-only and DG75 PLCG2
-/-
. (d) Expression level of EFGP-tagged PLCγ2 in PLCγ2 deficient DG75 and of 
EGFP only in parental cells (wt). Due to a slight overlap of EGFP and Indo-1 emission wavelength, the control cells DG75 
PLCG2
-/-
 and parental cells (wt) were transduced with EGFP-only for better comparability of the Ca
2+
 mobilization profiles. 
 
3.2.2.3 Generation of a PLCγ1/2-double deficient B cell line 
Since Ca2+ mobilization in PLCγ2-deficient DG75 cells was not completely abolished, I supposed 
that PLCγ2 can be functionally compensated by PLCγ1 which is also highly expressed in human 
B cells. Moreover, it has analogue functions to PLCγ2 in T cells regarding its role in Ca2+ 
mobilization. Hence, I generated a PLCγ1/2-double-deficient sub-cell line (PLCG1/2-/-) on the 
background of PLCγ2-deficient DG75 by TALEN-based genome editing for further investigation 
of Ca2+ independent Erk activation. The TALEN constructs for mutating the PLCG1 gene (kindly 
provided by K. Vanshylla) were designed to target exon 2 in transcript variant PLCG1-005 
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restriction site that was used for later activity tests of the TALEN constructs (figure 13 a). After 
introduction of TALEN constructs by nucleofection, cells were sorted for double positive cells as 
described before, expanded and tested for activity. Therefore, exon 2 of the PLCG1 gene was 
amplified by PCR from parental cells or TALEN-nucleofected cells and treated with BsmFI. Exon 2 
from the parental cells was completely digested by BsmFI, whereas exon 2 from TALEN-treated 
cells is almost completely intact, confirming the activity of the TALEN-constructs in the majority 
of cells from this population (figure 13 b). Following, cells were subcultured to obtain single-cell 
clones and analyzed by Western blot and Sanger sequencing. 18 subclones from 77 analyzed 
clones exhibited a loss of PLCγ1 protein expression. Exemplary Western blot analysis 
(figure 13 d) confirms complete PLCγ1 deficiency in PLCy1 single-deficient DG75 (PLCG1-/-; 
provided by K. Vanshylla) and PLCγ1/2-double deficient DG75 (PLCG1/2-/-) compared to parental 
cells (wt). Three out of four subclones analyzed by Sanger sequencing could be confirmed as 
PLCγ1-deficient on genomic level (figure 13 c). Subclone #2 exhibited a 4 bp deletion on allele 1 
and a 5 bp deletion on the second allele (figure 13 e). For further analysis I used subclone #2, in 
the following referred to as PLCγ1/2-double deficient DG75 (PLCG1/2-/-).  




Figure 13. Generation of PLCγ1/2-double deficient B cell line using TALEN. (a) Exon structure of the PLCG1 gene and 
sequence of the targeted exon 2. TALEN binding sites are highlighted in orange, TALEN cut site is indicated by a red arrow 
and BsmFI restriction site is highlighted in green. (b) TALEN activity test. Exon 2 was amplified from parental DG75 (wt) cells 
or TALEN-nucleofected cells and treated with BsmFI. Treated PCR product was analyzed by agarose gel electrophoresis. (c) 
Statistics of single-cell clone analysis. Single-cell clones were analyzed by Western blot. Clones lacking PLCγ1 expression were 
further analyzed by Sanger sequencing to verify mutation on genomic level. (d) Exemplary Western blot analysis of PLCγ1/2-
double deficient DG75 (PLCG1/2
-/-





). (e) Genomic DNA sequence and corresponding aa sequence of subclone #2 
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3.2.2.4  PLCγ1 and 2 are required for full Ca2+ mobilization in human B cells 
Against current textbook knowledge, I could show that the loss of PLCγ2 in human B cells did 
not lead to a complete abrogation of Ca2+ mobilization upon BCR stimulation. In order to test, 
whether residual Ca2+ mobilization can be attributed to functional compensation by PLCγ1, I 
analyzed the newly established PLCγ1/2-double deficient DG75 sub-cell line (PLCG1/2-/-) with 
regard to Ca2+ mobilization. In total, I analyzed 13 PLCγ1/2-deficient subclones for Ca2+ 
mobilization. Clone #2, #4 and #10 were plotted exemplarily in figure 14 a. In total, Ca2+ 
mobilization upon stimulation via the IgM-BCR was completely abolished in all 13 sublclones. 
IgM-BCR surface expression was similar to IgM expression in parental (wt) cells, excluding the 
possibility of low Ca2+ mobilization due to low IgM expression (figure 14 b).  
Consequently, I concluded, that PLCγ1 indeed can compensate for PLCγ2 function in human B 
cells. To exclude that the effect occurs due to off-target effects, I retrovirally transduced 
PLCγ1/2-double deficient DG75 with N-terminally EGFP-tagged PLCγ1 (PLCG1/2-/- EGFP-PLCγ1) 
and repeated the Ca2+ mobilization assay. Thereby, I compared these cells with untransduced 
PLCγ1/2-double deficient DG75 (PLCG1/2-/-), PLCγ2-deficient DG75 (PLCG2-/-) and DG75 parental 
cells (wt) expressing EGFP only (figure 14 c & d). Expression of citrine-tagged PLCγ1 in PLCγ1/2-
deficient cells could restore Ca2+ mobilization to the Ca2+ mobilization level observed in PLCγ2-
deficient DG75 (PLCG2-/-) (figure 14 c). As Ca2+ mobilization is completely abolished, PLCγ1/2-
double deficient DG75 are a suitable model for studying Ca2+ independent activation of Erk.  




Figure 14. Impaired Ca
2+
 mobilization in the PLCγ1/2-deficient B cells. (a) Ca
2+
 mobilization analysis of three representative 
PLCγ1/2-double deficient DG75 subclones (#2, #4, #10). Baseline was recorded for 30 s before cells were stimulated via the 
IgM-BCR with 10 µg/ml F(ab’)2 (time point of stimulation is indicated by arrow). Ca
2+
 mobilization was monitored for 300 s in 
total by flow cytometry using the ratiometric Ca
2+
 sensitive dye Indo-1. (b) IgM-BCR expression level in PLCγ1/2-double 
deficient DG75 subclones. 1x10
6
 cells were stained with a FITC-labelled α-IgM antibody and analyzed by flow cytometry. (c) 
Ca
2+
 mobilization assay of PLCγ1/2-double deficient DG75 reconstituted with N-terminally EGFP-tagged PLCγ1 (PLCG1/2
-/-
EGFP-PLCγ1), untransduced PLCγ1/2-double deficient DG75 (PLCG1/2
-/-
), PLCγ2-deficient DG75 (PLCG2
-/-
) and DG75 
parental cells (wt) transduced with EGFP-only. (d) Expression level of EFGP-tagged PLCγ1 and EGFP-only. Due to a slight 




 and parental cells (wt) 
were transduced with EGFP-only for better comparability of the Ca
2+
 mobilization profiles. 
 
3.2.2.5 Erk activation in human B cells does not depend on PLCγ activity 
Studies in DT40 chicken B cells and murine B cells revealed that PLCγ2 is indispensable for the 
activation of Erk via RasGRP3 and DAG. Hence, Erk activation in DT40 chicken B cells also 
correlates with the mobilization of Ca2+ (Oh-hora et al, 2003; Coughlin et al, 2005). However, my 
results showed that in the human B cell line DG75, Erk activation is mediated independently of 
the Ca2+ mobilization complex and presumably also independent of the activity of PLCγ, 
reflecting species specific differences between chicken, mice and human. In order to test this 
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(PLCG1/2-/-) with PLCγ1-deficient DG75 (PLCG1-/-) and parental cells (wt) with regard to Ca2+ 
mobilization (figure 15 a) and Erk phosphorylation (figure 15 b-d). As already shown in the 
previous sections, PLCγ2 deficiency alone led to a 50 % decrease in Ca2+ mobilization, while Ca2+ 
mobilization in PLCγ1/2-double deficient DG75 was completely abolished. In contrast, Ca2+ 
mobilization in PLCγ1-single deficient cells is similar to Ca2+mobilization in parental (wt) cells. 
Consequently, PLCγ1 can indeed partially compensate for PLCγ2 function, but does not play a 
major role in Ca2+ mobilization of human B cells (figure 15 a). However, analysis of Erk activation 
by Western blot probing for phosphorylated Erk, revealed no change of Erk phosphorylation in 
all PLCγ-deficient cell lines compared to parental (wt) cells (figure 15 b). This I could confirm by 
intracellular staining for phosphorylated Erk, following stimulation via the BCR for 0, 3, 10 and 20 
min (figure 15 c & d). The bar diagraph (figure 15 d) displays the average of the median 
fluorescence intensity (MFI) of five independent experiments. Taken together, these results 
confirm that Erk activation in the human B cell line DG75 occurs independently of PLCγ. 
 




Figure 15. BCR-mediated Erk activation occurs independently of PLCγ1 and 2. (a) Ca
2+
 mobilization assay of PLCγ-deficient 




), PLCγ1/2-double deficient 
(PLCG1/2
-/-
) and parental DG75 (wt) were stimulated with 10 µg/ml F(ab’)2 α-IgM (time point of stimulation indicated by 
arrow). Mobilization of Ca
2+
 was monitored for 300 s by flow cytometry using the ratiometric dye Indo-1. (b) Western blot 
analysis for phosphorylated Erk. Cells were stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min. Cells were lysed and 
analyzed by Western blot probing for phosphorylated Erk (α-pErk). Expression of total Erk, PLCγ1 and 2 was verified with 
respective antibodies. Actin served as loading control. (c & d) Intracellular staining of phosphorylated Erk. Cells were 
stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min, fixed, permeabilized and analyzed by flow cytometry using an 
ALEXA647 coupled antibody specific for phosphorylated Erk. (c) Representative histograms of Erk phosphorylation in 
different PLCγ-deficient cells. (d) Fold change of median fluorescence intensity (MFI)/Erk phosphorylation in PLCγ-deficient 
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3.2.2 Human B cells exhibit low expression levels of RasGRP 1 and 3 
Since activation of Erk in human B cells is mediated completely independently of PLCγ, I 
concluded that also RasGRP3, which is activated via PLCγ2 and DAG, does not play a role in Erk 
activation in human B cells. However, our model cell line DG75 exhibits low RasGRP3 expression 
levels, which could already limit activation of Erk by RasGRP3. In order to test whether the B cell 
line DG75 is a suitable representative physiological model to study Erk activation in human B 
cells, I compared expression of RasGRPs in DG75 cells with RasGRP expression in human primary 
B cells. To this end, I isolated human primary B cells from peripheral blood of a voluntary donor 
by CD19-positive selection. Isolated B cells were analyzed for CD19 and IgM expression 
(figure 16 a), lysed and analyzed by Western blot analysis for RasGRP expression (figure 16 b). 
Flow cytometry analysis for CD19 and IgM expression revealed a purification yield of 94.2 % 
CD19+ B cells. The major population (86.1 %) expressed IgM, thus it is probably constituted of 
naïve B cells. However, ca. 26 % of the CD19-positive population is IgM-negative. These cells 
probably resemble a memory B cell population (figure 16 a). RasGRP expression in human 
primary B cells was analyzed by Western blot and compared to RasGRP expression of the human 
B cell lines DG75, Raji as well as the human T cell line JURKAT. In contrast to Raji and JURKAT 
cells, DG75 cells and human primary B cells only express low levels of RasGRP1 and RasGRP3. 
However, RasGRP2 expression was detected to similar extents in Raji, DG75 and JURKAT cells, 
whereas human primary B cells expressed higher levels of RasGRP2. Grb2 and GRAP expression 
was equal in the cell lines, but slightly lower in the primary B cells. Btk was used as B cell- and 
SLAP130 as T cell-specific loading control. Actin served as additional loading control 
(figure 16 b). To sum up, the expression of RasGRP1 and 3 in human primary B cells isolated from 
peripheral blood is similar to RasGRP 1 and 3 expression of DG75 cells. Only RasGRP2 expression 
appeared to be higher in human primary B cells than in DG75. However, in terms of RasGRP1, 
RasGRP3, Grb2 and GRAP expression, DG75 cells resemble the situation of human primary 
B cells. Hence they are a representative model to study Erk activation in human B cells.  
  





Figure 16. Human B cells exhibit low expression levels of RasGRPs. (a) Purity analysis of human primary B cells isolated from 
peripheral blood. Cells were isolated by CD19-positive selection, before they were incubated in R10 for 30 min at 37°C in 
order to recycle CD19 expression. Isolation yield was analyzed by flow cytometry via surface staining of CD19 and IgM. (b) 
Comparison of RasGRP expression in human primary B cells and the human B cell lines Raji and DG75 as well as the JURKAT 
T cell line by Western blot analysis. Membrane was probed for RasGRP1, 2 and 3 as well as for Grb2 and GRAP. Btk served as 
B cell-specific and SLAP130 as T cell-specific loading control. Actin served as general loading control.  
 
3.2.3 Grb2 cooperates with GRAP in activation of Erk 
My results revealed that PLCγ1 and 2 are dispensable for the BCR-induced Erk activation in 
human B cells in contrast to Erk activation in chicken and mouse B cells which depends on 
PLCγ2. (Oh-hora et al, 2003; Bell et al, 2004). Further, I suppose that human B cells do not require 
RasGRPs for BCR-mediated activation of Erk but rather rely on another guanine nucleotide 
exchange factor, namely Sos, as described for EGFR signaling. Sos gets recruited to the EGFR by 
constitutive interaction with the adapter protein Grb2 (Lowenstein et al, 1992). Indeed, Erk 
a b 
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activation studies in Grb2-deficient DG75 (GRB2-/-) (figure 10) revealed that Grb2 is important for 
the activation of Erk, although Erk phosphorylation in Grb2-deficient cells was not completely 
abolished. This could be due to GRAP, another member of the Grb2-family of adapters, that 
shares 60 % structural homology with Grb2 and could be compensating for Grb2. In contrast to 
Grb2, GRAP expression is restricted to lymphocytes (Trüb et al, 1997). However, its role in B 
lymphocytes is yet unknown. In order to test this hypothesis, I generated a Grb2/GRAP-double 
deficient cell line and analyzed it for activation of Erk.  
3.2.3.1 Generation of a Grb2/GRAP-double deficient B cell line 
The Grb2/GRAP-double deficient DG75-sub-cell line (GRB2/GRAP-/-) was generated by using the 
TALEN-based genome editing technique on the background of the Grb2-deficient DG75-sub cell 
line (GRB2-/-). TALENs were designed to target exon 2 of the GRAP gene. TALEN cut site was 
chosen to be located in a BsRI restriction site, that was used for later TALEN activity test 
(figure 17 a). The TALEN pair was introduced in Grb2-deficient DG75 by nucleofection via an 
IRES-GFP, or IRES-RFP cassette containing vector. Double positive cells were sorted and analyzed 
for TALEN activity. Therefore, exon 2 was amplified from genomic DNA from the sorted 
population or parental cells, respectively and treated with BsRI. BsRI treatment revealed partial 
activity of the TALEN constructs of the TALEN-electroporated cell population (figure 17 b). Next, 
cells were subcultured in order to obtain single cell clones. Resulting clones were analyzed for 
GRAP-protein expression on Western blot and by Sanger-sequencing analysis. In total, 237 
potential Grb2/GRAP-double deficient clones were screened by Western blot. Thereof only 11 
subclones were tested negatively for GRAP-protein expression (figure 17 c). An exemplary 
Western blot analysis is depicted in figure 17 d, comparing GRAP-protein expression in 
Grb2/GRAP-double deficient (GRB2/GRAP-/-) clone #81, in GRAP-single deficient (GRAP-/-) clone 
#5 and Grb2-deficient (GRB2-/-) as well as DG75 parental cells (wt). Sequencing analysis of seven 
of these double-deficient clones revealed that the TALEN-mediated modification within the 
GRAP gene was either heterozygous or encompasses a bp-deletion of a multiple of three, 
leading to a loss of a few amino acids. This led to the assumption, that a homozygous 
modification of the GRAP-gene, along with a Grb2-deficiency, is lethal. However, I specified clone 
#81 as Grb2/GRAP-deficient subclone. It carries a 9 bp deletion on allele 1 and an 18 bp deletion 
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on allele 2, each leading to a loss of 3 and 6 amino acids including the tryptophan at position 
36 (W36) that is conserved among Grb2 and GRAP (figure 17 e). Loss of W36 leads to 
inactivation of the N-terminal SH2 domain, important for adapter-protein functions of Grb2 
(Cully et al, 2004) and GRAP. 
The GRAP-single deficient DG75 cell line (GRAP-/-) was generated with the same TALEN-
constructs as described for the double deficient cells. As for the Grb2/GRAP-double deficient 
cells (GRB2/GRAP-/-), sequencing analysis of the GRAP-deficient clones revealed either a 
heterozygous modification within the GRAP gene or deletions encompassing a bp-deletion of a 
multiple of three (not shown). In total, I analyzed 69 clones, whereof 13 were GRAP-negative on 
protein level. I specified clone #5 as GRAP-deficient which carries a 7 bp deletion on allele 1. The 
second allele could not be amplified and sequenced. 




Figure 17. Generation of a Grb2/GRAP-double deficient cell line using TALEN. (a) Exon structure of the GRAP gene and 
sequence of the targeted exon 2. TALEN binding sites for left and right arm are highlighted in orange, TALEN cut site is 
indicated by a red arrow and BsRI restriction site is highlighted in green. (b) TALEN activity test. Exon 2 was amplified from 
parental DG75 cells (wt) or TALEN-nucleofected cells and treated with BsRI. Treated PCR product was analyzed by agarose 
gel electrophoresis. (c) Statistics of single-cell clone analysis. Single cell clones were analyzed by Western blot. Clones lacking 
GRAP-protein expression were further analyzed by Sanger sequencing to verify mutation on genomic level. (d) Exemplary 
Western blot analysis of DG75 GRB2/GRAP
-/-
 subclone #81 compared with DG75 GRAP
-/-
 subclone #5, DG75- and DG75 
GRB2
-/-
 parental cells. (e) Genomic DNA sequence and corresponding aa sequence of DG75 Grb2/GRAP
-/-
 subclone #81. 
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3.2.3.2 GRAP partially can compensate for Grb2 in Erk activation 
Erk activation in Grb2-deficient DG75 (GRB2-/-) was remarkably diminished, but not completely 
abolished. In order to test, whether this is due to expression of GRAP, I analyzed Erk activation 
following BCR activation in the newly generated Grb2/GRAP-double deficient DG75-sub cell line 
(GRB2/GRAP-/-) by Western blot analysis probing for pErk (figure 18 a) and by intracellular 
staining for phosphorylated Erk for flow cytometry by using a fluorescence-labelled pErk 
antibody (figure 18 b & c). The Western blot analysis revealed that compared to DG75 parental 
cells (wt), Erk activation (pErk) in Grb2-deficient DG75 (GRB2-/-) upon 3 min of BCR stimulation 
was clearly diminished, while Grb2/GRAP-double deficient DG75 (GRB2/GRAP-/-) exhibited almost 
no Erk-phosphorylation. However, GRAP-single deficient DG75 (GRAP-/-) show normal, or even 
stronger Erk activation compared to parental cells (wt) (figure 18 a). These observations are 
supported by intracellular staining of phosphorylated Erk that allows better quantification of Erk-
phosphorylation (figure 18 b & c). Upon 3 min of BCR stimulation, Erk activation in GRAP-
deficient cells (GRAP-/-) was not changed compared to parental cells, while Erk activation in Grb2-
deficient cells (GRB2-/-) was more than 50 % diminished. Additional editing of GRAP 
(GRB2/GRAP-/-) almost reduced the p-Erk-signal to the p-Erk level of unstimulated cells (figure 18 
b & c). To sum up, to small extents GRAP indeed seems to be able to compensate for Grb2 in Erk 
activation. However, GRAP alone does not play an important role in Erk activation in human 
B cells.  




Figure 18. Cooperation of Grb2 and GRAP in Erk activation. (a) Western blot analysis for phosphorylated Erk. DG75 parental 




 and DG75 GRB2/GRAP
-/-
 B cells were stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 
20 min. Cells were lysed and analyzed by Western blot probing for phosphorylated Erk (α-pErk). Expression of total Erk, Grb2 
and GRAP was verified with respective antibodies. Actin served as loading control. (b & c) Intracellular staining for 




 and DG75 GRB2/GRAP
-/-
 B cells were stimulated 
with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min, fixed, permeabilized and analyzed by flow cytometry using an ALEXA647 
coupled antibody specific for phosphorylated Erk. (b) Representative histograms of Erk phosphorylation in DG75 parental 




) or both (GRB2/GRAP
-/-
). (c) fold change of median 





) or both (GRB2/GRAP
-/-
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In order to confirm the role of GRAP in Erk activation and exclude off target effects, I 
reconstituted the Grb2/GRAP-double deficient DG75 with GRAP cDNA by retroviral transduction 
and analyzed them for their ability to activate Erk upon BCR activation (figure 19). The Western 
blot analysis showed an increase in BCR-induced Erk activation (pErk) in Grb2/GRAP-double 
deficient DG75 (GRB2/GRAP-/-) reconstituted with GRAP compared to untransduced DG75 
GRB2/GRAP-/-(figure 19 a). ICS of phosphorylated Erk revealed a recovery of Erk activation upon 
GRAP reconstitution to the level of Erk activation in Grb2-deficient DG75 (GRB2-/-) (figure 19 b & 
c). Thus, the reconstitution of GRAP in Grb2/GRAP-double deficient DG75 (GRB2/GRAP-/-) 
excluded an off-target effect by the GRAP TALEN-construct, confirming a minor compensatory 
role for GRAP in BCR-induced Erk activation. Taken together, these results reveal a partial 
involvement of GRAP in the BCR-mediated activation of Erk when Grb2 is absent. 
Grb2/GRAP-double deficiency in the human B cell line DG75 almost led to a complete loss of 
their ability for Erk activation following BCR stimulation. 




Figure 19. Reconstitution of GRAP in Grb2/GRAP-double deficient B cells. (a) Western blot analysis for phosphorylated Erk. 




 and DG75 GRB2/GRAP
-/-
 GRAP (transduced with GRAP) were 
stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min. Cells were lysed and analyzed by Western blot probing for 
phosphorylated Erk (α-pErk). Expression of total Erk, Grb2 and GRAP was verified with respective antibodies. Actin served as 
loading control. (b & c) Intracellular staining for phosphorylated Erk. Cells were stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 
and 20 min, fixed, permeabilized and analyzed by flow cytometry using an ALEXA647 coupled antibody specific for 





 and DG75 GRB2/GRAP
-/-
 GRAP. (c) Fold change of median fluorescence intensity (MFI)/Erk phosphorylation in 




 and DG75 GRB2/GRAP
-/-
 GRAP (transduced with GRAP). Mean 
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3.2.4 Ectopic expression of RasGRP3 in Grb2/GRAP-double deficient B cells can reconstitute 
BCR-mediated Erk activation 
By disrupting Grb2 and GRAP expression, the human B cell line DG75 almost completely lost its 
ability for BCR-mediated Erk activation. This is probably due to the potential of Grb2, and 
presumably also of GRAP, to link the guanine nucleotide exchange factor Sos to the activated B 
cell receptor by constitutive interaction with Sos by virtue of both Grb2-SH3 domains 
(Lowenstein et al, 1992). Hence, Sos would loose its ability to activate Ras, which in turn would 
lead to activation of Erk via the Ras/MAPK pathway. The guanine nucleotide exchange factor 
RasGRP3, that has been shown to arbitrate BCR-mediated Erk activation via DAG and PKC in the 
chicken B cell line DT40 as well as in murine B cells, is only expressed to small amounts in human 
B cells and hence is dispensable for Erk activation in human B cells (figure 20). However, I 
hypothesized that ectopically expressed RasGRP3 can reconstitute BCR-mediated Erk activation 
in Grb2/GRAP-double deficient DG75. In order to test the hypothesis, I retrovirally transduced 
RasGRP3 in Grb2/GRAP-double deficient DG75 (GRB2/GRAP-/-) and analyzed their potential for 
Erk activation upon BCR stimulation. Western blot analysis following 3, 10 and 20 min of BCR 
stimulation showed that Erk activation (pErk) can be completely reconstituted in 
Grb2/GRAP-double deficient DG75 transduced with RasGRP3 (GRB2/GRAP-/- RasGRP3) 
(figure 20).  
To sum up, ectopic expression of RasGRP3 in Grb2/GRAP-double deficient DG75 could restore 
BCR-mediated Erk activation completely, revealing that human B cells potentially are able to use 
RasGRPs. However, low endogenous expression of RasGRP1 and RasGRP3 in human B cells limits 
RasGRP dependent Erk activation.  




Figure 20. Ectopic expression of RasGRP3 in Grb2/GRAP-double deficient DG75. Western blot analysis for phosphorylated 
Erk. DG75 parental cells (wt), Grb2/GRAP-double deficient DG75 (GRB2/GRAP
-/-
) and Grb2/GRAP-double deficient DG75 
transduced with RasGRP3 (GRB2/GRAP
-/-
 RasGRP3) were stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min. Cells were 
lysed and analyzed by Western blot probing for phosphorylated Erk (α-pErk). Expression of total Erk, Grb2, GRAP and 
ectopically expressed RasGRP3 was verified with respective antibodies. Actin served as loading control.  
 
3.2.5 Erk activation requires recruitment of Grb2 to the signalosome of the activated BCR 
3.2.5.1  Grb2 domains cooperate in the activation of Erk 
I could show that Grb2 is indispensable for the activation of Erk. The requirement of Grb2 in Erk 
activation in turn implemented that the activation of Erk in human B cells is dependent on Sos, 
which constitutively interacts with Grb2 via both Grb2-SH3 domains (Lowenstein et al, 1992). To 
functionally dissect which Grb2 domains in particular are important for Erk activation, I 
reconstituted Grb2-deficient cells with Grb2 variants harboring amino acid substitutions leading 
to inactivation of the ligand binding ability of the respective domains. Substitution of W by K (W 
being tryptophan, K being lysine) at position 36 (W36K) leads to inactivation of the N-terminal 
SH3 domain (N-SH3 mutant), R86K (R being arginine) inactivates the SH2 domain (SH2 mutant) 
and W193K the C-terminal SH3 domain (C-SH3 mutant, figure 21 a) (Cully et al, 2004). Erk 
phosphorylation analysis by ICS revealed that Erk activation capability following 3 min of BCR 
stimulation can be restored by reconstitution of Grb2-deficient DG75 (GRB2-/-) with Grb2 wt. 
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However, neither the N-SH3 mutant, the SH2 mutant nor the C-SH3 mutant can functionally 
replace the Grb2 wt variant in the activation of Erk. Erk activation in cells reconstituted with the 
triple mutant is comparable to Erk activation in Grb2-deficient cells (figure 21 c & d). To 
conclude, all three domains of Grb2 play an important role in the activation of Erk. The 
importance of both SH3 domains supports the involvement of Grb2 in Erk activation due to its 
role in facilitating Ras activation via Sos, since both SH3 domains were shown to be important 
for the interaction of Grb2 with Sos (Neumann et al, 2009). In addition, the requirement for a 
functional SH2 domain shows that BCR mediated Erk activation requires recruitment of Grb2 to 
the activated BCR complex, more precisely to a phosphorylated (p)YXN motif via its SH2 domain. 
However, in contrast to memory B cells, a ligand for the SH2 domain of Grb2 in naïve (IgM-
positive) B cells within the BCR complex has not been described, yet.  
 




Figure 21. Functional dissection of Grb2 in Erk activation. (a) Schematic depiction of Grb2 variants with respective amino acid 
substitution introduced by site directed mutagenesis in order to inactivate the domains. W36K = N-SH3 mutant, R86K = SH2 
mutant, W193K = C-SH3 mutant. Grb2 variant with all three mutations was termed as triple mutant. (b) Expression level of 
Grb2 variants in Grb2-deficient DG75 (GRB2
-/-
) compared to parental cells (wt). (c & d) Intracellular staining for 
phosphorylated Erk (pErk). Cells were stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min, fixed, permeabilized and 
analyzed by flow cytometry using an ALEXA647 coupled antibody specific for phosphorylated Erk. (c) Representative 
histograms of Erk phosphorylation in Grb2-deficient DG75 (GRB2
-/-
) transduced with different mutant variants of Grb2. (d) 
fold change of median fluorescence intensity (MFI)/Erk phosphorylation. Mean values and standard deviation of 7 
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3.2.5.2  Grb2 is recruited to the BCR signalosome by virtue of its SH2 domain 
Since the Grb2-SH2 domain seems to be important for BCR-mediated Erk activation, I concluded, 
that Erk activation requires recruitment of Grb2 to the signalosome of the activated BCR via the 
Grb2-SH2 domain. However, for direct recruitment in a SH2-domain dependent manner, Grb2 
requires a pYXN motif, which is neither present within IgM-BCR nor within the Igα/β 
heterodimer. In order to address SH2-mediated Grb2 recruitment to the activated BCR 
signalosome, I performed a GST-pulldown assay with cleared cellular lysates (CCL) from DG75 
cells stimulated via the BCR, using the recombinant GST-tagged SH2 domain of Grb2. Western 
blot analysis of the pulldown revealed an enrichment in tyrosine-phosphorylated proteins from 
lysates of cells stimulated via the BCR (not shown). To analyze the purified protein complexes, I 
repeated the GST-pulldown assay and sent the samples for Stable isotope labeling with amino 
acids in cell culture (SILAC)-based mass spectrometry (MS) analysis. SILAC-based MS is a 
quantitive proteomic approach allowing simultaneous relative quantification of proteins derived 
from different cellular conditions. Therefore, cells are cultured in different media containing 
normal (light) or heavy isotope amino acids that are metabolically incorporated into proteins 
during protein synthesis. Incorporation of heavy isotope amino acids into proteins leads to an 
increase of the molecular masses of the proteins. Thus, peptides derived from this sample can be 
easily identified and distinguished from the sample of cells cultured in normal (light) medium in 
the MS spectra (Zhang & Neubert, 2009). To identify Grb2-SH2 domain interaction partners, I 
cultured Grb2-deficient DG75 either in light (R0/K0) or heavy (R6/K4) SILAC medium. In heavy 
SILAC medium R (being arginine) and K (being lysine) are substituted by heavy labeled amino 
acids. In R6 six carbon atoms (C12) are replaced by C13 leading to a mass increase of 6 Dalton 
(Da), while K4 contains 4 deuterium instead of 4 hydrogens, leading to a 4 Da mass increase. 
Prior GST-pulldown assay, cells were stimulated via the BCR for 3 min. Lysates from cells cultured 
in the heavy medium were incubated with GST-Grb2 SH2 fusion protein for 2 h, whilst cells 
cultured in the light medium were incubated with the GST-Grb2 SH2 R86L (inactive) fusion 
protein that served as a negative control. GST-pulldown eluates of both samples were mixed in a 
1:1 ratio and analyzed by LC-MS/MS by the core facility at University medical center, Göttingen. 
Relative abundance (H/L ratio) of BCR relevant proteins enriched with the GST-Grb2 SH2 domain 
is shown in the scatter plot (figure 22) and is listed in table 26 including Uniprot accession 
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numbers. Proteins with a heavy/light ratio >2 were considered as enriched in the pulldown with 
the intact Grb2-SH2 domain. Proteins with relevance in BCR signaling were highlighted in blue 
(BCR complex) or in red (BCR associated proteins). The most abundant proteins I identified, were 
Igα, as well as several components of membrane IgM (highlighted in blue), confirming that Grb2 
via its SH2-domain indeed is directed to the signalosome of the activated BCR. Moreover, I 
identified several well-described interaction partners of Grb2, as for example the phosphatases 
SHP1, SHP2 and SHIP1 as well as the adapter proteins Dok3, Gab1 and SHC1, and the inhibitory 
BCR coreceptor CD22. However, a direct interaction via the Grb2-SH2 domain was only described 
for SHC1 (Harmer & DeFranco, 1997), SHP2 (Vogel & Ullrich, 1996), Dok3 (Honma et al, 2006; 
Stork et al, 2007), Gab1 (Bardelli et al, 1997; Holgado-Madruga et al, 1996) and CD22 (Yohannan 
et al, 1999; Otipoby et al, 2001). The interaction of Grb2 with SHP1 and SHIP1 so far has been 
attributed to the SH3 domains (Saci et al, 2002; Otipoby et al, 2001). Hence, the enrichment of 
SHP1 and SHIP1 could be explained by indirect interactions, for example via SHC1 (Poe et al, 
2000).  
 
Figure 22. Scatter plot of SILAC-based mass spectrometry analysis. DG75 cells were either incubated in light 
(arginine +0/lysine +0) or in heavy SILAC medium (arginine +6/lysine +4). For GST-pulldown assay cells were stimulated via 
the BCR for 3 min, lysed and incubated either with GST-GRB2 SH2 (heavy medium cultured cells) or with GST-GRB2 SH2 
R86L (inactive SH2 domain; light medium cultured cells). The eluate was pooled in a 1:1 ratio, processed and analyzed by LC-
MS/MS. In the scatter plot the log(2) transformed heavy/light (h/l) ratio was plotted against the log(10) transformed peptide 
intensity. Proteins with a H/L ratio >2 were considered as enriched by the Grb2-SH2 domain. Proteins with relevance to BCR 
signaling were highlighted in blue (BCR complex) or red (BCR associated proteins).  
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Table 26. Interactome of the Grb2-SH2 domain in the human B cell line DG75, activated via the B cell antigen receptor. DG75 
cells were either incubated in light (arginine +0/lysine +0) or in heavy SILAC medium (arginine +6/lysine +4). For GST-
pulldown assay cells were stimulated via the BCR for 3 min, lysed and incubated either with GST-GRB2 SH2 (heavy medium 
cultured cells) or with GST-GRB2 SH2 R86L (inactive SH2 domain; light medium cultured cells). The eluate was pooled in a 1:1 
ratio, processed and analyzed by LC-MS/MS. In the scatter plot the log(2) transformed heavy/light (h/l) ratio was plotted 
against the log(10) transformed peptide intensity. Proteins with a H/L ratio >2 were considered as enriched by the Grb2-SH2 
domain. Proteins with relevance to BCR signaling were highlighted in blue (BCR complex) or red (BCR associated proteins). 
 
The results acquired from the mass spectrometry analysis confirmed that upon stimulation Grb2 
gets recruited to the signalosome of the activated BCR via its SH2 domain. The most abundant 
protein in this analysis was the transmembrane protein Igα (CD79a), which is part of the BCR 
complex. Biochemical verification of the mass spectrometry data confirmed the recruitment of 
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the Grb2-SH2 domain to Igα as well as the interaction with SHC1 upon 3 min of BCR stimulation, 
whereas the inactivated Grb2-SH2 domain (R86L) failed to interact with Igα and SHC1 (figure 23). 
However, so far a binding motif for Grb2 (pYXN) in the Igα molecule has not been described, yet. 
Hence, I assumed that this interaction between Grb2 and Igα is mediated indirectly. A possible 
connection between Grb2 and Igα could be the adapter protein SHC1, which was shown to be 
recruited to the activated BCR via the phosphorylated ITAM of Igα and Igβ (Baumann et al, 1994; 
D'Ambrosio et al, 1996). Moreover, SHC1 was shown to form a complex with Grb2 and Sos upon 
BCR activation, already suggesting SHC1 as a linker for Grb2 to the BCR complex (Smit et al, 
1994). 
 
Figure 23. Confirmation of the association of SHC1 and Igα with the Grb2-SH2 domain. 35x10
6
 cells per sample were 
harvested and stimulated via the BCR for 3 min. For GST-pulldown assay, lysates were incubated either with the GST-Grb2-
SH2 fusion protein or with the GST-Grb2-SH2 (R86L; defective SH2 domain) for 2 h. Purified proteins were analyzed by 
Western blot, probing for SHC or Igα. CCL=Cleared cellular lysates; AP=affinity purification. 
  
  Results 
89 
 
3.2.6 Role of SHC1 in Erk activation 
The results of the mass spectrometry analysis and the GST-pulldown assay brought the adapter 
protein SH2 containing transforming protein 1 (SHC1) again into play. SHC1 was shown to be 
involved in many receptor systems, thereby amongst others contributing to the activation of Erk 
by linking Grb2:Sos to respective receptors (reviewed in Finetti et al, 2009). In B cells SHC1 was 
already suggested a long time ago to link Grb2 and Sos to the activated BCR and to be involved 
in the activation of Erk (Smit et al, 1994; Saxton et al, 1994). However, the discovery of the 
guanine nucleotide exchange factor RasGRP3 challenged the relevance of Sos in the activation of 
Erk (Oh-hora et al, 2003). Hence, the involvement of SHC1 in Grb2:Sos recruitment and Erk 
activation was not followed further. However, I showed that in human B cells rather Grb2 and Sos 
and not RasGRP3 play an important role in Erk activation. In order to test, whether SHC provides 
the linkage between the activated BCR and activation of Erk via GRB2:Sos, I generated a SHC1 
deficient DG75 sub-cell line by using CRISPR/Cas and analyzed it for Erk activation.  
3.2.6.1 Generation of a SHC1-deficient B cell line using CRISPR/Cas 
In order to target the major isoforms of SHC1 expressed in B cells, namely p66, p52 and p46 
(according to ensembl.org), I chose to target Exon 5 (p66) which all three isoforms have in 
common (figure 24 a). Western blot analysis of DG75 cell lysates showed high expression of p46 
and p52, whereas p66 was only expressed weakly (not shown). Constructs were designed by 
using the web based software http://crispr.mit.edu/. The guide RNA was chosen to direct the 
Cas9 nuclease to target an NspI restriction site (highlighted in green), allowing to check for 
CRISPR activity by NspI restriction digest (figure 24 a). The guide RNA construct was synthesized 
by MWG eurofins and cloned into the pSpCas9(BB)-2A-GFP vector. DG75 B cells were transfected 
by nucleofection and were enriched for GFP expression by flow cytometry 72 h later. In order to 
test the activity of the CRISPR/Cas9 construct, exon 5 was amplified from genomic DNA from 
parental cells or targeted cells and treated with NspI. After digest the PCR product was analyzed 
on agarose gel. Activity test of the CRISPR/Cas9 construct targeting SHC1 revealed only a partial 
digest of exon 5 in targeted cells indicating CRISPR/Cas9 activity, whereas exon 5 from parental 
cells was digested completely (figure 24 b). Following, cells were subcultured to obtain single cell 
subclones and analyzed by Western blot and Sanger sequencing. 7 of 88 clones analyzed by 
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Western blot were shown to be negative for all three SHC1 isoforms (figure 24 c and d). 5 of the 
7 clones were subjected to sequencing analysis, revealing a SHC1 deficiency on genomic level for 
clone #46, #72 and #82. Clone #33 exhibited a deletion of a multiple of three on both alleles and 
for clone #78 only one allele could be sequenced. Exemplarily, the exon sequences of both SHC1 
alleles of #72 are depicted in figure 24 e. Targeting by CRISPR/Cas9 led to a 1 bp insertion on 
allele 1 and to a 13 bp deletion on allele 2, both leading to a premature STOP codon and 
termination of the amino acid sequence (figure 24 e). 




Figure 24. Generation of a SHC1 deficient cell line using CRISPR/Cas. (a) Exon structure of the SHC1 gene (isoform p66) and 
sequence of the targeted exon 5. Binding site of the guide RNA is highlighted in orange, PAM sequence is indicated in 
yellow, blue arrow indicates Cas9 cut site 3 nucleotides upstream of the PAM sequence. NspI restriction site is highlighted in 
green. (b) CRISPR/Cas9 activity test. Exon 5 was amplified from parental DG75 cells or CRISPR-targeted cells and treated with 
NspI. Treated PCR product was analyzed by agarose gel electrophoresis. (c) Statistics of single-cell clone analysis. Single cell 
clones were analyzed by Western blot. Clones lacking SHC1-protein expression were further analyzed by Sanger sequencing 
to verify mutation on genomic level. (d) Western blot analysis of DG75 SHC1
-/-
 subclones compared to parental cells. (e) 
Genomic DNA sequence and corresponding aa sequence of DG75 SHC1
-/-
,#72.(* = premature STOP codon). Sequence is 
representative for at least seven sequencing analyses 
 
e 
c d b 
a 
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3.2.6.2 SHC1 is dispensable for BCR-induced Erk activation 
Resulting SHC1-deficient DG75 were analyzed for the mobilization of Ca2+ and phosphorylation 
of Erk (figure 25). Ca2+ mobilization was elevated in all SHC1 deficient clones except #82, where 
Ca2+ mobilization profile was similar to Ca2+ mobilization in parental cells (wt). In figure 25 a Ca2+ 
mobilization following BCR activation in clone #48, clone #72 and #82 is depicted. However, also 
clone #33, #46, clone #57 and clone #78 showed an elevated Ca2+ mobilization in response to 
BCR stimulation (not shown). This could be explained by the involvement of SHC1 in signaling of 
the inhibitory coreceptor CD22 (Poe et al, 2000). Erk activation analysis by Western blot (figure 
25 b) and intracellular staining for phosphorylated Erk (figure 25 c & d) revealed normal Erk 
phosphorylation in clone #46, #57, #78 and #82 upon 3, 10 and 20 min of BCR stimulation. 
However, Erk activation in clone #33, #48 and #72 was impaired or almost completely abolished. 
Erk phosphorylation of the clones #72 and #82 is shown representatively for each situation in 
figure 25 b, c and d. To sum up, disruption of SHC1 expression in DG75 cells led to divergent 
results in terms of BCR-mediated Erk activation. Three out of seven SHC1-deficient clones 
revealed a defect in Erk activation, while the rest exhibited normal Erk activation following BCR 
stimulation.  




Figure 25. Impact of SHC1 on Erk activation. (a) Ca
2+
 mobilization assay of SHC1-deficient DG75 clones compared to DG75 
parental cells (wt). Baseline was recorded for 30 sec. Different subclones were stimulated with 10 µg/ml F(ab’)2 α-IgM (time 
point of stimulation indicated by arrow). Mobilization of Ca
2+
 was monitored for 300 s by flow cytometry using the 
ratiometric dye Indo-1. (b) Western blot analysis for phosphorylated Erk. SHC1-defcient DG75 clones #72 and #82 or DG75 
parental cells (wt) were stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min. Cells were lysed and analyzed by Western 
blot probing for phosphorylated Erk (α-pErk). Expression of total Erk, and SHC1 was verified with respective antibodies. Actin 
served as loading control. (c & d) Intracellular staining for phosphorylated Erk. Cells were stimulated with 10 µg/ml F(ab’)2 for 
0, 3, 10 and 20 min, fixed, permeabilized and analyzed by flow cytometry using an ALEXA647 coupled antibody specific for 
phosphorylated Erk. (c) Representative histograms of Erk phosphorylation in SHC1-deficient DG75 clones #72 and #82. (d) 
Fold change of median fluorescence intensity (MFI)/Erk phosphorylation in SHC1-deficient cells. Mean values and standard 
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To rule out off target effects induced by the CRISPR construct, I transfected the DG75 SHC1 
knock-out clone #72, which exhibited a defect in Erk phosphorylation, with either the SHC1 
isoforms p52 or p46 and analyzed the transfectants for BCR induced Erk activation. Since 
endogenous expression of the isoform p66 in DG75 is only weak, I did not include exogenously 
expressed p66 into the reconstitution experiment. Since expression of the different SHC1 
isoforms is regulated by alternative start codons, transduction of the SHC1 p52 cDNA led to 
protein expression of both, the larger SHC1 p52 and the shorter p46 isoform (figure 26 a). SHC1 
p52 and SHC1 p46 were equipped with an IRES-EGFP cassette or with an IRES-RFP cassette 
respectively, allowing indirect control of SHC1 p52 and SHC1 p46 expression levels by flow 
cytometry (figure 26 b). Erk phosphorylation in SHC1-deficient DG75 following 0, 3 10 and 20 
min of BCR stimulation could neither be reconstituted by ectopically expressed SHC1 p52 nor by 
p46 (figure 26 c & d). Thus, I concluded that the defect of Erk phosphorylation in SHC1 deficient 
cells was due to an off target effect caused by the CRISPR construct. However, the off target 
analysis of the SHC1 CRISPR construct did not reveal any BCR relevant targets, but sequence 
comparison revealed sequence similarities between SHC1 and SHC2, especially in the CRISPR 
target site. Although, SHC2 expression in B cells has not been reported, it should be taken into 
account. In summary, the adapter protein SHC1 is not involved in Grb2 mediated Erk activation. 




Figure 26. Reconstitution of SHC1 in SHC1-deficient B cells. (a) Western blot for analysis of SHC1 expression in 
SHC1-deficient DG75 ectopically expressing SHC1 p52 or SHC1 p46. (b) Flow cytometry analysis of IRES-EGFP and IRES-RFP 
expression for indirect control of SHC1 p52 or SHC1 p46 expression, respectively. (c & d) DG75 parental cells (wt), DG75 
SHC1
-/-
 #72, DG75 SHC1
-/-
 #72 transduced with SHC1 p52 (p52) and DG75 SHC1
-/-
 #72 transduced with SHC1 p46 (p46). 
were stimulated with 10 µg/ml F(ab’)2 for 0, 3, 10 and 20 min, fixed, permeabilized and analyzed by flow cytometry using an 
ALEXA647 coupled antibody specific for phosphorylated Erk. Mean values and standard deviation of three independent 
experiments. 
 
Since SHC1 turned out to be dispensable for the activation of Erk following BCR-stimulation, the 
question for the Grb2-membrane anchor that is involved in BCR-mediated Erk activation 
remains. Direct SH2-dependent interaction of Grb2 requires a phospho-tyrosine motif with the 
consensus sequence pYXN. Unlike the IgG/E-BCR of memory B cells which harbors a pYXN 
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several inhibitory and activating coreceptors that are involved in the modification of BCR 
signaling, as for example CD19, CD22, CD27 or FcγRIIB, carry pYXN motifs, serving as docking 
sites for Grb2 and thereby mediating costimulatory functions (Neumann et al, 2009). The recently 
discovered FcµR was also shown to have an ITT-like motif within its cytoplasmic domain that by 
sequence homology could also serve as a Grb2 binding site upon phosphorylation (Shima et al, 
2010). However, the function of the FcµR is still unknown and is currently challenged by several 
groups.  
3.3 Molecular characterization of the cytoplasmic domain of FcµR 
Since the FcµR could serve as another membrane anchor for Grb2 in human B cells, I aimed to 
investigate the molecular signaling features of its cytoplasmic domain. The FcµR is expressed on 
B cells as well as on T cells and according to a few studies also on cells of the innate immune 
system (Kubagawa et al, 2009; Lang et al, 2013). Its role on B cells is still controversially 
discussed. I investigated the FcµR on the molecular level with regard to its potential Grb2 
binding site and costimulatory function.  
3.3.1 The cytoplasmic domain of FcµR can functionally replace the cytoplasmic domain of 
murine IgG2 
Endogenous expression of FcµR on our model cell line was relatively low and attempts of ectopic 
expression only led to low surface expression of FcµR that limited the ability for receptor 
stimulation. Thus, I generated chimeras consisting of the extracellular domain of murine 
(m)IgG2a and the intracellular domain of the FcµR, to analyze the signaling properties of the 
FcµR and expressed them in DG75 B cells (figure 27 a). In order to investigate the relevance of 
the ITT-like motif, I inactivated the motif by substituting the tyrosine at position 385 by a 
phenylalanine (Y385F) by using site directed mutagenesis (figure 27 b). Phenylalanine is 
structural identical to tyrosine except for the hydroxyl group, hence, it cannot be modified by 
phosphorylation. At first, I analyzed whether the ITT-like motif within the cytoplasmic domain of 
FcµR can serve as a binding site for Grb2. Therefore, I stimulated the cells expressing either 
mIgG2a-FcµR wt or mIgG2a-FcµR Y385F with F(ab’)2 α-mIgG, performed an 
immunoprecipitation (IP) and analyzed precipitated proteins by Western blot by probing for 
tyrosine phosphorylated proteins (α-pY100) and for Grb2 (figure 27 c). Following IgG2a 
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activation, the precipitation yield of surface IgG was much lower compared to unstimulated 
receptor. This is probably due to the clustering of activated BCRs in lipid rafts, which depending 
on the detergent used in the lysis buffer, exacerbated the purification. Nevertheless, tyrosine 
phosphorylation increased after 3 min of BCR stimulation, but was not abolished in the YF-
mutant. This indicated that at least one of the three other tyrosines present in the cytoplasmic 
domain also gets phosphorylated upon stimulation. However, the IgG2a-FcµR wt chimera 
recruited Grb2 upon stimulation, whereas the YF mutant lost its ability to interact with Grb2 
(figure 27 c). 
 
Figure 27. Grb2 interacts with the cytoplasmic domain of the FcµR. (a) Schematic depiction of the chimera assembly. The 
cytoplasmic domain of murine IgG2a was replaced with the cytoplasmic domain of FcµR by molecular cloning. The resulting 
chimera was expressed in DG75 B cells. (b) For analysis of the potential ITT-like motif the motif was inactivated by substituting 
the tyrosine residue at position 385 by phenylalanine (Y385F). (c) Immunoprecipitation of IgG2a-FcµR chimeras. 30-40 x106 
IgG2a-FcµR wt or IgG2a-FcµR Y385F expressing cells were stimulated with 10 µg/ml biotinylated α-mIgG for 0 and 3 min. 
Precipitation was performed by using streptavidin-beads for 1 h at 4°C. Precipitated proteins were eluted from the beads by 
boiling and analyzed by Western blot. 
To further analyze the properties of the cytoplasmic domain and the ITT-like motif of the FcµR, I 
compared both chimeras with regard to Ca2+ mobilization (figure 28 a). Therefore, I stimulated 
the cells with F(ab’)2 α-mIgG and monitored the Ca2+ mobilization by flow cytometry. Compared 
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inactivated ITT-like motif (Y385F) was remarkably decreased (figure 28 a), while surface 
expression of both IgG-chimeric receptors was equal (figure 28 b). To check the general ability 
for Ca2+ mobilization in the transduced cells, I analyzed Ca2+ mobilization induced by the 
endogenous IgM-BCR by stimulating the cells with F(ab’)2 α-IgM. Interestingly, Ca2+ mobilization 
in cells expressing the IgG2a chimera with the inactivated ITT-like motif (Y385) is stronger than 
Ca2+ mobilization in IgG2a-FcµR wt cells (figure 28 c), although IgM surface expression was 
similar (figure 28 d). In summary, the ITT-like motif in the cytoplasmic tail of the FcµR can serve 
as Grb2 docking site, at least in the IgG2a chimera setting and has costimulatory properties as it 
was described for the ITT (Engels et al, 2009). Thus, the cytoplasmic domain of the FcµR can 
functionally replace the cytoplasmic domain of mIgG2a.  
 
Figure 28. Functional replacement of the cytoplasmic domain of mIgG2a with the cytoplasmic domain of FcµR. (a & c) Ca
2+
 
mobilization analysis of cells expressing chimeric receptors. Baseline was recorded for 30 sec. DG75 FcµR wt or DG75 FcµR 
Y385F were stimulated with 10 µg/ml F(ab’)2 α-mIgG (a) or 10 µg/ml F(ab’)2 α-IgM (c) (time point of stimulation indicated by 
arrow). Mobilization of Ca2+ was monitored for 300 s by flow cytometry using the ratiometric dye Indo-1. (b & d) Surface 
expression analysis of IgG2a-chimeras and endogenous IgM-BCR by flow cytometry using fluorescence labeled antibodies 
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3.3.2 The FcµR-ITT like motif can functionally replace the ITT of murine IgG2a 
In order to test, whether the FcµR-ITT like motif functionally resembles the ITT, I mutated the ITT 
motif of the mIgG2a to an FcµR-ITT like motif (figure 29 a). Therefore, I exchanged four amino 
acids (depicted in red) by site directed mutagenesis and expressed the modified mIgG2a in DG75 
B cells (figure 29 b). For functional analysis of the ITT-like motif, I inactivated the ITT-like motif by 
replacement of tyrosine for phenylalanine (YF). Following, I compared tyrosine phosphorylation 
and Grb2 recruitment in the IgG2a and IgG2a-FcµR-ITT transduced cells by performing an IP as 
described in the previous section. The IP revealed that the FcµR-ITT like motif as well as the wt 
ITT gets phosphorylated upon 3 min of BCR stimulation, although phosphorylation of the FcµR-
ITT like motif is much stronger compared to phosphorylation of the wt ITT. Inactivation (YF) of 
the ITT in both cases led to ablation of tyrosine phosphorylation of the IgG2a. Corresponding to 
the strength of tyrosine phosphorylation, Grb2 coprecipitation is much stronger for the FcµR-ITT 
like motif than for the IgG2a-ITT. Substitution of Y to F led to ablation of Grb2 recruitment to 
IgG2a, as well as to IgG2a-ITT FcµR (figure 29 c). In accordance to the IP data, Ca2+ mobilization 
analysis exhibited a likewise lower Ca2+ mobilization for IgG2a YF (figure 29 d) and IgG2-FcµR-ITT 
YF (figure 29 e) as compared to the respective wildtype situation, where Ca2+ mobilization was 
much more sustained. These data confirm that the FcµR-ITT like motif indeed has the potential 
to serve as a costimulatory motif through the recruitment of Grb2. However, whether this 
resembles the situation for the full length molecule yet has to be elucidated. Still it is 
conceivable, that the FcµR interferes with BCR signaling via the ITT-like motif in an inhibitory or 
activating manner. 




Figure 29. Replacement of the ITT of mIgG by the FcµR ITT-like motif. (a) Amino acid sequence of the ITT of murine 
(m)IgG2a and the ITT-like motif of the FcµR. Amino acids depicted in red were substituted in order to replace the ITT 
by the FcµR-ITT like motif. For analysis of the potential ITT-like motif the motif was inactivated by substituting the 
tyrosine residue at position 385 by phenylalanine (Y385F). (b) For immunoprecipitation of IgG2a 30-40 x10
6
 DG75 
B cells expressing either mIgG2a wt, mIgG2a YF, mIgG ITT FcµR or mIgG ITT FcµR Y385F were stimulated with 10 
µg/ml biotinylated α-IgG for 0 and 3 min. Precipitation was performed by using streptavidin-beads for 1 h at 4°C. 
Precipitated proteins were eluted from the beads by boiling and analyzed by Western blot. (c & e) Ca
2+ 
mobilization 
analysis of cells expressing IgG2a wt and IgG2a YF, or IgG2a-FcµR ITT and IgG2a-FcµR ITT YF. Baseline was recorded 
for 30 sec. Cells were stimulated with 10 µg/ml F(ab’)2 α-IgG (time point of stimulation indicated by arrow). 
Mobilization of Ca2+ was monitored for 300 s by flow cytometry using the ratiometric dye Indo-1. (d & f) Surface 







IgG2a wt IgG2a ITT-FcµR 




BCR ligation leads to activation of multiple signaling pathways determining the B cells fate. 
Depending on developmental stage, type of antigen, strength of activation or costimulatory 
signals, BCR activation results in survival, proliferation, differentiation or apoptosis. The activation 
of different pathways following BCR activation is facilitated by a complex interplay of a plethora 
of different adapter and effector proteins and requires tight regulation by positive and negative 
regulatory elements. Regulation is mediated by several coreceptors as for example CD19 and 
CD22 as well as by costimulatory elements as the ITT within IgG/E containing BCRs and by Fc 
receptors that play a crucial role in regulating the humoral immune response. The simple but 
versatile adapter protein Grb2 has been shown to be a common element in the positive and 
negative regulation of the BCR via many coreceptors and effectors. Imbalance of this tight 
regulation can lead to autoimmune disorders as for example ITP or SLE.  
In the first part of this study, I analyzed the ability of human recombinant sFcγRIIB, a new 
treatment option for Ig-mediated autoimmune diseases, to bind to membrane IgG in vitro. 
Analysis of signal transduction upon BCR stimulation with multimeric variants of sFcγRIIB 
revealed induction of downstream BCR signaling, giving a first hint that the sFcγRIIB as such 
could bind to membrane IgG in vivo. Interestingly, stimulation with the multimeric variants of 
sFcγRIIB induced Erk activation without the phosphorylation of SLP65, which is crucial for the 
formation of the Ca2+ initiation complex and the activation of PLCγ2. This suggests an alternative 
pathway for the BCR-induced Erk activation in human B cells, different from chicken and murine 
B cells, where Erk activation crucially depends on PLCγ2 activity and thus on the formation of the 
Ca2+ initiation complex. 
Subsequently, I revisited BCR signaling with regard to the activation of the Ras/Raf/MEK/Erk 
pathway in human B cells in the second part of this study. This brought the adapter protein Grb2 
into play again, which was originally suggested to mediate BCR-induced Erk activation via its 
constitutive interaction with Sos. The findings revealing that Grb2 is indispensable for the 
activation of Erk following BCR liagtion in human B cells, gave rise to the question for the 
membrane anchor for Grb2 leading me to the third part of this study. Here, I investigated the 
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molecular signaling properties of the recently discovered FcµR as a potential membrane anchor 
for Grb2. 
4.1 Multimerized sFcγRIIB induces IgG-specific BCR signaling 
The recombinant soluble human FcγRIIB is being tested as a new treatment option for Ig 
mediated autoimmune diseases in phase II clinical studies. Due to the long lasting effects that 
have been observed in ITP patients, we hypothesized a dual mode of function for the human 
recombinant sFcγRIIB. Besides competing with membrane bound FcγRIIB in binding of 
IgG-immune complexes, sFcγRIIB could also interfere with the formation of plasma cells and 
hence with the formation of new autoantibodies by binding to membrane IgG on memory 
B cells. 
To test, whether the sFcγRIIB binds to membrane IgG, I used functional read-out systems as Ca2+ 
mobilization and western blot analysis monitoring the activation of the BCR. Due to the low 
binding affinity of the sFcγRIIB (Maenaka et al, 2001) it was not possible to directly test 
sFcγRIIB-binding by fluorescently labelled sFcγRIIB-specific antibodies or fluorescently labelled 
sFcγRIIB itself. Treatment of IgG-expressing B cells with the dimeric and tetrameric sFcγRIIB led 
to mobilization of the second messenger Ca2+ as well as to activation of Akt and Erk, although 
phosphorylation of SLP65 was not detectable. However, Ca 2+ mobilization appeared to be 
weaker but more sustained compared to IgG-expressing B cells stimulated with IgG-specific 
F(ab’)2 fragment. SLP65 is important for the formation of the Ca2+ initiation complex and hence 
for the activation of PLCγ2, which mediates the mobilization of Ca2+ and the activation of Erk via 
DAG and RasGRP. The fact that Erk activation in IgG-expressing cells stimulated with multimeric 
sFcγRIIB variants was as high as in cells stimulated with IgG-specific F(ab’)2 can be explained in 
different ways. First, low undetectable levels of phosphorylated SLP65 could be sufficient for the 
activation of Erk. Second, other adapter proteins could compensate for SLP65 in Ca2+ 
mobilization. This would explain why IgG-expressing B cells upon stimulation with multimeric 
sFcγRIIB still mobilize Ca2+, although SLP65 phosphorylation is diminished. Furthermore, gene 
targeting studies in mice revealed that SLP65 is not exclusively essential for Ca2+ mobilization in 
B cells (Gerlach et al, 2003). The third option is that Erk in human B cells is activated by an 
alternative pathway different from the RasGRP3 axis described for mice and chicken B cells.  
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The monomeric sFcγRIIB representing the molecule that is being tested in clinical studies did not 
induce any signaling in IgG expressing B cells in vitro. Nevertheless, results obtained from the 
functional analysis with the dimeric and tetrameric variant of sFcγRIIB suggest that the molecule 
per se can bind to membrane IgG. However, since I could not detect any signaling events 
induced by the monomeric sFcγRIIB, it is unlikely that it induces BCR activation in vivo, unless it 
dimerizes by interaction with serum proteins. Indeed, the sFcγRIIB comprises a large uncharged 
patch forming a hydrophobic ridge which could serve as binding site for other proteins than the 
IgG (Sondermann et al, 1999). Another conceivable model is that the monomeric sFcγRIIB does 
not activate the BCR itself but rather modulates (auto) antigen mediated BCR activation in vivo.  
To sum up, functional assays revealed BCR activation upon stimulation of IgG-B cells with 
dimeric and tetrameric but not with monomeric sFcγRIIB. Even though I could not show it 
biochemically, I can conclude that B cell activation via the sFcγRIIB occurs in a BCR-dependent 
manner, most probably via direct interaction of the sFcγRIIB with the IgG-BCR. Furthermore, it is 
conceivable that also the monomeric sFcγRIIB is able to bind to the IgG-BCR, although it did not 
induce BCR signaling in our read-out systems. However, it is not possible to predict how the 
monomeric sFcγRIIB behaves in vivo. Whether it interferes with plasma cell formation in vivo still 
remains to be investigated. Therefore, a suitable in vitro model including an IgG-B cell line that is 
able to differentiate into plasma cells is required to test the influence of sFcγRIIB on plasma cell 
formation. 
4.2 Revisiting the role of Grb2 in Erk activation in human B cells 
Activation of Erk requires PLCγ2 activity and thus is accompanied by the mobilization of Ca2+. 
However, experiments that contributed to this conclusion were performed in the DT40 chicken 
B cell line and in mice. Stimulation of human IgG-B cells with multimeric sFcγRIIB led to 
induction of signaling events downstream of the BCR including Ca2+ mobilization as well as 
activation of Erk despite the absence of SLP65 phosphorylation. These observations revealed 
species specific differences between chicken, mice and human regarding the BCR-induced 
activation of Erk. This led us to the hypothesis that Erk activation upon BCR stimulation in human 
B cells occurs independently of the Ca2+ initiation complex via an alternative pathway.  
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4.2.1 Erk activation following BCR stimulation occurs independently of PLCγ but requires 
Grb2 
Consistent with the role of SLP65 and Btk in formation of the Ca2+ initiation complex (Engelke et 
al, 2007), DG75 B cells deficient for SLP65 or Btk exhibited a remarkable decrease in mobilization 
of Ca2+ upon BCR activation, while Grb2-deficiency had no effect on Ca2+mobilization. In 
contrast, Erk activation was not affected in SLP65- and Btk- deficient DG75 and thus occurred 
independently of the mobilization of Ca2+. Grb2-deficient DG75 B cells on the other hand 
revealed a defect in Erk activation following BCR activation, leading to the hypothesis that Erk 
activation in human B cells occurs independently of PLCγ2 activity but requires Grb2.  
To directly test the involvement of PLCγ2, I generated a PLCγ2-deficient DG75 sub-cell line. 
Unexpectedly, PLCγ2-deficient DG75 B cells only revealed a reduction of about 50 % in Ca2+ 
mobilization following BCR stimulation. The functional homologue of PLCγ2 in T cells, namely 
PLCγ1 (Kane et al, 2000), appeared to be redundant in B cells in the presence of PLCγ2. Yet, in 
the absence of PLCγ2 it can partially compensate for the loss of PLCγ2 as became evident by 
comparing Ca2+ mobilization in PLCγ2 single-deficient and Ca2+ mobilization in PLC1/2 double-
deficient B cells. The ability to mobilize Ca2+ was completely abrogated in PLCγ1/2-double 
deficient DG75 B cells, while Erk phosphorylation was not affected. Thus, Erk activation following 
BCR stimulation in human B cells is completely independent of PLCγ activity.  
4.2.2 Human B cells exhibit low RasGRP1 and 3 expression levels 
Since I showed that PLCγ is dispensable for the activation of Erk following BCR activation, I thus 
proposed that human B cells in contrast to chicken and mouse B cells do not require the RasGEF 
RasGRP3, which is activated via DAG and PLCγ2. RasGRP3 protein expression in the model B cell 
line DG75 was shown to be rather low. To test whether this is representative for the human 
system, I compared expression of RasGRP isoforms in different B- and T cell lines and human 
primary B cells isolated from peripheral blood. RasGRP1, which is the functional analogue of 
RasGRP3 in T cells (Stone, 2011), as well as RasGRP3 expression was low in both, DG75 B cells 
and human primary B cells. Compared to the Raji B cell line and the Jurkat T cell line, DG75 B 
cells and human primary B cells revealed a higher RasGRP2 expression. According to several 
studies, RasGRP2 expression within the hematopoietic system is restricted to platelets, 
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megakaryocytes and neutrophils (Crittenden et al, 2004; Carbo et al, 2010). Detailed studies 
regarding RasGRP2 expression and function in T and B cells have not been published. In platelets 
and neutrophils RasGRP2 has been shown to mediate the activation of integrins via Rap, a small 
GTPase that is similar to Ras (Yamashita et al, 2000). Integrins mediate extracellular adhesion, 
facilitating platelet aggregation as well as neutrophil adhesion and chemotaxis (Crittenden et al, 
2004; Stolla et al, 2011). Despite structural homology to RasGRP3, the C1 domain of RasGRP2 
does not bind DAG and is not recruited to the plasma membrane by DAG analogs (Irie et al, 
2004; Johnson et al, 2007; Czikora et al, 2016). Hence, plasma membrane recruitment of RasGRP2 
is facilitated via an alternative membrane anchor, probably independent of PLCγ activity. 
Although there is no hint for RasGRP2 involvement in Erk activation in general, this should be 
addressed in future experiments. To sum up, RasGRP1 and RasGRP3 expression levels in the 
DG75 B cell line as well as in human primary B cells are similarly low. Also expression levels of 
Grb2 and GRAP are similar between DG75 and primary B cells, confirming the DG75 B cell line as 
a suitable representative model to investigate Erk signaling.  
Compared to DG75 B cells, Raji B cells that also represent a Burkitt lymphoma cell line, expressed 
higher levels of RasGRP1 and RasGRP3. Beside Raji B cells, upregulated RasGRP3 expression was 
also observed in the Burkitt lymphoma cell lines Daudi and Ramos as well as in the pre-B cell 
leukemia cell line Hoon (Teixeira et al, 2003). My results show that the DG75 B cell line 
constitutes an exception among Burkitt lymphoma cell lines and rather resembles the 
physiological situation in terms of RasGRP3 expression in human B cells.  
4.2.3 The Grb2 family member GRAP partially compensates for Grb2 function 
Lack of Grb2 in the human B cell line DG75 led to a decreased Erk phosphorylation following 
BCR activation. Nevertheless, Erk activation was not abrogated completely. Thus, I hypothesized 
that the adapter protein GRAP, which belongs to the Grb2 family of adapter proteins and shares 
60 % homology with Grb2 (Feng et al, 1996), could account for residual activation of Erk. Indeed, 
analysis of Grb2/GRAP double-deficient DG75 B cells revealed further reduction of Erk activation 
following BCR activation. Like Grb2, GRAP has been shown to interact with Sos via both SH3 
domains and is suggested to be involved in Ras/Raf/MEK/Erk cascade following T cell receptor 
activation (Feng et al, 1996; Trüb et al, 1997). Thus, I concluded that GRAP can partially 
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compensate for Grb2 function. When Grb2 is present, GRAP seems to be redundant for 
BCR-mediated Erk activation. GRAP single-deficient DG75 B cells exhibited no change in Erk 
activation following BCR stimulation. Expression of GRAP in Grb2/GRAP double-deficient B cells 
reconstituted Erk phosphorylation to the level of Erk phosphorylation in Grb2 single-deficient 
B cells, but could not completely compensate for the lack of Grb2. Nevertheless, I can conclude 
that residual Erk activation following BCR stimulation is due to partial compensation of Grb2 
function by GRAP and not due to other effectors.  
4.2.4 The PLCγ/RasGRP axis is dispensable for the activation of Erk in human B cells 
In the nineties the DT40 chicken B cell line has become an elegant model to analyze BCR 
signaling by gene disruption experiments. Compared to other eukaryotic systems, where gene 
targeting efficiency is low, DT40 B cells exhibit a high potential for efficient gene targeting due to 
its exceptional high level of homologues recombination. Most of what we know about the 
complex network of BCR signaling has been elucidated in this cell line (reviewed in Winding & 
Berchtold, 2001).  
Data from DT40 chicken cells and mice implied that Erk activation following BCR stimulation is 
exclusively mediated via PLCγ/RasGRP, while Sos was thought to be redundant (Oh-hora et al, 
2003; Coughlin et al, 2005). However, more recent data from different T and B cell lines have 
shown that RasGRP and Sos cooperate to establish a sensitive and robust activation of Erk by 
virtue of a Sos-mediated positive feedback loop (Roose et al, 2007). This is mediated by binding 
of RasGTP as a product of RasGRP and Sos to an allosteric pocket within the Sos molecule, 
thereby greatly accelerating Sos activity (Margarit et al, 2003). RasGRP was shown to be 
dominant over Sos leading to an impaired Ras/Erk activation in the absence of RasGRP, although 
the absence of Sos also led to a reduction of BCR-induced Erk activation, but only upon 
suboptimal BCR stimulation. Hence, the interplay of both ensures maximal Ras/Erk activation 
even in response to physiological low levels of antigen (Roose et al, 2007). 
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New gene targeting techniques as Zinc finger nucelases (ZFN)-, TALEN- and 
CRISPR/Cas-genome editing techniques that are based on the introduction of DSBs by 
site-specific nucleases, enable efficient gene disruption also in mammalian cells (Gaj et al, 2013). 
I could show by gene targeting experiments using the TALEN-based genome editing technique 
that in the human DG75 B cell line the PLCγ/RasGRP pathway plays a neglectable role in 
BCR-induced Erk activation. On the other hand, the adapter protein Grb2 appeared to be 
indispensable for BCR-mediated Erk activation, suggesting that Erk activation in human B cells is 
mediated via Grb2:Sos. These experiments are in contrast to the findings in chicken DT40 B cells 
and mice, revealing species specific differences in Erk activation following BCR stimulation. 
However, this raised the question of whether these observations apply on human B cells in 
general or whether the preference of either the Grb2/Sos or the PLCγ/RasGRP3 pathway 
depends on developmental stages of the B cell.  
A simple explanation was delivered by analysis of RasGRP expression levels, revealing low 
RasGRP1 and RasGRP3 expression levels in the B cell line DG75 as well as in human primary 
B cells. Furthermore, exogenous expression of RasGRP3 in Grb2/GRAP-double deficient B cells 
could completely reconstitute their ability to activate Erk upon BCR stimulation. Consequently, I 
concluded that human B cells potentially can use the Ras/Raf/MEK/Erk pathway, but due to a 
lack of RasGRP3 expression, human B cells predominantly use another RasGEF to mediate Erk 
activation following BCR stimulation, most presumably Sos. 
Since the B cell line DG75 represents a naïve B cell expressing surface IgM, it would be 
interesting to test RasGRP3 expression in human B cells from other developmental stages. The 
memory-like B cell lines HF1 (follicular lymphoma) and SUDHL-4 (Non-hodgkin lymphoma) 
exhibited high RasGRP3 expression levels compared to DG75 (data not shown). RasGRP3 
expression in memory-like primary B cells should be addressed in further experiments.  
4.2.5 Grb2 is recruited to the signalosome of the activated IgM-BCR by virtue of its SH2 
domain 
To further dissect Grb2 function in BCR-mediated Erk activation, I investigated Erk activation 
following BCR stimulation in Grb2 single-deficient DG75 B cells reconstituted with different Grb2 
  Discussion 
108 
 
variants either defective for one of the SH3 domains, the SH2 domain or for all of the three 
domains. Interestingly, all domains appeared to be important for sufficient activation of Erk. The 
importance of both Grb2-SH3 domains for Erk activation can be explained by the fact that 
Sos-interaction requires both Grb2-SH3 domains (Neumann et al, 2009). This also confirms the 
suggested involvement of Sos in BCR-mediated Erk activation, although definite confirmation by 
Sos gene targeting for example would be necessary. The need of the Grb2-SH2 domain for 
sufficient Erk activation upon BCR activation reflects the requirement for the recruitment of Grb2 
to the activated BCR via a phosphorylation motif. Unlike the IgG/IgE-BCR of memory B cells, the 
IgM-BCR complex of naïve B cells lacks a suitable Grb2 docking site.  
Indeed, mass spectrometry based interactome analysis of Grb2-SH2 interaction partners 
following BCR stimulation revealed interaction of the Grb2-SH2 domain with the BCR complex 
including Igα as well as heavy and light chain regions of IgM. Furthermore, I identified several 
BCR associated proteins whose interaction with Grb2 has been reported in several studies 
(Neumann et al, 2009).  
Due to the lack of a putative Grb2 binding site, I assumed that interaction of Grb2-SH2 domain 
with the BCR complex occurs indirectly. A potential Grb2 interaction partner that could link Grb2 
to the activated BCR complex is the adapter protein SHC1. SHC1 belongs to the SHC adapter 
family that encompasses four members with multiple isoforms being involved in signaling of 
various surface receptors (Finetti et al, 2009). Early studies already reported SHC1 association 
with Grb2 and Sos by virtue of the Grb2-SH2 domain upon BCR activation, suggesting its 
involvement in the activation of Ras and MAPKs (Smit et al, 1994; Saxton et al, 1994). 
Transfection of transformed murine pre-B cells with variants of SHC1 defective for Grb2-binding 
sites led to a decrease in Ras and Erk activation, supporting the hypothesis of SHC1 involvement 
in the Ras/Raf/MEK/Erk pathway (Baughn & Rosenberg, 2005). SHC1 constitutively interacts with 
a DCSM (Asp-Cys-Ser-Met) motif within Igα and additionally gets recruited to the 
phosphorylated ITAMs of Igα/β via its SH2 domain upon BCR stimulation (Baumann et al, 1994; 
D'Ambrosio et al, 1996). However, when RasGRP1 and 3 were identified to mediate Erk activation 
downstream of the T and B cell antigen receptor in a PLCγ dependent manner, SHC1 faded from 
the spotlight. However, later studies revealed a tight interplay between RasGRP and Grb2:Sos in 
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the activation of Erk (Roose et al, 2007). Since Erk activation in the B cell line DG75 seems to be 
mediated via Grb2:Sos, this cell line provides a good model to study SHC1 involvement in the 
Grb2:Sos pathway. To this end, I generated a SHC1-deficient DG75 sub cell-line and analyzed it 
with regard to Erk activation following BCR activation. Interestingly, three out of seven SHC1 
deficient clones exhibited a remarkable decrease in Erk phosphorylation. This effect could not be 
reconstituted by expression of the SHC1 isoforms p52 and p46, revealing the effect on Erk 
phosphorylation as an off-target effect of the CRISPR construct. Yet, it is striking that three out of 
seven clones designated as SHC1 deficient are defective in Erk activation following BCR 
stimulation. Off-target analysis of the CRISPR/Cas construct did not reveal BCR relevant off-
targets. However, sequence alignment of SHC family members revealed similarities between 
SHC1 and SHC2 (also termed ShcB), especially in the CRISPR target site. SHC2 is predominantly 
expressed in the CNS (Central nervous system) (O'Bryan et al, 1996). Currently, there are no 
reports about expression and function of SHC2 in immune cells, but SHC2 should be taken into 
account in future experiments.  
4.2.6 The search for the membrane anchor of Grb2 
Grb2 has been shown to be recruited to the plasma membrane following BCR activation in 
multiple ways by virtue of its SH3 domains or its SH2 domain. My results showed that 
BCR-induced Erk activation does not solely depend on the Grb2-SH3 domains but also on the 
Grb2-SH2 domain, suggesting the requirement for plasma membrane recruitment of Grb2 to a 
phosphorylation-motif within the BCR signalosome for sufficient Erk activation. 
Via its SH2 domain, Grb2 was shown to associate with SHC1, CD19 and SLP65 as well as with 
SHP2 and several inhibitory coreceptors (Neumann et al, 2009). However, none of these 
interactions appeared to be important for the activation of Erk, as shown in this study for SHC1 
and SLP65. Moreover, Erk activation following BCR activation in CD19-deficient cells was also not 
affected (data not shown). Grb2 was shown to interact with Btk which is translocated to the 
plasma membrane by virtue of its PH domain (Engels et al, 2014; Takata & Kurosaki, 1996). Since 
the Btk:Grb2 interaction depends on the Grb2-SH3 domain and not on the Grb2-SH2 domain, 
Btk might not be the missing link recruiting Grb2 to the signalosome of the activated BCR. 
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Furthermore, Erk activation following BCR stimulation in Btk-deficient B cells was not or only to 
small extents impaired. 
A study in the Burkitt lymphoma cell line BL41 suggested Grb2-asscociated binding protein 1 
(Gab1) as a major regulator of Erk. siRNA knockdown of Gab1 almost completely blocked the 
activation of Erk. Gab1 is constitutively associated with Grb2 via proline rich sequences of Grb2 
and associates with phosphorylated signaling molecules as for example SHC1 by virtue of its SH2 
domains. Via its PH domain it is able to bind to PIP3 and thus is recruited to the plasma 
membrane (Angyal et al, 2006). Therefore, Gab1 which was also identified in the Grb2-SH2 
interactome in this study, provides a further potential membrane anchor for Grb2.  
Igα was the most abundant protein identified in the mass spectrometry interactome of the Grb2-
SH2 domain. This implies a direct interaction with Grb2, although it does not encompass a Grb2-
docking site matching the consensus phosphorylation motif. To examine, whether Grb2 is 
capable to be recruited to phosphorylated ITAMs directly, synthetic phosphorylated and 
unphosphorylated peptides containing the ITAMs or the non-ITAM could be used for pulldown 
analysis in DG75 B cell lysates in future experiments.  
Taken together, I assume that the recruitment of the adapter protein Grb2 to the signalosome of 
the activated BCR complex does not rely on single protein interactions but rather is mediated by 
many factors involved in Grb2 recruitment via interaction with either the Grb2-SH3 domains or 
the Grb2-SH2 domain. Yet another protein that could serve as potential membrane anchor for 
the Grb2-SH2 domain is the newly identified FcµR, which harbors a putative Grb2 docking site 
(ITT-like motif) within its cytoplasmic domain. 
4.3 The FcµR constitutes another membrane anchor for Grb2 
For quite a long time the FcµR defied identification, although its existence has been suggested 
for more than 30 years (Sanders et al, 1987; Ohno et al, 1990; Nakamura et al, 1993). Different 
from other Fc receptors, the Fc receptor for IgM does not carry a conventional ITAM or ITIM 
signaling motif in its cytoplasmic domain. Instead it harbors a phosphorylation motif similar to 
the ITT in the cytoplasmic domain of the IgG/E BCR that could serve as a potential Grb2 binding 
site (Kubagawa et al, 2009). Considering the multifaceted properties of Grb2, the potential 
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ITT-like motif within the FcµR could either have costimulatory or inhibitory functions. Since 
exogenous expression of the full length FcµR only led to low surface expression levels, I 
investigated the molecular signaling properties of the cytoplasmic domain of the FcµR in the 
context of the murine IgG2a-BCR. The results obtained with DG75 B cells expressing the 
IgG2a-FcµR chimera indeed confirmed the FcµR-ITT motif as a Grb2 binding site. Moreover, the 
FcµR-ITT was able to functionally replace the original ITT in terms of costimulatory functions. 
Whether this also resembles the properties of the full-length FcµR has to be elucidated in future. 
Nevertheless, co-crosslinking of the FcµR and the BCR on human primary B cells using BCR 
specific IgM suggested a costimulatory role for the FcµR, although the costimulatory effect was 
rather low. Furthermore, the same study revealed a costimulatory role for the FcµR also when co-
crosslinked with CD2 or the T cell antigen receptor of the Jurkat T cell line (Honjo et al, 2015). 
The FcµR ITT-like motif (Y385) as well as the tyrosine at position 366 was shown to be involved in 
receptor internalization following IgM binding (Honjo et al, 2015). This could also be mediated 
via Grb2 which was shown to be involved in receptor internalization by interacting with dynamin 
(Malhotra et al, 2009). To conclude, the FcµR-ITT-like motif once phosphorylated indeed 
constitutes a Grb2 docking site, which in context of the IgG2a-chimera fulfills costimulatory 
functions. Thus, the FcµR can be added to the list of Grb2 membrane anchor. 
 
 




5 Summary and Conclusion 
In my PhD project I investigated different modes of BCR activation and the outcome in 
intracellular signaling. Antigens and BCR specific antibodies are well established reagents to 
activate the BCR. However, multimeric soluble FcγRIIB is able to interact with the IgG-BCR on 
memory-like B cells leading to BCR specific induction of signaling events. Thus, multimeric 
soluble FcγRIIB represents a new tool to induce BCR signaling in different strength and quality 
compared to stimulation with BCR specific antibodies. BCR stimulation with soluble FcγRIIB 
suggested a signaling pathway leading to the activation of Erk independent of SLP65 and hence 
independent of the Ca2+ initiation complex. In contrast to chicken DT40 B cells, my results show 
that Erk activation following BCR ligation in human B cells is independent of the PLCγ/RasGRP 
axis revealing species specific differences between chicken and human with regard to BCR-
induced Erk activation. Erk activation in human B cells depends on the adapter protein Grb2, 
which most likely mediates Erk activation by linking the RasGEF Sos to the signalosome of the 
activated BCR. However, the Grb2 membrane anchor within the signalosome of the activated 
BCR which is important for the activation of Erk is still unknown. Indirect recruitment of Grb2 to 
the BCR complex via SHC1 turned out to be dispensable for Erk activation following BCR 
activation. With the newly identified FcµR, I found a new membrane anchor for Grb2. However, 
its role with regard to BCR signaling remains to be elucidated.  
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